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This dissertation contains five chapters covering three major projects in my 
doctoral studies to understand natural product biosynthesis from different perspectives. 
Chapter 1 is an introduction of my studies to develop drugs from natural products and is 
partially adapted from one book chapter written by me and David in Comprehensive 
Natural Products Chemistry Edition II, which is in press. Chapter 2 describes my studies 
to generate cryptophycin analogs through chemoenzymatic approaches and to 
characterize novel biosynthetic enzymes. It is mainly adapted from two of our papers 
published in Journal of the American Chemical Society (2008, 130: 5492-5498) and ACS 
Chemical Biology (2006, 1: 766-779), and twos manuscripts to be submitted. Chapter 3 
focuses on characterization of fungal alkaloid biosynthesis with different approaches and 
is adapted from four of our papers (Organic Letters 2008, 10: 4863-4866; Journal of 
Natural Product 2008, 71: 1574-1578; Journal of Biological Chemistry 2008, 283: 
16068-16076; and Journal of Organic Chemistry 2008, 73: 3116-3119), and one 
manuscript to be submitted. Chapter 4 represents our latest understanding about 
trichothecene macrolide biosynthesis in a marine fungal strain and is adapted from one 
manuscript in preparation. Chapter 6 describes my own points of view about future work 
of these three projects and summarizes my entire doctoral research in this thesis. Due to 
the limitation of space, several other projects I conducted in my studies are notincluded 
here.
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Chair: David H. Sherman 
Complex secondary metabolites display diverse biological activities and together 
with their derivatives have provided over two-thirds of new pharmaceutical agents 
introduced during the past two decades. However, limitations in isolation and in rapid 
structural determination continue to be inherent hurdles for using natural products as 
leads in drug discovery and design. My dissertation research focused on selected 
biosynthetic pathways with the hope to overcome some of these limitations. Three 
projects are described in this dissertation thesis. The first project demonstrates my efforts 
to generate natural product analogs using the biocatalysts, a strategy that provides 
significant advantages in catalytic specificity, efficiency, and impacts on the environment. 
Several natural and synthetic anticancer agent analogs were produced with a single P450 
epoxidase and an excised thioesterase involved in the production of cryptophycin in 
Nostoc sp. Moreover, the homotropic and heterotropic cooperativity of the bacterial P450 
epoxidase toward its substrates was characterized in details. This enzyme may serve as a 
more operable model to study the same features in several human P450s involving
 xvii
in xenobiotcs metabolism. The second project describes how unique prenylated indole 
alkaloids are biosynthesized in various fungal genera. These biosynthetic pathways were 
extensively investigated by isolation and characterization of several key biosynthetic 
intermediates from Penicillium, Aspergillus, and Malbranchea sp. Subsequently, these 
pathways were examined at the first time through the elucidation of the biosynthetic gene 
cluster for stephacidin/notoamide from a marine Aspergillus strain and biochemical 
characterization of two critical aromatic prenyltransferases catalyzing two committed 
steps. Finally, one trichothecene macrolide gene cluster was cloned from a marine 
Myrothecium verrucaria strain and validated with biochemical characterization of a 
sesquiterpene synthase and a multifunctional P450, representing the latest understanding 
of the biosynthesis of structurally complex mycotoxins. With the identification and 
characterization of natural product gene clusters, more new fungal secondary metabolite 










 A significant number of natural products contain pharmacological activities that 
are beneficial to human health.  There are many examples of natural product compounds 
that are in clinical use, including antibacterial penicillins, cephalosporins, 
immunosuppressive cyclosporine A, and the cholesterol-lowering HMG-CoA reductase 
inhibitors best known as the “statins” 1. These natural products, which have achieved 
their functions over the course of millions of years of evolution, offer chemical scaffolds 
for development of new analogs with improved or altered functions. New bioactive 
analogs that contain novel structural elements may be generated by both semisynthesis 
and total synthesis efforts 2, 3. In fact, more than two-thirds of newly introduced drugs 
worldwide were natural products or natural product derivatives in the past two decades 4.  
 
 The number of natural products that function in biological systems is large but 
represents only a small fraction of the total possible number of small carbon-based 
compounds, indicating the importance of stereochemistry and functional groups in 
natural product functions 5. Modern synthetic chemistry has encountered difficulty in 
preparation of complex, high molecular weight natural products containing a great 
number of reactive groups and stereocenters for the generation of drug leads in the 
pharmaceutical industry. Incorporating the use of biocatalysts during natural product 
synthesis represents a promising strategy for the production of compounds that are 
desperately needed for pharmaceutical development 6, 7. For example, all anti-cholesterol 
statins have a common 3,5-dihydroxyacid side chain, which contains two chiral hydroxyl 
groups. In the current manufacturing process of atorvastatin side chain, (R)-4-cyano-3-
hydroxybutyrate, a key side chain precursor, was produced by a two-enzyme system 8. In 
this process, ethyl 4-chloroacetoacetate was first reduced by a ketoreductase to form (R)- 
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4-chloro-3-hydroxybutyrate, followed by a halohydrin dehydrogenase- catalyzed 
cyanation to produce the desired product. Moreover, enzymes residing in living cells 
have been extensively used as biocatalysts in the food and beverage industry, and isolated 
enzymes also play critical roles in performing chemical transformations on organic 
compounds in many areas 9-12. Often, these remarkable catalysts are able to perform a 
wide array of reactions on structurally diverse compounds. Furthermore, enzymes can  
also selectively catalyze reactions with chiral (enantio-) and positional (regio-) 
selectivities 12. With these advantages, enzymes are applied in organic synthesis to avoid 
tedious protection and deprotection steps commonly required for enantio- and 
regioselective synthesis. The inherent selectivity of enzymes generates few by-products, 
making it an environmentally friendly alternative to chemical catalysts. Enzymes used in 
organic synthesis include acyl transferases (e. g., lipases, esterases, peptidases, amidases, 
and acylases), carbohydrate processing enzymes (e. g., glycosidases, glycosyl-
transferases), hydrolytic enzymes (e. g., epoxidases, nitrilases, nitrile hydratases), 
reductases, oxidases and oxygenases, aldolases, and oxynitrilases 9. 
 
 Polyketides (PKs), nonribosomal peptides (NRPs), and PK/NRP or NRP/PK 
hybrids represent three large subclasses of highly diverse natural products with various 
bioactivities 13. These natural products are produced by large megaenzymes, polyketide 
synthases (PKSs) and nonribosomal peptide synthetases (NRPSs). Type I PKSs consist of 
multiple modules, with each module minimally containing three core domains: 
acyltransferase (AT) domain, ketosynthase (KS) domain, and thiolation (T) domain [also 
called acyl carrier protein (ACP) domain].  Typically, one type I PKS module catalyzes a 
single elongation cycle for PK production (Figure 1-1). During elongation, the AT 
domain serves as the gatekeeper for specificity, responsible for selecting the appropriate 
CoA extender unit (e. g., malonyl-CoA, methylmalonyl-CoA) and transferring the 
extender unit to the sulfhydryl terminus of the phosphopantetheinyl arm on the T domain 
14. The KS domain catalyzes the decarboxylation of acyl-S-T to generate a carbanion that 
reacts with the PK intermediate linked to T domain generated in the previous elongation 
cycle. The resulting α-ketoacyl-S-T becomes the substrate for the next cycle of elongation 
catalyzed by the subsequent module. In addition to type I PKSs, there are two other PKS 
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classes, type II PKSs and type III PKSs 15, 16. Unlike the type I class, type II PKSs consist 
of discrete enzymes that are organized as a multi-component system 16. The type III PKSs 
are distinguished from the others by lack of an AT and T domain. Type III PKS systems 
typically use CoA substrates (i. e. malonyl-CoA), but there is precedent for their ability to 
accept acyl-S-T substrates 15, 17. Similar to the type I PKSs, NRPSs are comprised of 
multifunctional enzymes that are arranged into modules. Each NRPS module contains 
three core domains: adenylation (A), condensation (C), and thiolation (T) [also called 
peptidyl carrier protein (PCP) domain] 18 (Figure 1-1). The A domain is responsible for 
selecting and activating the natural or modified amino acid monomer. The activated 
amino acid monomer is covalently attached via a thioester bond to the cysteamine group 
of a phosphopantetheinyl arm in the holo-T domain. The condensation (C) domain 
catalyzes formation of the peptide bond between the amino acid monomer and the 
peptidyl intermediate tethered to a T domain in an adjacent module. Similar to type I PKS 
modules, each NRPS module performs a single elongation step of the growing peptidyl 
chain. In both NRPSs and PKSs, there are several additional domains that contribute to  
 
Figure 1-1. Schematic representations of one elongation cycle catalyzed by the 
minimal module of PKS (A) and NRPS (B). A common phosphopantetheinyl arm is 
found in the holo-T domain of both PKS and NRPS as shown in A.  
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natural product structural diversity. Ketoreductase (KR), dehydratase (DH), and enoyl 
reductase (ER), and methyltransferase (MT) domains are commonly found in PKS 
modules while N-MT and epimerase (E) domains are generally embedded within NRPS 
modules. These additional domains contribute significantly to the diversity and 
bioactivity of PKs and NRPs. Thioesterase (TE) domains, typically found at the C- 
terminus of the final elongation module in both PKSs and NRPSs are responsible for 
terminating biosynthesis. In most cases, TE domains catalyze intra-molecular 
macrocyclization or hydrolysis of the thioester bond between the final T domain and the 
PK or NRP intermediate 19. The structures of the nascent PK and NRP products are often 
further modified through oxidation, glycosylation, acylation, alkylation, and halogenation 
reactions catalyzed by tailoring enzymes in natural product biosynthetic pathways 20, 21. 
 
 Recent advances in recombinant DNA technology, genetics, and DNA synthetic 
methodology have further boosted the development of natural products for clinical 
practice through heterologous production and metabolic engineering 22-24. For example, 
the antibiotic erythromycin has been heterologously produced in E. coli, presenting the 
first example of the production of complex PKs in heterologous microbes (Figure 1-2) 25. 
Although E. coli produces propionyl-CoA, the starting unit for 6-deoxyerythronolide B 
(6DEB) biosynthesis, this substrate is not formed in high-cell density conditions, 
requiring metabolic engineering of host strain to fulfill specific requirements. Pfeifer et al. 
circumvented this problem by introducing one propionyl-CoA synthetase (PrpE) gene, 
propionyl-CoA carboxylase (PCC) genes, and one phosphopantetheinyl transferase (Sfp) 
gene to E. coli while disrupting its prp operon and one methylmalonyl-CoA 
decarboxylase (ygfG) gene 25. These engineering efforts avoided squandering propionyl-
CoA and (2S)-methylmalonyl-CoA, another building block for 6DEB biosynthesis, by 
unexpected metabolism in E. coli. Moreover, the engineered E. coli strain produced both 
CoAs after feeding propionic acid. After further optimization, the titer of 6dEB was 
improved to 1.1 g per liter of fermentation culture 26. More importantly, replacing the 
loading module for 6DEB biosynthesis with that for rifamycin biosynthesis made E. coli 
to produce a 6DEB analog carrying an aromatic moiety, further suggesting feasibility of 
metabolic engineering in generation of novel natural product analogs for pre-clinical and 
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clinical studies 25. Furthermore, one mature erythromycin analog, erythromycin C, was 
prepared at 0.4 mg/L of culture after co-expressing two biosynthetic gene clusters 
responsible for the production of deoxysugars, TDP-L-mycarose and TDP-D-desosamine 
in the above engineered E. coli strain 27. These results indicated that heterologous 
microbes with well-developed genetic engineering tools have the ability to produce  
 
Figure 1-2. Metabolic engineering and heterologous production of 6DEB in E. coli. 
The efficiency and feasibility of metabolic engineering and heterologous production of 
pharmaceutically valuable natural products and analogs thereof is exemplified by the 
production of 6DEB and its analog in E. coli. 6DEB analog was produced after replacing 
DEBS1 loading module with one NRPS module with specificity to benzoic acid.  
 
pharmaceutically valuable both natural and novel natural product analogs through DNA 
recombination and metabolic engineering. 
 
 Complex secondary metabolites display diverse biological activities, and along 
with their derivatives, have provided over two-thirds of new pharmaceutical agents 
introduced during the past two decades. However, drug-resistant bacteria like methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus 
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faecalis continue to emerge as a threat to human health 28-30. Along with medical needs to 
treat a spectrum of diseases, an increasing number of natural products have been isolated 
and screened for potential bioactive secondary metabolites 31. Adversely, limitations in 
isolation and rapid structural determination continue to be inherent hurdles for natural 
products as leads in drug discovery and design. Chemoenzymatic approaches along with 
natural product heterologous production and metabolic engineering have proven to be 
effective and feasible for producing natural product analogs regardless of the above 
challenges. On the other hand, identification and characterization of natural product 
biosynthetic pathways are prerequisite and indispensable to these strategies. My Ph.D. 
dissertation research under the mentorship of Professor David H. Sherman was designed 
to broadly investigate selected natural product biosynthetic pathways and to extensively 
employ biocatalysts discovered from the characterized pathways to identify compounds 
with enhanced anticancer activity. The specific aims of my project included (1) 
development of chemoenzymatic routes to cryptophycin analogues, (2) isolation of key 
biosynthetic intermediates to dissect fungal alkaloid biosynthetic pathways; (3) genome 
mining and detailed characterization of notoamide biosynthetic gene cluster; (4) cloning 
and characterization of a novel macrocyclic trichothecene gene cluster. The details of 
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Chemoenzymatic Synthesis of Anticancer Agent Cryptophycin Analogs 
with Biocatalysts from Nostoc sp. 
 
2.1. Summary 
This chapter contains three successive stories toward developing chemoenzymatic 
routes to synthesize cryptophycin analogs and biochemically characterizing the substrate 
cooperativities in cryptophycin P450 epoxidase. The first study focused on the 
mechanistic understanding of the incorporation of L-leucic acid into the cryptophycin 
structure as its Unit D. Non-amino acid substrate incorporation into NRPs has been 
reported previously but the complete characterization of this process was lacking and 
only preliminarily addressed in this study. The substrate selectivity of the A domain of 
the CrpD second module (CrpD-M2) was predicted to be specific toward non-amino acid 
chemicals in bioinformatics analysis, and this was subsequently confirmed using a 
radioactive ATP-PPi assay. Both 2-ketoisocaproic acid (2KIC) and 2-hydroxyisocaproic 
acid (2HIC) were activated by the CrpD-M2 A domain and loaded onto its T domain. 
Substrate loading was further confirmed with high-resolution fourier transform ion 
cyclotron resonance mass spectrometry (FT-ICR-MS). After 2KIC loading, the unique α-
ketoreductase (KR) embedded into CrpD-M2 reduced 2KIC into 2HIC with the 
consumption of either NADPH or NADH. Working in progress is to characterize the 
formation of a seco-cryptophycin biosynthetic intermediate with chemically synthesized 
UnitABC-NAC ester using the CrpD-M2 C domain. The full understanding of L-leucic 
acid incorporation will establish one chemoenzymetic route relying on one 
multifunctional enzyme, which has the potential to generate cryptophycin analogs 
carrying unnatural Unit D moieties. The second study addressed the most challenging 
issue in chemical synthesis of cryptophycin analogs. The most potent natural 
cryptophycin analogues retain a β-epoxide at the C2’-C3’ position of the molecule. 
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Chemical installation of this functional group faces problems of selectivity, specificity, 
and undesirable byproducts. A P450 epoxidase encoded by crpE was shown to install this 
key functional group in a regio- and stereospecific manner. A detailed characterization of 
the CrpE epoxidase using an engineered maltose binding protein (MBP)-CrpE fusion 
investigated the substrate tolerance of the CrpE polypeptide, and a series of structurally 
related cryptophycin analogues were generated by chemoenzymatic synthesis. The 
kcat/Km values of the enzyme for these substrates were determined to provide further 
insights into how the P450 epoxidase catalytic efficiency was affected by substrate 
structural variation. Finally, binding analysis revealed cooperativity of MBP-CrpE 
toward natural and unnatural desepoxy cryptophycin substrates. The last story in this 
chapter continued my efforts to understand the unusual cooperativity feature of this 
bacterial P450. I further characterized its homotropic cooperativity from different aspects 
using Job’s titration to calculate ligand:enzyme molar ratio, substrate titration under high 
concentration salt to exclude enzyme oligomerization contributing to observed 
cooperativity, and linear fatty acids titration to estimate enzyme active pocket size. 
Furthermore, steroid testosterone was found to be a both homotropic and heterotropic 
ligand of CrpE, suggesting CrpE as a good model system for human P450 cooperativity 
studies. Most importantly, testosterone was an enhancer for CrpE catalytic reaction, 




Cryptophycins are isolated from the cyanobacterial symbiont Nostoc sp. ATCC 
53789, and Nostoc sp. GSV 224 1, 2. They are potent anticancer agents due to their ability 
to stimulate cellular microtubule instability, inhibit microtubule assembly, and induce 
tubulin self-association, resulting in a G2/M phase transition block in the cell cycle 3, 4. 
The cryptophycin mode of action and cellular target resembles both the vinca alkaloids 
and taxol 5, 6. Significantly, the cryptophycins are not active substrates of P-glycoprotein 
and/or multiple drug resistance-associated protein, making them viable chemotherapeutic 
alternatives to the vinca alkaloids and taxol for treatment of vinca alkaloid- and taxol-
resistant cancers 7, 8. The clinical potential, validated mode of action, and synthetically 
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challenging structure of cryptophycins, as well as the lack of large-scale fermentation 
methods for their production, have stimulated the development of synthetic methods to 
provide suitable amounts of material and new analogs with improved physiochemical 
properties for clinical studies. 
  
The cryptophycin gene cluster from Nostoc sp. ATCC 53789 and Nostoc sp. GSV 
224 was recently identified in a 40-kb of region DNA, offering potential chemoenzymatic 
tools for cryptophycin production (Figure 2-1) 9. The gene cluster is comprised of two 
type I PKS genes, crpA and crpB, two NRPS genes, crpC and crpD, and four tailoring 
enzyme genes including a P450 epoxidase gene (crpE), a putative 2-ketoglutarate iron-
dependent hydroxylase gene (crpF), a decarboxylase gene (crpG), and a flavin-dependent 
halogenase gene (crpH). CrpA and CrpB each contain two elongation modules that are 
hypothesized to generate the δ-hydroxy phenyloctenoic acid polyketide moiety (Unit A) 
 
 
Figure 2-1. Schematic organization of cryptophycin gene cluster (crp) and its 
biosynthetic pathway with CrpA, CrpB, CrpC and CrpD. The structure of 
predominant natural cryptophycin, Cr-1, is shown and dissected into four Units (A-D). 
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in cryptophycin 1 (Cr-1) (1) from one molecule of phenylacetate or its derivative as a 
starter unit, and three molecules of malonyl-CoA as extender units. CrpC is a 
monomodular NRPS containing a single elongation module that activates and epimerizes 
L-tyrosine to D-tyrosine and subsequently condenses the activated D-tyrosine (Unit B) 
with the PK acyl intermediate tethered to the CrpB T domain. The activated amino acid 
may also be methylated by a single MT domain in CrpC. CrpD is a bimodular NRPS 
enzyme. Its first module activates methyl-β-alanine (Unit C) that is converted from L-
aspartic acid by CrpG, a β-methylaspartate-α-decarboxylase 10. The second module of 
CrpD assembles an activated 2KIC (Unit D) to produce the final PK/NRP hybrid 
intermediate. The immediate source of 2KIC remains unknown, but may result from 
transformation of L-leucine. Interestingly, this NRPS module contains one KR domain, 
which may convert 2KIC into 2HIC. The final domain of CrpD is a thioesterase that 
catalyzes release of the linear intermediate from the final T domain of CrpD and 
generates a cyclic 16-membered ring natural product.  This cyclic depsipeptide is further 
structurally diversified by tailoring enzymes whose genes are encoded within the 
cryptophycin biosynthetic gene cluster. More than 25 naturally occurring cryptophycin 
analogues are produced by this biosynthetic machinery in Nostoc sp. ATCC 53789 9, with 
the major isolate being Cr-1 (Figure 2-1).   
 
The large number of cryptophycins produced by Nostoc sp. ATCC 53789 is 
indicative of the flexibility of the cryptophycin biosynthetic system, including PKSs, 
NRPSs, and tailoring enzymes. The versatility of this assembly line was first assessed 
using a precursor directed biosynthesis approach 9. In total, 22 unnatural amino acids and 
halogen sources were introduced to the Nostoc culture and 44 unnatural cryptophycin 
analogs including cryptophycin 52, the synthetic lead molecule that later advanced to 
clinical trials, were isolated and identified. This result highlighted the exciting possibility 
that the cryptophycin biosynthetic machinery could be employed to generate and identify 
new bioactive cryptophycin analogs as anti-cancer leads 9.  
 
The extended growth period of Nostoc sp. ATCC 53789 and GSV224 limits their 
ability to produce cryptophycin analogs in large-scale fermentation. Alternatively, total 
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synthetic strategies have been developed to provide adequate supplies for clinical 
evaluation 11. Several effective synthetic approaches have been employed for the 
generation of cryptophycins, including sufficient quantities of cryptophycin 52 required 
for clinical trials. Besides, a number of cryptophycin analogs with unnatural Unit A, B, 
and C moieties have been produced by chemical methods and their activities were 
examined to identify novel chemical with improved bioactivities and reduced toxicity. 
However, proper macrocyclization and efficient epoxidation are still the two most 
challenging issues for cryptophycin chemical synthesis, and chemical reagents to address 
these issues add considerable time and expense to achieve the final desired products. 
Cryptophycin TE has the potential to solve the problem of proper macrocyclization in 
both an environmentally friendly and economical manner. In a recently described 
approach, the Crp TE was excised and heterologously overexpressed as a recombinant 
enzyme 12. Four NAC activated seco-cryptophycins were chemically synthesized and 
utilized to interrogate the in vitro activity and substrate specificity of Crp TE (Figure 2-
2). Naturally occurred cryptophycin 4 (2), cryptophycin 24 (3), and an unnatural C6 gem-
dimethyl analog, cryptophycin-B (4), were produced as the major products in the 
chemoenzymatic reactions, suggesting the termination enzyme is robust in its ability to 
produce both natural and unnatural products and tolerant to variants at the cryptophycin 
β-alanine moiety. TE specificity was further investigated using a substrate lacking the 
phenyl group in its PK A-subunit moiety. Interestingly, Crp TE was also capable of 
generating the cyclic product (5) but with significantly increased levels of hydrolysis 
(cyclization:hydrolysis = 1: 8.3) 12.  
 
Solid-phase peptide synthesis is widely used in preparation of NRP substrates for 
NRPS TE domain studies. Recently, this approach was applied to PK/NRP natural 
product studies 13. Several seco-cryptophycin analogs were synthesized on safety-catch 
PEGA resin and subjected to chemoenzymatic reactions with Crp TE (Figure 2-2). Crp 
TE also recognized these substrates and catalyzed macrocyclization to produce 
cryptophycin 29 (6) and the unnatural des-epoxy cryptophycin 24 (7) 13. Since the ester 
bond between methyl-β-alanine and α-ketoisocaproate moieties in cryptophycins is labile 
to hydrolysis, Crp TE was probed for its tolerance regarding replacement of this ester 
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Figure 2-2. Chemoenzymatic synthesis of cryptophycin analogs using the excised 
Crp TE domain. Recombinant TE from this prototypical PKS/NRPS system tolerates 
structural modifications on its native seco-cryptophycin substrates. Two different tags are 
used to mimic the T domain to which the PK/NRP intermediate is tethered in vivo. 
 
with an amide linkage. Generation of a novel cyclic compound bearing the amide (8) in 
the Crp TE reaction demonstrates the unusual versatility of this enzyme. Thus, Crp TE is 
an attractive tool to overcome the macrocyclization challenge in chemical synthesis, and 
to generate an array of new analogs in sufficient quantity for bioactivity analysis. 
 
The most significant challenge in cryptophycin chemical preparation is the late-
stage regio- and stereospecific installation of the epoxide moiety due to the labile and 
highly reactive nature of this functionality 11. Initial efforts with mCPBA or dimethyl 
dioxirane (DMD) resulted in conversion of 25% of the starting material into the 
unfavorable α-epoxy-cryptophycin. The potency of this isomer is at least 100 times less 
than the β-epoxy-product 14, 15. Although several other stereospecific epoxidation 
methods have been developed, there remains significant need for improvement in yield 
and selectivity 16, 17. In this chapter, I will describe my studies to develop the cytochrome 
P450 CrpE as an effective biocatalyst to fulfill this demand. In addition, efforts to 
investigate less explored Unit D biosynthesis will also expand the current understanding 
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of NRP biosynthesis and provide one more chemoenzymatic route to generate numerous 
novel cryptophycin analogs.  
 
2.3. Results and Discussion 
 
2.3.1. Chemoenzymatic Synthesis of Cryptophycin with a Single Multifunctional 
Cryptophycin Biosynthetic Enzyme 
 
To activate and install CrpD-M2 substrates into the cryptophycin structure, the 
DNA fragment of this megaenzyme consisted of condensation (C), adenylation (A), 
ketoreductase (KR), and thiolation (T) domains was amplified by PCR, cloned into the 
BamHI and XhoI sites of pET28a, and heterologously overexpressed in E. coli BAP1 
strain with the chromosomally integrated sfp phosphopantetheinyl transferase gene 18. 
The N-terminally His-tagged protein was purified with Ni-NTA resin to reach about 80 
% purity (Figure S2-1A). Fourier transform ion cyclotron resonance mass spectrometry 
(FTICR-MS) was used to verify that the protein was the full length, and 
phosphopantetheinated on the T domain active site (Figure S2-1B). 
  
Subsequently, the well-proven radioactive ATP-PPi exchange assay with ten acids 
as enzyme substrates was used to determine the substrate specificity of the CrpD-M2 A 
domain by measuring reversible acyl-AMP formation (Figure S2-1C). CrpD-M2 was 
found to preferentially activate 2KIC over L-leucine, which was consistent with results of 
CrpD-M2 substrate bioinformatic prediction and feeding experiment (Figure 2-3, Table 
S2-1) 9. Moreover, CrpD-M2 showed the similar selection to natural substrate 2-
oxovalerate while its specificity to two other natural Unit D fragments, 3-methyl-2-
oxovalerate and 3-methly-2-oxobutyrate, was decreased about 50 % and 90 %, 
respectively, compared to 2KIC. This result along with the weak activation of unnatural 
substrates 2-oxobutyrate and phenylpyruvate strongly suggested the importance of side 
chains for substrate recognition by CrpD-M2. More importantly, the unnatural substrate, 
2-keto-γ-(methylthio) butyrate (AKGB), was effectively activated, suggesting that CrpD-
M2 might have the potential to produce cryptophycin analogs with enhanced 
hydrophilicity. Interestingly, L-2HIC was the best substrate in the assay. Thus, CrpD-M2 
A domain is the first example with similar selectivity toward both 2-keto and 2-hydroxy  
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Figure 2-3. CrpD-M2 A domain substrate selectivity. Totally, ten chemicals were used 
in ATP-PPi exchanging assay. They were (1) 2KIC, (2) AKGB, (3) L-2HIC, (4) 3-
methyl-2-oxovalerate, (5) L-leucine, (6) 2-oxovalerate, (7) 3-methly-2-oxobutyrate, (8) 2-
oxobutyrate, (9) 4-methyl-valerate, and (10) phenylpyruvate. The structures of these 
substrates were shown in Figure S2-1C. 
 
acids, although 2-keto acid activating A domains have been described in bacillaene, 
barbamide, cereulide, and valinomycin NRPS 19-21. The weak activation of 4-methyl-
valerate by CrpD-M2 firmly suggested the importance of functional group at its C-2 for 
enzyme recognition.  
 
     Both 2KIC and L-2HIC were activated by CrpD-M2 in an in vitro assay, however, 
only 2KIC is a direct precursor of leucine in amino acid biosynthetic pathway and may 
serve as the physiological substrate of this NRPS module. Following 2KIC activation and 
loading onto CrpD-M2 T domain, 2HIC may be produced in one α-keto reduction 
reaction catalyzed by one unusual KR domain embedded in CrpD-M2. Bioinformatic 
analysis indicated that this KR was grouped with other NRPS KR domains while was 
separated from any type of PKS β-KR domain (Figure S2-2).  
 
FTICR-MS was utilized to monitor substrate loading directly on the T-domain 22-
24.  Interestingly, both L-2HIC and D-2HIC were loaded on the T domain, indicating an 
unusual degree of substrate flexibility (Table 2-1). However, as only L-2HIC 
cryptophycin analogs have been isolated and characterized, one of the following 
hypotheses is likely true: 2KIC is stereoselectivly reduced to L-2HIC, only L-2HIC is 
productively processed to seco-cryptophycin, and/or D-2HIC is not physiologically 
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available. A further degree of substrate flexibility, with possible applications for 
combinatorial biosynthesis, was displayed by the loading of 2KIC and the unnatural 
substrate AKGB, in agreement with the ATP-PPi results (Table 2-1). 
 
Table 2-1. FTICR-MS analysis of substrate loading to CrpD-M2 and ketoreduction by its 
domain  
 





1 L-2HIC 4,116.21 4,116.12 2.1E+05 82 
2 D-2HIC 4,116.18 4,116.12 4.3E+05 82 
3 AKGB 4,151.28 4,151.16 2.8E+04 79 
4 KIC 4,114.15 4,114.12 8.8E+04 81 
5 KIC+NADPH 4,116.14 4,116.12 1.5E+05 82 
6 KIC+NADH 4,116.20 4,116.12 7.6E+05 82 
 
A mass shift was evident after loading of 2KIC and addition of either NADH or 
NADPH (Table 2-1). The mass shift of 2 Da, consistent with 2KIC to 2HIC, indicated 
the occurrence of α-ketoreduction reaction. Both NADH and NADPH appeared to 
operate with qualitatively similar efficiency as hydride donors.  
 
Next, the ability of CrpD-M2 to form the full-length cryptophycin was 
investigated with newly synthesized UnitABC-NAC ester (Figure S2-3). The synthetic 
scheme followed one previously established route and the final product was confirmed 
with NMR and high resolution mass spectrometry. The UnitABC-NAC ester was then 
mixed with CrpD-M2 and L-2HIC. Despite numerous attempts, T-domain tethered seco-
cryptophycin could not be identified by LC FTICR-MS. Possible reasons include: 
product instability (although other advanced NRPS intermediates can be observed25-27 
using similar methodologies), low steady-state concentrations of enzyme bound seco-
cryptophycin, or the cleavage of C domain from CrpD-M2 during storage. Now, the 
CrpD-M2 C domain is being overexpressed as a single domain to investigate these 
possibilities.  
 
The presumed seco-cryptophycin intermediate may be macrocylized from CrpD-
M2 T domain by addition of the CrpD thioesterase domain in trans. Furthermore, this 
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putative substrate will be analyzed with HPLC, FTICR-MS and MS/MS. Finally, the 
feasibility of the above cryptophycin chemoenzymatic route will be tested with one 
unnatural substrate. In consistence with ATP-PPi exchange assay, AKGB was effectively 
loaded onto CrpD-M2 T domain, which was then reduced to 2-hydroxy species with the 
consumption of NAD(P)H (Table 2-1). Feeding of the UnitABC-NAC ester may initiate 
the formation of unnatural seco-cryptophycin. I expect that CrpD-M2 has the potential to 
generate novel cryptophycin analogs with altered physicochemical properties that may be 
beneficial to clinical application.   
 
   Previously, understanding of non-amino acid moieties incorporation into many 
bioactive nonribosomal peptides came from two separate systems. The biochemical 
studies of NRPS systems in bacillaene, cereulide, and valinomycin biosyntheses are the 
only examples so far to investigate 2-keto acid activation, loading, and reduction while 
the subsequent formation of ester bonds in natural product biosynthesis was indirectly 
deduced from studies of Fum14p consisted of T and C domains for fumonisin 
biosynthesis and of SgcC5, a standalone C domain for C-1027 biosynthesis 19, 21, 28, 29. 
Herein, one complete scheme will be presented by the characterization of CrpD-M2 in 
cryptophycin biosynthesis. CrpD-M2 may also have the potential to generate novel 
cryptophycin analogs with improved therapeutic index and reduced toxicity, as 




2.3.2. Analysis of the Cryptophycin P450 Epoxidase Reveals Substrate Tolerance 
and Cooperativity 
 
Overexpression of crpE in E. coli. The 1.4-kb crpE gene was identified at the 3’-end of 
cryptophycin biosynthetic gene cluster9 and cloned into the pSJ8 expression vector to 
produce CrpE tagged with maltose-binding protein (MBP) at its amino-terminus. The 
MBP-CrpE fusion protein, when co-expressed with select chaperones, resulted in 
significant levels of soluble protein that displayed the expected red-brown color.30 A 
protein of molecular weight ~57 kD (presumed to be GroEL) was co-purified with MBP-
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CrpE (Figure S2-4) and all attempts to separate this contaminant from the fusion protein 
by addition of ATP and urea31, 32 were unsuccessful (Figure S2-4). Thus, the studies 
described in this report were performed on the MBP-CrpE fusion protein in the presence 
of this bound polypeptide.  
 
Reconstruction of P450 MBP-CrpE Reaction System. CrpE was hypothesized to be an 
epoxidase based on bioinformatic analysis. Comparison of its sequence to four bacterial 
P450 epoxidases from secondary metabolic pathways (EpoK, PimD, MycG, and OleP) 
revealed that all share two conserved motifs (Figure S2-5).33-38 A Ser or Thr residue in 
motif-I is likely responsible for O2 binding and cleavage, and an invariant Cys residue in 
motif-II presumably serves as the fifth ligand for the heme iron. The presence of these 
conserved sequence motifs suggested that CrpE is a P450 enzyme. Subsequently, UV-
visible CO difference spectrum analysis of MBP-CrpE gave direct evidence for this 
conclusion (Figure S2-4). Although TEV protease digestion provided native CrpE, this 
protein lacked suitable stability (estimated half time of 2 hours) for biochemical studies, 
and therefore the studies reported in this paper utilized the MBP fusion protein.  
 
The native Nostoc sp. electron donor partners for CrpE are unknown. In our 
studies, spinach ferredoxin (Fer) and ferredoxin NADP+ reductase (FNR) were used to 
provide electrons for MBP-CrpE catalytic turnover (Figure 2-4). An NADPH 
regenerating system (e.g. glucose-6-phosphate and glucose-6-phosphate 
dehydrogenase33) had only a minor effect on MBP-CrpE activity. Thus, the reconstituted 
MBP-CrpE reaction included Fer, FNR, MBP-CrpE, NADPH, and O2. Maximal enzyme 
activity occurred in 50 mM sodium phosphate buffer, pH 6.4 at 25 °C.  
 
Analysis of MBP-CrpE Substrate Tolerance. Compounds used to assess the substrate 
specificity of MBP-CrpE (Cr-438, Cr-424, Cr-442, Cr-430, and Cr-537, see Figure 2-5) 
were synthesized chemoenzymatically (Figure S2-6) from the corresponding N-
acetylcysteamine (SNAC) seco-cryptophycin. The structure of each compound was 
confirmed by 1H NMR, 13C NMR and MS analysis. In the final step, CrpD TE was used 




Figure 2-4. Investigation of MBP-CrpE reaction system components. The standard 
enzyme reaction with Cr-3 as substrate contained MBP-CrpE, spinach ferredoxin (Fer), 
spinach ferredoxin NADP+ reductase (FNR), glucose-6-phosphate, and glucose-6-
phosphate dehydrogenase (G6PDH) in 100 μl of storage buffer, and was analyzed by 
HPLC-UV. Lane 1, standard Cr-3; lane 2, standard enzyme reaction; lane 3, standard 
reaction with CrpE replacing MBP-CrpE; lane 4, standard reaction omitting G6PDH; lane 
5, standard reaction with E. coli flavodoxin (Fld) and NADPH-flavodoxin reductase (Fpr) 
instead of Fer and FNR; lane 6, standard reaction with rat NADP+ P450 reductase instead 
of Fer and FNR; lane 7, standard reaction omitting Fer; lane 8 the standard reaction 
omitting FNR. Only Fer and FNR were accepted by MBP-CrpE to produce Cr-1 from Cr-
3. The presence of an NADPH regenerating system was not necessary for P450 activity. 
CrpE was capable of producing Cr-1 from Cr-3, although a decrease in overall production 
was observed. Thus, subsequent studies utilized MBP-CrpE as the enzyme source. 
 
and Cr-538, respectively. Two additional members in the library included SNAC-Unit A 
as a linear CrpE substrate, and Cr-B as a cyclic substrate (Figure 2-5). 
 
MBP-CrpE substrate selectivity was investigated with the above twelve-member 
library that was designed to probe the affect of structural variation in Unit B and Unit C 
on P450 catalysis and binding. None of the linear compounds were converted to product, 
while all cyclic cryptophycin analogs were epoxidized by MBP-CrpE (Figure 2-6). 
Products of Cr-1, Cr-2, and Cr-16 in the reactions gave m/z values of 655.3, 621.4, and 
641.3, respectively, consistent with their calculated molecular weights (Figure 2-6). Cr-
41, (the product of MBP-CrpE conversion of Cr-43) represents a new cryptophycin 
analog, not observed previously in nature. MBP-CrpE was also able to utilize unnatural 
cyclic cryptophycins as substrates to provide Cr-BE and Cr-539, respectively, as 





Figure 2-5. Chemical structure of several epoxy natural products and MBP-CrpE 
substrates. A: cryptophycin-1 (Cr-1) and other examples of natural products containing 
an epoxide moiety installed by P450s. B: six seco- and six cyclic cryptophycin substrates 
used in MBP-CrpE studies. The six observed reaction products are also shown. 
 
The stereochemistry and position of the β-epoxide in Cr-2 produced from Cr-4 
has been confirmed previously by 1H NMR analysis (Table S2-2).9 Additionally, the two 
unnatural substrates, Cr-B and Cr-538, were treated with mCPBA, a reagent known to 
provide non-selective epoxidization,39 in order to generate both the α- and β-epoxide 
stereoisomers, for comparison with the CrpE catalyzed reaction product (Figure S2-7). 
The β-epoxide products from mCPBA reactions had the same retention times as those 
from enzyme reactions in HPLC analysis, and thus confirming that in each case, CrpE 
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Figure 2-6. HPLC-UV and MS analyses of MBP-CrpE reactions with Cr-3, Cr-4, 
Cr-17, Cr-43, Cr-B, and Cr-538 as substrates. All substrates and products yielded the 
expected [M+H]+ values. The Blue squares and the red circles represent substrates and 
products, respectively. A single contaminant (labeled with dark star) was found in all 
reactions and is attributed to DMSO used to dissolve all substrates. 
 
 
Kinetic Analysis of MBP-CrpE with Different Substrates. Further studies of MBP-
CrpE were conducted to establish the kinetic parameters for epoxidation. In these 
experiments, all plots of v (pmol·min-1) vs [S] (µM) were linear with 100 µM as the 
highest substrate concentration. Thus, the expected Km values are much larger than final 
cyclic substrate concentrations ([S]) in the assays. In this study, the Michaelis-Menten 
equation was converted into v = kcat·[E]·[S]/Km giving slopes in the plots equal to 
kcat/Km·[E]. The data (Table 2-2) show that MBP-CrpE most efficiently epoxidized Cr-
538, whose kcat/Km value is 0.272 µM-1·min-1, while Cr-4 had the lowest kcat/Km value at 
0.029 µM-1·min-1. Among the group of natural substrates, Cr-3 was most efficiently 
epoxidized by CrpE, consistent with Cr-1 as the predominant cryptophycin isolated from 
Nostoc sp. ATCC 53789. Structural modifications at Unit B and Unit C revealed 
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significant affects on MBP-CrpE catalytic efficiency, although substrate solubility 
ultimately limited kinetic analysis. 
 
Table 2-2. Substrates, slopes, R, and kcat/Km values in kinetic analysis of MBP-CrpE 
Substrate Slope R kcat/Km
Cr-3 0.396 0.9999 0.099 
Cr-4 0.116 0.9981 0.029 
Cr-17 0.121 0.9965 0.031 
Cr-43 0.320 0.9973 0.080 
Cr-B 0.242 0.9999 0.061 
Cr-538 1.086 0.9956 0.272 
All experiments were performed in duplicate. The final MBP-CrpE concentration was 0.2 
µM in all experiment. The volume of all reaction here was 100 µl. The units of Slope and 
kcat/Km are pmol·µM-1·min-1 and µM-1·min-1, respectively. 
 
Binding Analysis of MBP-CrpE. The characteristics of MBP-CrpE were assessed 
further by analyzing spectral changes caused by substrate binding to the enzyme. Each 
cyclic depsipeptide substrate generated a type I binding spectrum with a peak at ~388 nm 
and a trough at ~422 nm (Figure 2-7). The initial plot of ΔA vs. S for most substrates 
could not be fit to the ΔA = ΔAmaxS/(Kd+S) equation. Instead, an equation ΔA = 
ΔAmaxSn/(Kdn+Sn) was used to generate sigmoidal curves. Here n is the Hill coefficient, a 
measure that normally indicates substrate cooperativity. By this equation, ΔAmax, Kd, and 
the n value of each cyclic substrate were generated (Table 2-3). All substrates had n 
values larger than 1, indicating cooperative binding to MBP-CrpE. Interestingly, the 
calculated Hill coefficient values varied according to specific structural modifications on 
cryptophycin Unit B and Unit C, suggesting the importance of these subunits in binding 
of substrates in the enzyme active site pocket. As shown in Eadie-Hofstee plots, all 
macrocyclic substrates except Cr-43 displayed cooperativity curves (Figure S2-8).  
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The Kd values of all CrpE substrates evaluated in this study were very similar. Cr-
17 had the tightest binding with the Kd value of 1.06 ± 0.03 µM, while Cr-3 had the 
highest Kd value of 1.72 ± 0.03 µM, indicating that the interaction between substrates and 




Figure 2-7. Spectral titration of 0.3 µM MBP-CrpE. Cr-3 (0.5-6 µM) (A), Cr-4 (0.5-5 
µM) (B), Cr-17 (0.5-5 µM) (C), Cr-43 (0.5-6 µM) (D), Cr-B (0.5-6 µM) (E), and Cr-538 
(0.35-3.5 µM)(F). The difference spectra resulting from different substrates are shown as 
insets (A to F). The direction of spectral shift upon substrate addition is shown (arrows). 
Absorbance changes were determined by subtracting A388 with A422 and were fitted to 
the equation ΔA = ΔAmaxSn/(Kdn+Sn).  
 
these substrates do not significantly affect substrate binding affinity. Maximal absorbance 
changes caused by different substrate binding varied from 0.0179 ± 0.0015 µM-1cm-1 of 
Cr-43 to 0.0744 ± 0.0047 µM-1cm-1 of Cr-538. Five seco-cryptophycin analogues and the 
linear SNAC-Unit A were also assessed in binding analysis (data not shown). Up to 
100µM of each linear substrate was added to the protein solution, but none induced a 
spectral change, indicating the importance of the cryptophycin macrocyclic core for 
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substrate binding to MBP-CrpE. As a control, GroEL was substituted in place of MBP-
CrpE (Figure S2-9), and when titrated with Cr-538, no meaningful spectral change was 
observed. 
 
Table 2-3. Binding analysis of MBP-CrpE with cyclic substrates 
Substrates ΔAmax Kd n 
 (µM-1·cm-1) (µM)  
Cr-3 0.0536 ± 0.0007 1.72 ± 0.03 2.37 ± 0.10 
Cr-4 0.0511 ± 0.0014 1.57 ± 0.07 1.66 ± 0.09 
Cr-17 0.0343 ± 0.0004 1.06 ± 0.03 2.20 ± 0.12 
Cr-43 0.0179 ± 0.0015 1.50 ± 0.27 1.11 ± 0.16 
Cr-B 0.0590 ± 0.0021 1.13 ± 0.07 1.56 ± 0.16 
Cr-538 0.0744 ± 0.0047 1.43 ± 0.14 1.53 ± 0.13 
All experiments were performed in triplicate. 
 
2.3.3. Characterization of Homotropic and Heterotropic Cooperativity in 
Cryptophycin Biosynthetic P450 Epoxidase 
 
Stoichiometry of Cr-3 binding to CrpE. In previous studies, CrpE showed homotropic 
cooperativity to five natural and unnatural cyclic cryptophycin analogs in spectral 
titration 40. The Hill coefficient (n) was greater than 2 for Cr-3 in previous assay, 
presumably indicating at least 3:1 of Cr-3 to CrpE. Although P450 x-ray studies might 
provide direct evidence to explain substrate cooperativity, the presence of co-purified 
contaminant, putative chaperone protein GroEL, with CrpE enzyme significantly 
hampered x-ray studies of this biosynthetic P450 but also triggered efforts to probe 
deeply into its cooperativity with other methods 41-46. Job’s titration was chosen for its 
unbiased measurement of ligand to protein molar ratio 47. Equal concentrations of Cr-3 
and CrpE enzyme were used in the assay and the data for Cr-3 binding were fit to 
produce a bell-shaped graph with its vertex at around 0.25 (Figure 2-8). The value of 
molar fraction (defined as [CrpE]/([CrpE] + [Cr-3])) literally indicated an approximate 
1:3 enzyme/substrate molar ratio. This result is consistent with the observation in our 
previous report and strongly supports CrpE substrate homotropic cooperativity 40. 
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Figure 2-8. Stoichiometry of Cr-3 binding to CrpE. The Job’s plot at a total protein 
and substrate concentration of 2 µM showed a peak with the mole fraction of about 0.25. 
This value indicated an approximate 3:1 ratio for the Cr-3 binding to CrpE. 
 
Protein Oligomerization upon Substrate Binding. To exclude the possibility of CrpE 
oligomerization, which might be reflected as substrate cooperativity in substrate titration 
assay, the concentrations of KCl were varied in the substrate binding analysis (Table 2-4). 
The binding cooperativity of Cr-4 substantially remained the same with up to 300 mM 
KCl, whose ionic intensity is unambiguously high enough to abolish most protein-protein 
interaction induced by ligand binding. Moreover, both ΔAmax and Kd values kept nearly 
unchanged in the presence of elevated ionic strength, possibly providing sights into non-
ionic interaction between Cr-4 and CrpE. Accordingly, this experiment further confirmed 
CrpE substrate cooperativity in another respect. 
 
Table 2-4. Salt effect on cryptophycin-4 binding to CrpE. 
 
KCl (mM) ΔAmax (µM-1·cm-1) Kd (µM) n 
0 0.0511 ± 0.0014 1.57 ± 0.07 1.66 ± 0.09 
50 0.0575 ± 0.0020 1.02 ± 0.01 1.60 ± 0.13 
100 0.0618 ± 0.0069 1.37 ± 0.26 1.39 ± 0.24 
200 0.0565 ± 0.0068 1.37 ± 0.29 1.36 ± 0.25 
300 0.0457 ± 0.0022 1.34 ± 0.11 1.46 ± 0.11 
All experiments were performed in duplicate. 
 
Fatty Acid Binding Studies. Linear fatty acids with different lengths have been used to 
measure the effective spaces in P450 active site pockets 34, 48. In this study, all four linear 
saturated fatty acids (C12 –C18) induced a “type I” binding spectrum (Figure S2-10, 
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Table 2-5). This type of spectral shift suggests the increasing of high-spin state of heme 
ion along with the elevated concentration of the fatty acids. The poor binding of stearic 
acid (C18) indicated that longer chain fatty acid can not displace the distal water ligand of 
CrpE heme in its substrate binding pocket to produce the high spin ferric state. This result 
essentially estimated the substrate binding cavity size in CrpE. Interestingly, P450 EpoK 
in epothilone biosynthesis also accepted linear fatty acids with length from C10 to C18 in 
its binding pocket, possibly suggesting the similar effective sizes in two biosynthetic 
P450s both accommodating 16-membered macrocyclic substrates 34. However, no 
cooperativity was observed in EpoK. 
 
Table 2-5. Binding of linear fatty acids to CrpE. 
 
 C12 C14 C16 C18 
ΔAmax (µM-1·cm-1) 0.061±0.002 0.067±0.002 0.077±0.002 - 
Kd (µM) 152±10 79±5 119±6 - 
All experiments were performed in duplicate. Symbol “-” represents that the constants 
were too big to be determined. 
 
Testosterone Binding to CrpE. Steroid testosterone is a positive cooperative substrate 
for human CYP3A4 and also bacterial P450EryF mutants 49, 50. The relative large binding 
pocket in CrpE estimated by fatty acid binding suggested that this biosynthetic P450 from 
cyanobacterium could accommodate this chemical. As shown in Figure 2-9A, a blue-
shift of Soret absorbance band was indeed observed in CrpE spectrum upon testosterone 
binding. The collected ΔA values generated by adding 0-900 µM testosterone were fitted 
to the Hill equation (Figure 2-9B). The binding affinity of testosterone to CrpE (Kd = 
548.4 ± 42.2 µM) was about two-fold and ten times lower than its affinities to P450EryF 
(Kd = 278 ± 35 µM) and CYP3A4 (Kd = 56 ± 3 µM), respectively. Furthermore, plot of 
ΔA vs [Testosterone] gave the ΔAmax value of 0.23 ± 0.02 µM-1 and a Hill coefficient 
number of 1.97 ± 0.13. Thus, testosterone is a positive cooperative ligand toward 
cyanobacterial biosynthetic P450 CrpE, making this enzyme the second bacterial P450 
featured with homotropic cooperativity toward steroid. Moreover, this result provided 
further sights into the substrate binding pocket size of this remarkable enzyme. 
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Figure 2-9. Spectral titration of 0.3 μM CrpE with 0-900 μM of testosterone. A: The 
difference spectra induced by different concentrations of testosterone. The direction of 
spectral shift upon substrate addition is shown (arrows). B: Plot of absorbance change vs 
ligand concentration. Absorbance changes were determined by subtracting A388 with A418 
and were fitted to the equation ΔA = ΔAmaxSn/(Kdn+Sn). 
 
Interestingly, no hydroxylated or epoxidized testosterones were produced in the CrpE 
reaction as determined by HPLC analysis, indicating substrate non-catalytic effective 
binding (Figure S2-11). 
 
Heterotropic Cooperativity in CrpE. The similar physical properties of cryptophycin 
analogs possibly indicate the same binding mode and position of substrate in CrpE. In 
this study, Cr-3 and Cr-538 were used as two competitive ligands in binding assays to 
validate this hypothesis. Indeed, the presence of 1 µM Cr-538 in the binding solution 
significantly reduced both ΔAmax and n values of Cr-3 (ΔAmax = 0.068 ± 0.005 µM-1·cm-1; 
n = 1.31 ± 0.16) (Figure 2-10, Table 2-6). Also, Cr-538 slightly changed Cr-3 binding 
affinity (Kd = 1.55 ± 0.22 µM). Similarly, 1 µM Cr-3 caused the same effects on Cr-538 
binding (ΔAmax = 0.058 ± 0.002 µM-1·cm-1; n = 1.47 ± 0.10; Kd = 1.13 ± 0.06 µM), which 
indicated the same site for CrpE to interact with two ligands. Although epothilone D 
doesn’t cooperatively bind to P450EryF, both homotropic and heterotropic cooperativites 
were observed in this bacterial P450 with foreign substrates and effectors including 
flavones and steroids 51. In this study, CrpE was also examined with testosterone for its 
effects on natural substrate binding. A series of testosterone (0, 50, 100, 300, and 500 µM) 
were included in the binding solution and both Cr-3 and Cr-538 were gradually added 
(Figure 2-10). Both ΔAmax and n values of Cr-3 and Cr-538 were decreased step-by-step 
with the elevated concentrations of testosterone in the solution, while their Kd values 
were mainly constant (Table 2-6). At 500 µM testosterone, ΔAmax values of Cr-3 and Cr-




Figure 2-10. Effect of testosterone on substrate binding to CrpE. A: Cr-3 (0-5.5 µM) 
induced absorbance changes in the presence of testosterone (0, 50, 100, 300, 500 µM) 
and 1 µM Cr-538. B: Cr-538 (0-6.0 µM) induced absorbance changes in the presence of 
testosterone (0, 50, 100, 300, 500 µM) and 1 µM Cr-3. The curves represent the results of 
fitting data sets to the Hill equation. 
 
Table 2-6. Testosterone effects on cryptophycin-3 and cryptophycin-538 binding to CrpE 
 
Testosterone Cr-3 Cr-538 
(µM) ΔAmax n Kd (µM) ΔAmax n Kd (µM) 
0 0.083±0.002 2.10±0.13 1.46±0.05 0.075±0.001 2.10±0.11 1.39±0.04 
50 0.063±0.002 1.89±0.17 1.11±0.06 0.065±0.001 2.00±0.14 1.25±0.05 
100 0.059±0.002 1.72±0.13 1.33±0.07 0.060±0.002 1.80±0.18 1.22±0.07 
300 0.050±0.002 1.64±0.18 0.98 ±0.06 0.046±0.002 1.46±0.12 1.21 ±0.08 
500 0.050±0.003 1.26±0.15 1.24±0.16 0.040±0.004 1.21±0.23 1.31±0.26 
All experiments were performed in duplicate. 
 
these values of Cr-3 and Cr-538 were 0.083 ± 0.002 µM-1·cm-1 and 0.075 ± 0.001 µM-
1·cm-1, respectively, in the absence of testosterone. Similarly, the Hill coefficient values 
of Cr-3 and Cr-538 were decreased from 2.10 ± 0.13 and 2.10 ± 0.11 in the absence of 
testosterone to 1.26 ± 0.15 and 1.21 ± 0.23 with 500 µM testosterone, respectively. Thus, 
the hetereotropic cooperativity in CrpE was revealed with steroid testosterone and natural 
cryptophycin substrates, representing the first example in any bacterial biosynthetic P450 
with its natural substrate as one of ligands. 
 
Testosterone Effects on CrpE Catalysis. Many chemicals including drugs on the 
market may alter human P450 catalytic activities by acting as activators or inhibitors 52.  
Previously, P450eryF A245F was the only bacterial P450 investigated with various 
effectors including testosterone, which also served as its substrate 51. In this study, 
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testosterone was also examined for its effects on CrpE kinetic parameter. From Table 2-7, 
it was shown that the increased concentrations of testosterone triggered significant 
enhancement of CrpE catalytic efficiency to epoxidize both Cr-3 and Cr-538. In the 
presence of 500 µM testosterone, the kcat/Km values of CrpE toward Cr-3 and Cr-538 
 
Table 2-7. Testosterone effects on epoxidizing Cr-3 and Cr-538 by CrpE 
 
Testosterone Cr-3 Cr-538 
(µM) Slope kcat/Km Slope kcat/Km
0 0.105 0.525 0.538 2.690 
50 0.276 1.380 0.671 3.355 
100 0.435 2.175 0.833 4.165 
300 0.698 3.490 1.523 7.615 
500 0.876 4.380 1.657 8.285 
All experiments were performed in duplicate. The final CrpE concentration was 0.2 μM 
in all experiment. The volume of all reactions was 100 μl. The units of Slope and kcat/Km 
are pmol·μM-1·min-1 and pmol·min-1, respectively. 
 
were 4.380 pmol·min-1 and 8.285 pmol·min-1, respectively, which were enhanced 
respectively by 8.3 and 3.1 times compared with those in the absence of steroid. 
Subsequently, testosterone effect on overall epoxidation conversion of Cr-538 by CrpE 
was explored. The amount of Cr-539 in the reactions was increased along with 
testosterone elevated concentration (Figure 2-11). In the presence of 900 µM 
testosterone, Cr-539 concentration was increased about 6.9 times in CrpE reaction 
compared to its productivity in the enzyme reaction lack of testosterone, suggesting  
 
Figure 2-11. Testosterone effect on the overall epoxidation of Cr-538 by CrpE. The 
amount of Cr-539 was increased with the elevated concentration of testosterone (0, 50, 
100, 300, 500, 700, 900 µM). 
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testosterone potential application in efficiently generating anticaner cryptophycin analogs. 
Interestingly, testosterone did not have any significant effect on reactions of two other 
bacterial P450s, PikC in pikromycin biosynthesis and MycG in mycinamicin production 
(Figure S2-12) 53, 54. In these two P450 reactions, product levels had no considerable 
changes regardless of the presence of 500 µM testosterone. Spectral titration analysis 
revealed that up to 750 µM testosterone didn’t induce any type I spectral shifts in both 
PikC and MycG solution (data not shown). This result possibly indicated bacterial P450 
activity enhancement induced by testosterone might be stemmed from its specific type I 
binding to CrpE. 
 
2.4. Materials and Methods 
 
General Chemicals, DNA Sub-cloning, and Bacterial Strains. Molecular biology 
reagents and enzymes were supplied by New England Biolabs with the exception of for 
Pfu DNA polymerase (Stratagene), dNTPs (Takara), T4 DNA Ligase (Invitrogen).  
Chemicals were purchased from Sigma-Aldrich, Fisher Scientific and BaChem. 
Escherichia coli XL-1 Blue (Stratagene) was used for cloning and plasmid harvesting 
while E. coli BL21 (DE3) (Invitrogen) was used for protein overexpression. All E. coli 
strains were grown in Luria-Bertani broth. Preparation and manipulation of plasmid DNA 
from E. coli was accomplished following manufacture protocols from Qiagen. DNA 
sequencing was performed at the University of Michigan DNA Sequencing Core. A 
Beckman Coulter HPLC, fitted with an XBridge C18 column (5µm, 4.6 x 250 mm), 
coupled with a System Gold I68 Detector was used for HPLC-UV analysis. A 
SHIMADZU LCMS-2010EV system was used for LC-MS analysis in the studies. 
 
Heterologous Overexpression and Purification of Proteins. A). CrpD-M2 The crpD-
M2 gene was amplified by PCR using cosmid pDHS500 as template. A typical 50 μl 
reaction mixture contained 5 ng pDHS500, 2 μM forward primer (5’- CAA GGA TCC 
TTA CGT ACT ACT AAT AGC GCA-3’) and 2 μM reverse primer (5’- ATG CTC GAG 
TAG TTG TTG AAT TGG TAC TAA TGG-3’) (BamHI and XhoI sites are underlined), 
200 μM dNTP, 5 μl 10 X PCR buffer. Conditions for crpD-M2 amplifications included 
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an initial 5 min. denaturation step (94°C) and cycling conditions of 94°C (30 sec), 55°C 
(30 sec) and 72°C (7 min 45 sec) for 30 cycles followed by a final 72°C extension step 
(10 min). The amplicon was purified and digested with corresponding enzymes to clone 
into pET28a.  The construct was then transformed into E. coli BAP1 competent cell for 
protein overexpression, which was induced with 0.1 mM IPTG at 15 °C with constant 
shaking (200 rpm) for 16 hours. The cells were pelleted by centrifugation and 
resuspended in 20 mL/L cell pellet of lysis buffer (200 mM NaCl, 50 mM Tris-Cl, pH 7.5, 
3 mM β-mercaptoethanol, 10 % glycerol, and 20 mM immidazole). The cell suspension 
was sonicated and the lysate collected following centrifugation (36,000 x g for 32 min). 
The resulting supernatant was collected, incubated with pre-equilibrated Ni-NTA resin at 
4 °C for 2 hours with agitation. The resin was washed (40 column volumes of lysis buffer 
and lysis buffer with 30 mM immidazole) and CrpD-M2 was eluted with lysis buffer 
containing 200 mM immidazole. The protein was desalted with a PD-10 column and its 
purity was assessed with 4-12 % SDS-PAGE. The concentration of the purified protein 
was determined by its predicted extinction coefficient (259000 M-1 cm-1 at 280 nm).  
 B). MBP-CrpE. The crpE CrpE gene was amplified by PCR using cosmid pDHS500 as 
template. A typical 50 μl reaction mixture contained 5 ng pDHS500, 2 μM forward 
primer (5’-TGC GGA TCC ATG ATT AAT ACT GCT AAA TCC-3’) and 2 μM reverse 
primer (5’- ACG CGA ATT CTT ACA ATA CAA CCA TTT TTA ATC C-3’) (BamHI 
and EcoRI sites are underlined), 200 μM dNTP, 5 μl 10 X PCR buffer. Conditions for 
crpE amplifications included an initial 5 min. denaturation step (94°C) and cycling 
conditions of 94°C (30 sec), 58.5°C (30 sec) and 72°C (1 min 45 sec) for 35 cycles 
followed by a final 72°C extension step (7 min). The crpE amplicon was phosphorylated 
using T4 Kinase and ligated into pSMart-HCKan to produce pDing1.  The insert within 
pDing1 was sequenced and shown to be free of PCR error. Insert in pDing1 was digested 
with BamHI and EcoRI and ligated into linear pSJ8 (EcoRI/BamHI cut). The resulting 
plasmid, pDing2, and chaperone expressing plasmid pGRO7 were used to co-transform E. 
coli BL21(DE3). Transformants were selected by ampcilin (amp) (50 μg /ml) and 
chloramphenicol (cml) (25 μg /ml). A 5 mL overnight culture was diluted in 1 L LB 
supplemented with amp (50 μg /ml), cml (25 μg /ml), 0.25 mM Fe(NH4)2(SO4)2, 1 mM 
thiamine, and 0.25 mM of 5-aminolevulinic acid that was added 30 minutes prior to 
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induction (OD600 ~ 0.6). The culture was then induced with 0.1 mM IPTG and 1 g /L L-
arabinose. The culture was grown at 15 °C with constant shaking (200 rpm) for 20 hours. 
The cells were pelleted by centrifugation and resuspended in 80 mL of PBS buffer (140 
mM NaCl, 2.7 mM potassium chloride, 10 mM sodium hydrogen phosphate, and 1.8 mM 
potassium dihydrogen phosphate, pH 7.4, 3 mM β-mercaptoethanol, 10 % glycerol). The 
cell suspension was sonicated and the lysate collected following centrifugation (40,000 x 
g for 45 min). The resulting supernatant was collected, incubated with pre-equilibrated 
amylase agarose resin at 4 °C for three hours with agitation. The amylase agarose resin 
was washed (100 column volumes of lysis buffer) and MBP-His-CrpE eluted with lysis 
buffer containing 8 mM maltose. Maltose was removed from the protein sample with a 
PD-10 column, and the MBP-His-CrpE fusion protein was then treated with His-TEV 
protease at 4 °C overnight to remove the MBP-His portion. The CrpE protein was 
separated from the MBP-His polypeptide and His-TEV by passing the mixture through a 
Ni-agarose column. The concentration of the purified protein was determined by its 
predicted extinction coefficient (81820 M-1 cm-1 at 280 nm). The active CrpE 
concentration was determined using previously described methods55. 
 
Identification of CrpD-M2 and Determination of Phosphopantetheinylation. Full 
length expression of CrpDm2 was determined by peptide map finger printing.  Briefly, 
CrpDm2 was reduced and digested with trypsin (Pierce TPCK modified). The sample 
was desalted with Handee Microspin columns (Pierce) packed with 20 μl of 300 Å 
polymeric C4 resin (Vydac). Samples were loaded onto the columns and washed with 30 
column volumes of 0.1% formic acid prior to elution with 10 column volumes of 50% 
acetonitrile plus 0.1% formic acid.  Peptides were then introduced into the FTICRMS at 
70ul/hour with direct infusion. Peaks were identified with the thrash algorithm as 
implemented in MIDAS data analysis workstation (National High Magnetic Field 
Laboratory). Peaks were matched against a theoretical digest of CrpDm2 (Protein 
Prospector) with a tolerance of +/-20ppm for the uncelebrated mass spectrum. Due to the 
extremely large size of the protein (221 kDa) the bottom-up approach was identified as 
more convenient.  Note that low sequence is not surprising due to lack of LC separation, 
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however, sequence coverage is obtained from residue 3-1,922 out of 1,964 suggesting 
that the purified protein is full-length. 
 
Determination of CrpD-M2 active site loading. The CrpD-M2 T domain active site 
peptide (QLVEIFQEVLNLPSIGIHDNFFSLGGHSLLAVR) was then loaded with the 
substrates: L-2HIC, D-2HIC, AKGB, and 2KIC. Peaks were initially identified through 
LC FITCR-MS using accurate mass. For online confirmation of peak identity the same 
LC gradient (described below) was run using a Thermo LTQ linear ion trap (LIT) MS.  
Product peaks were subjected to MS2 and MS3 for further confirmation. Notably, the 
phosphopantetheine ejection assay performed well on the low resolution instrument, as 
previously described 56. The KR reduction reaction was monitored with the same 
procedure. 
 
ATP-[32P]PPi Exchange Assays for Aminoacyl-AMP Formation. To determine 
substrate specificity of CrpD-M2 A domains, ATP-[32P]PPi reactions (100 μL) containing 
Tris-HCl (pH 7.5) (75 mM), MgCl2 (10 mM), TCEP (5 mM), ATP (5 mM), NaPPi (1 
mM), α-amino acid, 2-keto acids, 2-hydroxy acid substrates (5 mM), [32P]PPi (2 Ci/mM) 
to give at least 400,000 cpm, and 1 µM CrpD-M2 were performed at room temperature. 
Reactions were initiated by addition of protein. At 5 min, the reactions were quenched 
into 500 μL of 100 mM NaPPi, 5 % perchloric acid (70 %), and 1.6 % activated charcoal. 
The charcoal was collected by centrifugation, washed twice with 500 μL of 100 mM 
NaPPi and 5% (v/v) perchloric acid, then resuspended in 500 μL of water, added to 
scintillation fluid, and counted by a Beckman Coulter LS 6500 liquid scintillation counter. 
 
Chemical Synthesis and Characterization: 
(S)-S-2-Acetamidoethyl-2-(tert-butoxycarbonyloxy)-4-methylpentanethioate (2). To a 
stirring solution of Boc-protected (S)-leucic acid (1) (295 mg, 1.27 mmol) in CH2Cl2 (8 
mL) was added EDC (268 mg, 1.40 mmol), DMAP (16 mg, 0.13 mmol) and N-
acetylcysteamine (149 μL, 1.40 mmol). The reaction was stirred for 18 h at room 
temperature then washed with water, dried with Na2SO4, filtered and concentrated in-
vacuo. Flash chromatography (2% MeOH/CH2Cl2) afforded the title compound 2 (387 
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mg, 91%) as a colorless oil. TLC Rf = 0.32 (5% MeOH/CH2Cl2, vanillin stain); 1H NMR 
(CDCl3, 400 MHz) δ 5.98 (br t, 1H), 4.99 (dd, J = 9.9, 3.8, 1H), 3.30–3.49 (m, 2H), 2.97–
3.10 (m, 2H), 1.93 (s, 3H), 1.69–1.82 (m, 2H), 1.53–1.61 (m, 1H), 1.48 (s, 9H), 0.92 (d, J 
= 6.6, 3H), 0.91 (d, J = 6.6, 3H); 13C NMR (CDCl3, 101 MHz) δ 200.4, 170.5, 152.9, 
83.6, 79.8, 40.8, 39.4, 27.8, 27.8, 24.5, 23.2, 23.1, 21.5; MS (ESI+) m/z 334.0 [M + H]+ 
(C15H28NO5S requires 334.2). 
 (R)-((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-(tert-
butoxycarbonyl-amino)-2-methylpropanoate (4a). Compound 2 (387 mg, 1.16 mmol) 
was treated with anhydrous 4 M HCl in dioxane (5 mL) at room temperature for 40 min 
then the reaction was concentrated in-vacuo. The residue was dissolved in CH2Cl2 (20 
mL) and (R)-3-tert-butyloxycarbonylamino-2-methylpropanoic acid (3a) (236 mg, 1.16 
mmol), EDC (222 mg, 1.16 mmol) and DMAP (14 mg, 0.12 mmol) was added. The 
reaction was stirred for 18 h at room temperature then washed with water, dried with 
Na2SO4, filtered and concentrated in-vacuo. Flash chromatography (2% MeOH/CH2Cl2) 
afforded the title compound 4a (285 mg, 59%) as a light yellow solid. TLC Rf = 0.23 (5% 
MeOH/CH2Cl2, KMnO4 stain); 1H-NMR (CDCl3, 500 MHz) δ 5.83 (br t, 1H), 5.22–5.25 
(m, 1H), 5.00 (br t, 1H), 3.35–3.44 (m, 3H), 3.23–3.29 (m, 1H), 3.05 (t, J = 6.3, 2H), 
2.75–2.83 (m, 1H), 1.96 (s, 3H), 1.61–1.80 (m, 3H), 1.43 (s, 9H), 1.25 (d, J = 7.2, 3H), 
0.95 (d, J = 6.4, 3H), 0.93 (d, J = 6.4, 3H); MS (ESI+) m/z 441.2 [M + Na]+ 
(C19H34N2NaO6S requires 441.2). 
((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-(tert-butoxycarbonyl-
amino)-propanoate (4b). Compound 2 (170 mg, 0.51 mmol) was treated with anhydrous 
4 M HCl in dioxane (5 mL) at room temperature for 30 min then the reaction was 
concentrated in-vacuo. The residue was dissolved in CH2Cl2 (8 mL) and Boc-β-Ala-OH 
(3b) (104 mg, 0.55 mmol), EDC (105 mg, 0.55 mmol) and DMAP (7 mg, 0.06 mmol) 
was added. The reaction was stirred for 18 h at room temperature then washed with water, 
dried with Na2SO4, filtered and concentrated in-vacuo. Flash chromatography (10% 
MeOH/CH2Cl2) afforded the title compound 4b (163 mg, 78%) as a colorless oil. TLC Rf 
= 0.20 (5% MeOH/CH2Cl2, PMA stain); 1H-NMR (CDCl3, 400 MHz) δ 5.96 (br t, 1H), 
5.21–5.24 (m, 1H), 5.09 (br t, 1H), 3.37–3.46 (m, 4H), 2.97–3.08 (m, 2H), 2.56–2.70 (m, 
2H), 1.95 (s, 3H), 1.57–1.78 (m, 3H), 1.42 (s, 9H), 0.93 (d, J = 6.4, 3H), 0.91 (d, J = 6.5, 
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3H); 13C NMR (CDCl3, 101 MHz) δ 199.7, 171.9, 170.6, 155.9, 77.7, 40.9, 40.8, 39.4, 
36.3, 34.7, 28.5, 28.1, 27.9, 24.7, 23.1, 21.7; MS (ESI+) m/z 427.2 [M + Na]+ 
(C18H32N2NaO6S requires 427.2). 
 (R)-((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-(tert-butoxy–
carbonylamino)-3-(3-chloro-4-methoxyphenyl)propanamido)-2-methylpropanoate 
(6a).  Compound 4a (46 mg, 0.11 mmol) was treated with anhydrous 4 M HCl in dioxane 
(2 mL) at room temperature for 30 min then the reaction was concentrated in-vacuo. The 
residue was dissolved in CH2Cl2 (5 mL) and Boc-3-Cl-D-Tyr(Me)-OH (5a) (40 mg, 0.12 
mmol), TBTU (39 mg, 0.12 mmol) and DIEA (63 μL, 0.36 mmol) was added. The 
reaction was stirred for 3 h at room temperature then washed with water, dried with 
Na2SO4, filtered and concentrated in-vacuo. Flash chromatography (3% MeOH/CH2Cl2) 
afforded the title compound 6a (67 mg, 96%) as a colorless oil. TLC Rf = 0.14 (5% 
MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3,  400 MHz) δ 7.24 (br s, 1H), 7.04–7.08 
(m, 2H), 6.83 (d, J = 8.4, 1H), 6.56 (br t, 1H), 5.33 (d, J = 7.6, 1H), 5.23–5.27 (m, 1H), 
4.37 (dt, J = 8.2, 7.0, 1H), 3.86 (s, 3H), 3.63–3.70 (m, 1H), 3.45–3.52 (m, 1H), 2.98–3.22 
(m, 5H), 2.91 (dd, J = 13.8, 7.3, 1H), 2.75–2.81 (m, 1H), 1.94 (s, 3H), 1.63–1.82 (m, 3H), 
1.37 (s, 9H), 1.19 (d, J = 6.8, 3H), 0.96 (d, J = 6.3, 3H), 0.92 (d, J = 6.3, 3H); MS (ESI+) 
m/z 652.0 [M + Na]+ (C29H44ClN3NaO8S requires 652.2). 
 (R)-((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-(tert-butoxy–
carbonylamino)-3-(3-chloro-4-hydroxyphenyl)propanamido)-2-methylpropanoate 
(6b).  Compound 4a (42 mg, 0.10 mmol) was treated with anhydrous 4 M HCl in dioxane 
(2 mL) at room temperature for 30 min then the reaction was concentrated in-vacuo. The 
residue was dissolved in CH2Cl2 (5 mL) and Boc-3-Cl-D-Tyr-OH (5b) (35 mg, 0.11 
mmol), TBTU (35 mg, 0.11 mmol) and DIEA (57 μL, 0.33 mmol) was added. The 
reaction was stirred for 3 h at room temperature then washed with water, dried with 
Na2SO4, filtered and concentrated in-vacuo. Flash chromatography (4% MeOH/CH2Cl2) 
afforded the title compound 6b (30 mg, 49%) as a colorless oil. TLC Rf = 0.64 (10% 
MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3, 400 MHz) δ 7.18 (s, 1H), 7.00 (d, J = 8.0, 
1H), 6.93 (br s, 1H), 6.91 (d, J = 8.4, 1H), 6.55 (br t, 1H), 5.32 (d, J = 7.8, 1H), 5.25 (dd, 
J = 10.0, 3.1, 1H), 4.34 (dt, J = 8.2, 7.0, 1H), 3.62–3.68 (m, 1H), 3.44–3.52 (m, 1H), 
2.90–3.26 (m, 6H), 2.72–2.79 (m, 1H), 1.95 (s, 3H), 1.62–1.79 (m, 3H), 1.38 (s, 9H), 
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1.18 (d, J = 7.0, 3H), 0.95 (d, J = 6.1, 3H), 0.92 (d, J = 6.3, 3H); MS (ESI+) m/z 638.0 
[M + Na]+ (C28H42ClN3NaO8S requires 638.2). 
(R)-((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-(tert-butoxy–
carbonylamino)-3-(4-methoxyphenyl)propanamido)-2-methylpropanoate (6c). 
Compound 4a (45 mg, 0.11 mmol) was treated with anhydrous 4 M HCl in dioxane (2 
mL) at room temperature for 20 min then the reaction was concentrated in-vacuo. The 
residue was dissolved in CH2Cl2 (5 mL) and Boc-D-Tyr(Me)-OH (5c) (35 mg, 0.12 
mmol), TBTU (39 mg, 0.12 mmol) and DIEA (63 μL, 0.36 mmol) was added. The 
reaction was stirred for 2 h at room temperature then washed with water, dried with 
Na2SO4, filtered and concentrated in-vacuo. Flash chromatography (3% MeOH/CH2Cl2) 
afforded the title compound 6c (58 mg, 90%) as a white solid. TLC Rf = 0.32 (5% 
MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3, 500 MHz) δ 7.07–7.12 (m, 2H), 6.78–
6.84 (m, 3H), 6.52 (br t, 1H), 5.20–5.26 (m, 2H), 4.32–4.38 (m, 1H), 3.77 (s, 3H), 3.58–
3.64 (m, 1H), 3.42–3.49 (m, 1H), 3.16–3.28 (m, 2H), 2.92–3.10 (m, 4H), 2.71–2.78 (m, 
1H), 1.94 (s, 3H), 1.62–1.78 (m, 3H), 1.37 (s, 9H), 1.18 (d, J = 6.6, 3H), 0.95 (d, J = 6.2, 
3H), 0.92 (d, J = 6.5, 3H); 13C NMR (CDCl3, 125 MHz) δ 200.4, 173.7, 171.5, 170.9, 
158.7, 155.4, 130.5, 128.9, 114.1, 80.1, 56.1, 55.4, 40.8, 40.4, 39.3, 39.2, 38.8, 29.8, 28.4, 




Compound 4a (40 mg, 0.10 mmol) was treated with anhydrous 4 M HCl in dioxane (2 
mL) at room temperature for 30 min then the reaction was concentrated in-vacuo. The 
residue was dissolved in CH2Cl2 (5 mL) and Boc-D-Tyr-OH (5d) (31 mg, 0.11 mmol), 
TBTU (35 mg, 0.11 mmol) and DIEA (57 μL, 0.33 mmol) was added. The reaction was 
stirred for 2 h at room temperature then washed with water, dried with Na2SO4, filtered 
and concentrated in-vacuo. Flash chromatography (3% MeOH/CH2Cl2) afforded the title 
compound 6d (51 mg, 92%) as a white solid. TLC Rf = 0.21 (5% MeOH/CH2Cl2, PMA 
stain); 1H NMR (CDCl3, 500 MHz) δ 7.62 (br s, 1H), 7.01–7.04 (m, 2H), 6.76 (d, J = 8.4, 
2H), 6.63 (br s, 1H), 6.50 (br s, 1H), 5.22–5.27 (m, 2H), 4.27–4.32 (m, 1H), 3.53–3.60 (m, 
1H), 3.41–3.47 (m, 1H), 3.19–3.32 (m, 2H), 2.85–3.07 (m, 4H), 2.67–2.74 (m, 1H), 1.96 
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(s, 3H), 1.57–1.77 (m, 3H), 1.39 (s, 9H), 1.16 (d, J = 6.6, 3H), 0.93 (d, J = 6.3, 3H), 0.90 
(d, J = 6.2, 3H); 13C NMR (CDCl3, 125 MHz) δ 200.3, 173.8, 171.7, 171.5, 155.8, 155.4, 
130.5, 127.9, 115.7, 80.1, 56.4, 41.7, 40.8, 40.4, 39.4, 38.8, 29.8, 28.4, 28.1, 24.8, 23.2, 
23.2, 21.6, 14.7; MS (ESI+) m/z 604.1 [M + Na]+ (C28H43N3NaO8S requires 604.3). 
 ((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-(tert-butoxy–
carbonylamino)-3-(3-chloro-4-methoxyphenyl)propanamido)-propanoate (6e).  
Compound 4b (160 mg, 0.40 mmol) was treated with anhydrous 4 M HCl in dioxane (5 
mL) at room temperature for 30 min then the reaction was concentrated in-vacuo. The 
residue was dissolved in CH2Cl2 (8 mL) and Boc-3-Cl-D-Tyr(Me)-OH (5a) (148 mg, 0.45 
mmol), TBTU (144 mg, 0.45 mmol) and DIEA (226 μL, 1.30 mmol) was added. The 
reaction was stirred for 90 min at room temperature then washed with water, dried with 
Na2SO4, filtered and concentrated in-vacuo. Flash chromatography (7% MeOH/CH2Cl2) 
afforded the title compound 6e (235 mg, 95%) as a white foam. TLC Rf = 0.67 (10% 
MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3,  400 MHz) δ 7.26 (d, J = 1.9, 1H), 6.98–
7.06 (m, 2H), 6.82 (d, J = 8.4, 1H), 6.43 (br t, 1H), 5.30 (d, J = 7.6, 1H), 5.21–5.23 (m, 
1H), 4.33–4.37 (m, 1H), 3.85 (s, 3H), 3.48–3.56 (m, 3H), 3.22–3.27 (m, 1H), 2.95–3.12 
(m, 4H), 2.58 (d, J = 6.8, 2H), 1.94 (s, 3H), 1.58–1.77 (m, 3H), 1.36 (s, 9H), 0.93 (d, J = 
6.3, 3H), 0.90 (d, J = 6.3, 3H); 13C NMR (CDCl3, 101 MHz) δ 200.4, 171.3, 171.2, 171.0, 
155.4, 154.0, 131.2, 130.2, 128.7, 122.3, 112.1, 77.7, 56.2, 55.8, 40.7, 39.1, 38.1, 35.0, 
34.3, 28.4, 28.3, 28.2, 24.7, 23.2, 23.1, 21.5; MS (ESI+) m/z 638.2 [M + Na]+ 
(C28H42ClN3NaO8S requires 638.2). 
 (R)-((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-phenylocta-2,7-dienamido)-3-(3-chloro-4-
methoxyphenyl)propan-amido)-2-methylpropanoate (Cr-438). Compound 6a (67 mg, 
0.11 mmol) and the tert-butyl ester of unit A (7) (32 mg, 0.11 mmol) were stirred in 
CH2Cl2 (4 mL) and TFA (1 mL) for 1 h at room temperature. The solvents were 
evaporated in-vacuo and residual TFA was removed by co-evaporation with toluene. The 
residue was dissolved in CH2Cl2 (5 mL) and TBTU (35 mg, 0.11 mmol) and DIEA (57 
μL, 0.33 mmol) was added. The reaction was stirred for 2 h at room temperature then 
washed with water, dried with Na2SO4, filtered and concentrated in-vacuo. Flash-
chromatography (3% MeOH/CH2Cl2) afforded the title compound Cr-438 (52 mg, 65%) 
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as a white foam. TLC Rf = 0.57 (10% MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3, 400 
MHz) δ 7.36 (d, J = 7.4, 2H), 7.30 (t, J = 7.6, 2H), 7.19–7.25 (m, 2H), 7.05–7.07 (m, 2H), 
6.95 (br t, 1H), 6.79–6.83 (m, 2H), 6.59 (d, J = 8.0, 1H), 6.44 (d, J = 16.0, 1H), 6.15 (dd, 
J = 16.0, 8.5, 1H), 5.91 (d, J = 15.4, 1H), 5.22 (dd, J = 9.9, 3.4, 1H), 4.79 (dt, J = 7.6, 7.1, 
1H), 3.85 (s, 3H), 3.60–3.67 (m, 2H), 3.44–3.53 (m, 1H), 3.12–3.26 (m, 2H), 3.09 (t, J = 
6.6, 2H), 2.97–3.02 (m, 2H), 2.72–2.78 (m, 1H), 2.26–2.45 (m, 3H), 2.12 (br s, 1H), 1.96 
(s, 3H), 1.59–1.77 (m, 3H), 1.15 (d, J = 6.6, 3H), 1.13 (d, J = 6.3, 3H), 0.94 (d, J = 6.1, 
3H), 0.90 (d, J = 6.1, 3H); 13C NMR (CDCl3, 101 MHz) δ 200.6, 173.5, 171.2, 171.0, 
165.6, 154.0, 142.3, 137.2, 131.8, 131.3, 131.2, 130.0, 128.7, 128.7, 127.5, 126.3, 125.6, 
122.3, 112.2, 77.6, 73.9, 56.2, 54.6, 43.4, 42.0, 40.7, 40.5, 39.2, 37.9, 37.5, 28.3, 24.9, 




hydroxyphenyl)propan-amido)-2-methylpropanoate (Cr-441). Compound 6b (48 mg, 
0.08 mmol) and the tert-butyl ester of unit A (7) (24 mg, 0.08 mmol) were stirred in 
CH2Cl2 (4 mL) and TFA (1 mL) for 1 h at room temperature. The solvents were 
evaporated in-vacuo and residual TFA was removed by co-evaporation with toluene. The 
residue was dissolved in CH2Cl2 (5 mL) and TBTU (25 mg, 0.08 mmol) and DIEA (41 
μL, 0.23 mmol) was added. The reaction was stirred for 2 h at room temperature then 
washed with water, dried with Na2SO4, filtered and concentrated in-vacuo. Flash-
chromatography (3%, 5% MeOH/CH2Cl2) afforded the title compound Cr-441 (26 mg, 
45%) as a white solid. TLC Rf = 0.59 (10% MeOH/CH2Cl2, PMA stain); 1H NMR 
(CDCl3, 400 MHz) δ 7.36 (d, J = 7.4, 2H), 7.30 (t, J = 7.5, 2H), 7.18–7.23 (m, 2H), 6.97–
7.03 (m, 2H), 6.80–6.92 (m, 3H), 6.64 (br s, 1H), 6.44 (d, J = 15.8, 1H), 6.15 (dd, J = 
15.8, 8.5, 1H), 5.91 (d, J = 15.4, 1H), 5.22 (dd, J = 9.9, 3.4, 1H), 4.76 (dt, J = 8.0, 6.9, 
1H), 3.56–3.66 (m, 2H), 3.43–3.50 (m, 1H), 3.18–3.28 (m, 2H), 3.07 (t, J = 6.7, 2H), 2.97 
(d, J = 6.8, 2H), 2.70–2.77 (m, 1H), 2.26–2.45 (m, 4H), 1.96 (s, 3H), 1.60–1.77 (m, 3H), 
1.14 (d, J = 7.2, 3H), 1.13 (d, J = 6.6, 3H), 0.94 (d, J = 6.0, 3H), 0.90 (d, J = 6.1, 3H); 13C 
NMR (CDCl3, 101 MHz) δ 200.6, 173.6, 171.5, 171.1, 165.6, 150.9, 142.5, 137.2, 131.8, 
131.3, 130.2, 129.7, 129.2, 128.7, 127.5, 126.3, 125.6, 120.1, 116.6, 77.6, 73.9, 54.8, 43.5, 
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41.9, 40.7, 40.4, 39.3, 38.1, 37.4, 28.2, 24.9, 23.2, 23.1, 21.6, 17.0, 14.6; MS (ESI+) m/z 
744.0 [M + H]+ (C38H51ClN3O8S requires 744.3). 
 (R)-((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-phenylocta-2,7-dienamido)-3-(4-
methoxyphenyl)propanamido)-2-methylpropanoate (Cr-424). Compound 6c (58 mg, 
0.10 mmol) and the tert-butyl ester of unit A (7) (29 mg, 0.10 mmol) were stirred in 
CH2Cl2 (4 mL) and TFA (1 mL) for 1 h at room temperature. The solvents were 
evaporated in-vacuo and residual TFA was removed by co-evaporation with toluene. The 
residue was dissolved in CH2Cl2 (5 mL) and TBTU (32 mg, 0.10 mmol) and DIEA (52 
μL, 0.30 mmol) was added. The reaction was stirred for 2 h at room temperature then 
washed with water, dried with Na2SO4, filtered and concentrated in-vacuo. Flash-
chromatography (3% MeOH/CH2Cl2) afforded the title compound Cr-424 (46 mg, 66%) 
as colorless oil. TLC Rf = 0.23 (5% MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3, 500 
MHz) δ 7.36 (d, J = 7.4, 2H), 7.30 (t, J = 7.4, 2H), 7.21 (t, J = 6.9, 1H), 7.11 (d, J = 8.3, 
2H), 6.96 (br t, 1H), 6.90–6.95 (m, 1H), 6.80–6.85 (m, 1H), 6.79 (d, J = 8.1, 2H), 6.48 (br 
t, 1H), 6.44 (d, J = 16.0, 1H), 6.15 (dd, J = 16.0, 8.6, 1H), 5.90 (d, J = 15.2, 1H), 5.20–
5.23 (m, 1H), 4.76 (app q, J = 7.4, 1H), 3.76 (s, 3H), 3.57–3.65 (m, 2H), 3.44–3.51 (m, 
1H), 3.13–3.22 (m, 2H), 3.08 (t, J = 6.4, 2H), 3.02 (d, J = 6.6, 2H), 2.72–2.78 (m, 1H), 
2.26–2.47 (m, 3H), 2.15 (br s, 1H), 1.96 (s, 3H), 1.60–1.75 (m, 3H), 1.14 (d, J = 6.7, 3H), 
1.13 (d, J = 6.3, 3H), 0.94 (d, J = 6.0, 3H), 0.90 (d, J = 6.0, 3H); 13C NMR (CDCl3, 125 
MHz) δ 200.3, 173.6, 171.1, 171.1, 165.5, 158.7, 142.2, 137.2, 131.8, 131.3, 130.4, 128.7, 
128.7, 127.5, 126.3, 125.7, 114.1, 77.5, 73.9, 55.3, 54.8, 43.4, 41.9, 40.7, 40.4, 39.2, 38.0, 
37.5, 28.4, 24.9, 23.2, 23.2, 21.6, 17.0, 14.7; MS (ESI+) m/z 724.3 [M + H]+ 
(C39H54N3O8S requires 724.4). 
 (R)-((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-phenylocta-2,7-dienamido)-3-(4-
hydroxyphenyl)propanamido)-2-methylpropanoate (Cr-430). Compound 6d (58 mg, 
0.09 mmol) and the tert-butyl ester of unit A (7) (27 mg, 0.09 mmol) were stirred in 
CH2Cl2 (4 mL) and TFA (1 mL) for 1 h at room temperature. The solvents were 
evaporated in-vacuo and residual TFA was removed by co-evaporation with toluene. The 
residue was dissolved in CH2Cl2 (5 mL) and TBTU (28 mg, 0.09 mmol) and DIEA (46 
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μL, 0.26 mmol) was added. The reaction was stirred for 2 h at room temperature then 
washed with water, dried with Na2SO4, filtered and concentrated in-vacuo. Flash-
chromatography (3%, 10% MeOH/CH2Cl2) afforded the title compound Cr-430 (38 mg, 
61%) as a white solid. TLC Rf = 0.17 (5% MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3, 
500 MHz) δ 7.34 (d, J = 7.2, 2H), 7.28 (t, J = 7.4, 2H), 7.20 (t, J = 7.2, 1H), 7.00 (d, J = 
8.4, 2H), 6.94 (t, J = 5.6, 1H), 6.79–6.89 (m, 3H), 6.72 (d, J = 8.4, 2H), 6.42 (d, J = 16.0, 
1H), 6.15 (dd, J = 16.0, 8.5, 1H), 5.90 (d, J = 15.4, 1H), 5.20 (dd, J = 9.8, 3.5, 1H), 4.70 
(dt, J = 7.6, 7.2, 1H), 3.59–3.65 (m, 1H), 3.37–3.52 (m, 2H), 3.21–3.30 (m, 2H), 3.02 (t, J 
= 6.6, 2H), 2.92–2.98 (m, 2H), 2.66–2.75 (m, 1H), 2.24–2.42 (m, 4H), 1.93 (s, 3H), 1.57–
1.77 (m, 3H), 1.12 (d, J = 6.4, 6H), 0.92 (d, J = 6.1, 3H), 0.88 (d, J = 6.2, 3H); 13C NMR 
(CDCl3, 125 MHz) δ 200.2, 173.7, 171.7, 171.7, 165.9, 155.8, 142.5, 137.3, 131.5, 131.4, 
130.4, 128.7, 127.7, 127.4, 126.3, 125.6, 115.8, 77.6, 74.0, 55.2, 43.4, 41.8, 40.7, 40.2, 
39.3, 38.2, 37.5, 28.1, 24.8, 23.2, 23.1, 21.6, 17.0, 14.6; MS (ESI+) m/z 710.2 [M + H]+ 
(C38H52N3O8S requires 710.4). 
 ((S)-1-(2-Acetamidoethylthio)-4-methyl-1-oxopentan-2-yl) 3-((R)-2-((2E,5S,6R,7E)-
5-hydroxy-6-methyl-8-phenylocta-2,7-dienamido)-3-(3-chloro-4-
methoxyphenyl)propan-amido)-propanoate (Cr-537). Compound 6e (50 mg, 0.08 
mmol) and the tert-butyl ester of unit A (7) (24 mg, 0.08 mmol) were stirred in CH2Cl2 (4 
mL) and TFA (1 mL) for 1 h at room temperature. The solvents were evaporated in-
vacuo and residual TFA was removed by co-evaporation with toluene. The residue was 
dissolved in CH2Cl2 (6 mL) and TBTU (26 mg, 0.08 mmol) and DIEA (42 μL, 0.24 
mmol) was added. The reaction was stirred for 1 h at room temperature then washed with 
water, dried with Na2SO4, filtered and concentrated in-vacuo. Flash-chromatography (3% 
MeOH/CH2Cl2) afforded the title compound Cr-537 (40 mg, 67%) as a white solid. TLC 
Rf = 0.48 (10% MeOH/CH2Cl2, PMA stain); 1H NMR (CDCl3, 400 MHz) δ 7.36 (d, J = 
7.2, 2H), 7.29 (t, J = 7.2, 2H), 7.21–7.25 (m, 2H), 7.12 (t, J = 5.6, 1H), 7.06 (dd, J = 8.4, 
2.1, 1H), 6.75–6.87 (m, 3H), 6.66 (d, J = 7.8, 1H), 6.43 (d, J = 15.8, 1H), 6.15 (dd, J = 
15.8, 8.5, 1H), 5.90 (d, J = 15.2, 1H), 5.22 (dd, J = 9.8, 3.7, 1H), 4.78 (dt, J = 7.8, 7.0, 
1H), 3.85 (s, 3H), 3.61–3.66 (m, 1H), 3.46–3.57 (m, 3H), 3.21–3.29 (m, 1H), 2.95–3.11 
(m, 4H), 2.28–2.58 (m, 6H), 1.96 (s, 3H), 1.56–1.75 (m, 3H), 1.13 (d, J = 6.6, 3H), 0.94 
(d, J = 6.4, 3H), 0.90 (d, J = 6.4, 3H); 13C NMR (CDCl3, 101 MHz) δ 200.4, 171.3, 171.3, 
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171.0, 165.7, 154.0, 142.4, 137.2, 131.7, 131.3, 131.2, 130.0, 128.7, 128.7, 127.5, 126.3, 
125.6, 122.3, 112.1, 77.8, 73.9, 56.2, 54.6, 43.4, 40.7, 39.2, 37.6, 37.5, 35.2, 34.3, 28.3, 
24.7, 23.2, 23.2, 21.5, 17.0; MS (ESI+) m/z 744.3 [M + H]+ (C38H51ClN3O8S requires 
744.3). 
 
mCPBA Reactions with Cr-B and Cr-538 as Substrates. 0.5 mg (~ 0.8 µmol) of Cr-B 
and Cr-538 were dissolved in DCM. About 1.0 µmol of mCPBA in DCM was added to 2 
mL reaction mixture dropwise with stirring in water-ice bath. After 1 h, the reaction was 
naturally warmed to room temperature and continued for 16 h. The reaction mixture was 
dried under nitrogen gas and redissolved in MeOH for HPLC analysis, whose conditions 
were as the same as enzymatic reaction assays.  
 
Enzyme Activity Assay. A). CrpD-M2 To load and reduce substrates, the enzyme 
reaction mixture contained 100 mM Tris-Cl, pH 7.5, 10 mM MgCl2, 5 mM ATP, 1 mM 
TCEP, 2.5 mM substrate (2KIC, 2HIC, or AKGB), about 5 µM holo-CrpD-M2 in a total 
volume of 50 µl. The reaction mixture was incubated at room temperature for 30 minutes 
for loading reaction. The KR catalyzed reduction reaction was subsequently initiated with 
addition of 2 mM NADPH or NADH and incubated at room temperature for 30 minutes. 
UnitABC-NAC ester (100 µM) was added to start the condensation reaction catalyzed by 
CrpD-M2 C domain. The reaction was performed at room temperature for 1 h and then 
10 µM CrpD-TE was added to the above mixture. The reaction mixture was further 
incubated for 1-2 hours at room temperature and was then terminated by adding two 
volumes of MeOH. Products were detected and collected with analytical reverse-phase 
HPLC (XBridge C18 column, 1 mL/min, 30-100% acetonitrile/water + 0.1% TFA, 30 
min, 218 nm). The product was then re-dissolved and subjected to MS analysis. 
B). MBP-CrpE MBP-CrpE reactions contained 100 μg/ml ferredoxin from spinach, 0.2 
unit/ ml ferredoxin-NADP+ reductase from spinach, 1.4 mM NADPH, 10 mM glucose-6-
phosphate, 8 units/ml glucose-6-phosphate dehydrogenase in 100 μl storage buffer (50 
mM sodium phosphate solution, pH 6.4). The alternative redox partners tested were E. 
coli NADPH-flavodoxin reductase and flavodoxin or rat NADPH cytochrome P450 
reductase. A DMSO stock solution of Cr-3 (2 mM) was added to the reaction mixture to 
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reach a final concentration of 5 μM, such that the final concentration of DMSO in the 
reaction was 5%. The reaction mixture was pre-warmed at room temperature for 2 min. 
The reactions were initiated by addition of MBP-CrpE to a final concentration of 0.2 μM. 
Reaction mixtures were incubated at room temperature for 2-4 hours. In order to 
investigate optimal conditions for the MBP-CrpE reaction, reactions were performed at 4 
°C, 15 °C, 25 °C, 30 °C, 37 °C, and 42 °C. In addition, optimal pH of the reaction was 
determined by monitoring product formation as a function of reaction pH (pH of 5, 6, 6.4, 
7, 8, and 9). From these analyses, optimal reaction conditions were determined to be 50 
mM sodium phosphate buffer, pH 6.4 at 25 °C. Cr-4, Cr-17, Cr-43, Cr-B, Cr-538, SNAC-
Unit A, and seco-cryptophycin Cr-438, Cr-424, Cr-442, Cr-430, and Cr-537 (each at a 
final concentration of 5 μM) were used investigate MBP-CrpE substrate selectivity. 
Following incubation at 25 °C for 2-4 hours, reaction mixtures were extracted twice with 
equal volume of ethyl acetate. The combined ethyl acetate extracts were dried and 
subsequently concentrated in vacuo. The concentrated compounds were dissolved into 
DMSO:water (1:1) and separated by analytical reverse-phase HPLC (XBridge C18 
column, 1 mL/min, 30-100% acetonitrile/water + 0.1% TFA, 40 min, 218 nm).  
 
Kinetic Analysis of MBP-CrpE Reactions. MBP-CrpE reactions contained 100 μg/ml 
ferredoxin, 0.2 unit/ml ferredoxin-NADP+ reductase, and 1.4 mM of NADPH in 100 μl 
storage buffer. Substrate concentrations ranged from 2-100 μM for Cr-3, Cr-4, Cr-17, Cr-
43, Cr-B 2-60 μM for Cr-538. The reactions contained 5 % DMSO (v/v). The reaction 
mixture was pre-warmed at room temperature for 2 min, after which MBP-CrpE was 
added to a final concentration of 0.2 μM to initiate each reaction. The reactions were 
incubated at room temperature for 10 min and quenched with addition of two volumes of 
methanol. After centrifugation at 13,200 rpm for 5 minutes, the 300-μl solutions were 
subjected to HPLC analysis. The areas of the product peaks were calculated and 
converted to moles by fitting into Cr-4 standard curve. The kinetic data was analyzed 
with KaleidaGraph software and fit to the linear function. All experiments were 
performed in duplicate. 
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Binding Analysis of MBP-CrpE. Binding affinities of ligands to MBP-CrpE were 
determined using 0.3 μM of enzyme in a total volume of 1.0 ml of 50 mM sodium 
phosphate solution, pH 6.4. A Carey 300 Bio UV-Visible spectrophotometer was used to 
record the spectrum from 350 nm to 450 nm. Cryptophycin analogs and testosterone were 
dissolved in DMSO while fatty acids stock solutions were prepared in ethanol. The same 
amount of organic solvents was added to the reference cuvette. KCl (0-300 mM) was 
included in the binding buffer to examine binding constant changes under high ionic 
strength. To determine Kd, ΔAmax, and the Hill coefficient (n), titration data sets were 
fitted to the Hill equation of ΔA = ΔAmaxSn/(Kdn+Sn).  Here, ΔA is the absorbent shift, 
ΔAmax is the maximal absorbent shift, Kd is the apparent dissociation constant for ligand-
enzyme complex, S is the ligand concentration, and n is a measure of cooperativity. All 
experiments were conducted in duplicate. In the control experiment, 1 µM GroEL 
solution was used with Cr-538 as the ligand. 
 
Job’s Titration. This analysis followed a protocol in a previous report 41. Briefly, a 
Carey 300 Bio UV-Visible spectrophotometer was used to record the spectrum from 350 
nm to 450 nm. Both CrpE and Cr-3 were kept in 100 mM sodium phosphate solution, pH 
6.4 (binding buffer), and had the same concentration as 2 µM in the assay. Experiments 
were carried out at 25 °C. An aliquot of 100 µl CrpE solution was initially transferred 
into plastic 1-cm cuvette. The Cr-3 solution was gradually added to enzyme solution until 
the volume of the mixture reached 1580 µl and spectral changes were record. The total 
concentration of reactants was kept constant to be 2 µM. As the reference, an equal 
volume of binding buffer was gradually added to the enzyme solution. Spectral changes 
were calculated by subtracting A365~370 with A410-415 and the data were analyzed with 
Prism 4 (GraphPad). All experiments were conducted in duplicate. 
 
Testosterone Effects on CrpE Activity Assay. CrpE reaction contained 200 μg/ml Fer, 
0.2 unit/ml FNR, and 2.5 mM of freshly prepared NADPH. When testosterone (250 μM) 
was the enzyme substrate, the reactions were incubated at room temperature for 2 hours 
and putative products were analyzed by analytical reverse-phase HPLC (XBridge C18 
column, 1 mL/min, 254 nm). Solvent B (acetonitrile) was kept at 10 % for 5 min and then 
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increased to 24 % over next 5 min. Subsequently, solvent B was increased to 62 % in 7 
min, at which it was kept for 20 min. The solvent A was water. Testosterone was eluted 
at 21.7 min in HPLC trace. To investigate its effect on enzyme kinetics, testosterone (0, 
50, 100, 300, 500 µM) was added to the enzyme solutions containing Cr-3 or Cr-538. The 
kinetic analyses were followed the previously described protocol 40. The kinetic data 
were analyzed with Prism 4 and fitted to the linear function. All experiments were 
performed in duplicate. 
 
Testosterone Effect on Overall Catalytic Activity of Selected Bacterial P450s. 
Testosterone was further applied to investigate its effect on the overall catalytic activity 
of CrpE. A series of testosterone (0, 50, 100, 300, 500, 700, 900 µM) were added to the 
above CrpE reaction mixtures with Cr-538 as substrate, which were incubated at room 
temperature for 2 hours. The reactions were terminated with 2 volumes of methanol and 
centrifuged at top speed of centrifuge for 5 min before subjecting 250 µl to HPLC 
analysis as above. The amount of product, Cr-539, was calculated with the same method 
in the previous report 40. All experiments were performed in duplicated. 
 
 PikC and MycG, two P450 hydroxylases in macrocyclic natural products 
pikromycin and mycinamicin biosyntheses, respectively, were selected to investigate 
testosterone effect on their catalytic conversion 53, 54. Their 100-µl reaction mixtures 
contained 0.5 mM testosterone, 100 μg/ml Fer, 0.1 unit/ml FNR, 2.5 mM of freshly 
prepared NADPH, 1 µM P450, and 0.5 mM narbomycin for PikC or 0.5 mM 
mycinamicin-IV for MycG in 50 mM NaH2PO4, pH 7.3 with 1 mM EDTA, 0.2 mM 
dithioerythritol, and 10% glycerol. The reactions were incubated at 30 °C for 40 min and 
the products were extracted with an equal volume of chloroform twice. After chloroform 
evaporation, the residues were dissolved in 300 µl methanol. For HPLC analysis, 250 µl 
solutions were subjected with previously described methods 53, 54. All experiments were 
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Figure S2-1. A: 4-12 % SDS-PAGE analysis of N-terminally His-tagged CrpD-M2 after 
Ni-NTA resin. The enzyme purity was roughly about 80 %. B: FT-ICR-MS analysis of 
trypsin-digested CrpD-M2 oligopeptides. C: Ten chemicals for examination of CrpD-M2 






Figure S2-2. Phylogenetic analysis of CrpD-M2 KR domain.  The CrpD-M2 KR domain 
was grouped with other NRPS KR domains, which was separated from others from both 
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Figure S2-4. A: SDS-PAGE analysis of MBP-CrpE. Lane 1, molecular marker; lane 2, 
purified MBP-CrpE; lane 3, authentic GroEL; lane 4, MBP-CrpE treated with ATP; lane 
5, MBP-CrpE treated with ATP and denatured bacterial lysate. The red arrow indicates 
the MBP-CrpE enzyme while the blue arrow shows the position of contaminant. B: 
Spectral analysis of purified MBP-CrpE. The blue trace represents the absorbance 
spectrum of purified MBP-CrpE in storage solution, which has a peak at 420 nm. The 
pink trace denotes the spectrum of CO-saturated MBP-CrpE solution. The maroon trace 
represents the spectrum of the CO-saturated MBP-CrpE solution reduced by Na2S2O4. 
The spectrum of reduced CO-difference spectrum is shown by the red trace, which has a 






Figure S2-5. Multiple sequence alignment of CrpE with other P450s involved in natural 
product biosynthesis. CrpE shares two conserved motifs with other P450 epoxidases. The 
T/S residue in motif-1 is possibly responsible for O2 binding and cleavage while the 
invariant C in motif-2 is likely responsible for heme binding.  
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Figure S2-7. HPLC analysis of mCPBA reactions with Cr-B (A) and Cr-538 (B) as 
substrates. Both the α- and β-epoxide containing products were produced in chemical 
reactions utilizing mCPBA, whereas only the β-epoxide containing products were 
generated in enzymatic reactions using MBP-CrpE as catalyst. 
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Figure S2-8. Putative cooperativity in substrate binding to MBP-CrpE. The data were fit 



















Figure S2-9. Absorbance change caused by addition of different concentrations of Cr-
538. B, C, D, E, and F represent 1 µM, 2 µM, 3 µM, 4 µM, and 5 µM, respectively. 1 µM 
GroEL was used as a control in the assay. No meaningful absorbance change was caused 
by the addition of Cr-538 to GroEL. 
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Figure S2-10. Lauric acid binding to CrpE. A: The difference spectra induced by 
different concentrations of lauric acid (0-500 µM). The direction of spectral shift upon 
substrate addition is shown (arrows). B: Plot of absorbance change vs ligand 
concentration. Absorbance changes were determined by subtracting A410 with A432 and 
were fitted to a hyperbolic binding equation. Similar to lauric acid, C14, C16, and C18 
linear acids also induced the similar spectral shifts and the binding constants were 





Figure S2-11. HPLC analysis of CrpE reaction with testosterone as substrate. Lane 1, 
authentic testosterone; lane 2, negative control reaction with CrpE boiled at 100 °C for 10 
min as the enzyme source; lane 3, complete enzyme reaction. Testosterone was eluted at 
21.7 min but no additional peak was found in the complete enzyme reaction compared to 




Figure S2-12. Testosterone effect on reactions of bacterial P450s, MycG and PikC.  In 
contrast to CrpE reactions, the presence of testosterone didn’t cause obvious effect on 
these two bacterial biosynthetic P450 catalytic abilities.  
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Table S2-1: Specificity codes for A domains from CrpD-M2, one enniatin NRPS, two 
cereulide NRPSs, two valinomycin NRPSs, one bacillaene NRPS, and two barbamide 
NRPSs. 
 
A Domain 235 236 239 278 299 301 322 330 331 517 Specificity 
CrpDM2-A V A I F L G S S G K HIC 
ENSYN-A1 G A L H V V G I C K D-HIV 
CseA-A1 V G V W V G T S G K 2-KIC 
CseB-A1 V G F W V A V S D K 2-KIV 
Vlm1-A1 A A L W I A V S G K 2-KIV 
Vlm2-A1 V V I W I A E N M K Pyruvate 
PksJ-A1 V G W T T A A I C K 2-KIC 
BarE-A V G I L V G G T S K Trichloro-2-KIC




Table S2-2. 1H NMR data for Unit A of Cr-1, Cr-38, and enzyme product with Cr-4 as 
substrate in CDCl3* 
 
Position Enzyme Product Unit A Cr-1 Unit A57 Cr-38 Unit A58 
2 5.73 (d; 15.4) 5.74 (dt; 15.5, 0.9) 5.80 (d; 15.4) 
3 6.73 (ddd; 15.1, 10.1, 
4.8) 
6.68 (ddd; 15.5, 9.6, 
5.2) 
6.68 (ddd; 15.4, 9.9, 
5.4) 
4 (proS) 2.40 (ddd; 14.5, 10.8, 
10.5) 
2.45 (ddd; 14.2, 11.1, 
9.6) 
2.65 (dt; 14.5, 9.9, 
11.2) 
4 (proR) 2.58 (dm; 14.5) 2.55 (brdd; 14.2, 5.2) 2.55 (brdd; 14.5, 5.4) 
5 5.21 (ddd; 9.5, 4.8, 1.6) 5.16 (ddd; 11.1, 4.9, 
1.9) 
5.12 (ddd; 11.2, 5.0, 
1.6) 
6 1.73 (m) 1.80 (m) 1.76 (pd, 7-7.8, 5.0) 
6-Me 1.17 (d; 6.9) 1.14 (d; 7.1) 1.03 (d; 7.0) 
7 2.94 (dd; 7.5, 1.8) 2.92 (dd; 7.5, 2.0) 2.88 (dd; 7.8, 2.0) 
8 3.70 (d; 1.8) 3.69 (d; 2.0) 3.58 (d; 2.0) 
10/14 7.24-7.28 (m) 7.25 (m) 7.22 (m) 
11/12/13 7.35-7.42 (m) 7.34-7.39 (m) 7.28-7.36 (m) 
*: (1) δH (multiple; J in Hz); 
(2) The chemical shifts of H-7 and H-8 indicates the stereochemistry of epoxide in these 
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Chemical and Biochemical Characterization of Unique Prenylated 




Four consecutive studies are included in this chapter to investigate the 
biosynthetic pathways of one group of unique prenylated fungal indole alkaloids 
containing a characteristic bicyclo[2.2.2]diazaoctane core. The first study focused on 
identification of the secondary metabolites VM55599 and pre-paraherquamide by LC-
MSn analysis as natural metabolites in cultures of Penicillium fellutanum and Aspergillus 
japonicus. The identification of both metabolites, which have a diastereomeric 
relationship, provides indirect support for a previously proposed unified biogenetic 
hypothesis. The second study continued my efforts to identify and characterize key 
biosynthetic intermediates in the prenylated fungal indole alkaloid biosynthesis. An 
advanced metabolite, pre-malbrancheamide, involved in the biosynthesis of 
malbrancheamide, was synthesized as a double 13C-labeled form and was incorporated 
into the indole alkaloid malbrancheamide B by Malbranchea aurantiaca. In addition, 
pre-malbrancheamide has been detected as a natural metabolite in cultures of M. 
aurantiaca. Besides the chemical characterization, my efforts to biochemically 
investigate the fungal alkaloid biosynthesis led to the last two studies. One 
prenyltransferase gene was isolated from genomic DNA of M. aurentiaca. Enzyme 
specificity was investigated with a series of amino acid substrates, revealing its function 
as a 4-dimethylallyltryptophan synthase. MaPT activity was not dependent on a divalent 
cation co-factor, although it was reversibly inactivated by 5 mM EDTA. Analysis of 
kinetic parameters showed reduced enzyme efficiency upon simple modification of L-Trp. 
Moreover, D-Trp had 0.5% relative activity and functioned as a competitive inhibitor 
with Ki = 40.41 µM. Finally, T105, D179, K189 and K261 in MaPT were serially
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mutated and the resulting lesions displayed low or complete loss of activity. Finally, the 
whole genome sequencing of marine notoamide-producing Aspergillus MF-297-2 
generated 480-Mb genome information. One putative stephacidin/notoamide biosynthetic 
gene cluster was identified by genome mining. Two putative prenyltransferase genes, two 
P450 genes, and one bi-module NRPS gene were predicted from the gene cluster.  The 
cDNAs of two prenyltransferase genes were prepared, cloned, and overexpressed to 
produce two soluble polypeptides. Biochemical characterization of the second 
prenyltransferase (NotD) indicated this enzyme is a 6-deoxybrevianamide E synthase, 
one long-seeking enzyme in fungal alkaloid studies, and catalyzes a reverse prenylation 
reaction. Subsequent biochemical characterization included enzyme activity metal 
dependence, kinetic analysis, and substrate specificity. E108, R122, and W424 in NotD 
were serially mutated and the resulting lesions displayed low or nearly complete loss of 
activity. Moreover, the first prenyltransterase (NotA) exhibited considerable activities to 
keto-premalbrancheamide, premalbrancheamide, and pre-paraherquamide. These results 




Fungi are phylogenetically diverse microorganisms that produce thousands of 
low-molecular-weight natural products. A significant number of these metabolites are in 
clinical use as human therapeutics, including antibacterial penicillins, cephalosporins, 
immunosuppressive cyclosporine A, and cholesterol-lowering HMG-CoA reductase 
inhibitor “statins” 1. However, drug-resistant bacteria like methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis 
continue to emerge as a threat to human health 2-4. Along with medical needs to treat a 
spectrum of diseases, an increasing number of natural products have been isolated from 
fungal sources and screened for potential bioactive secondary metabolites 5.  
 
Numerous secondary metabolic indole alkaloids and related nitrogenous 
substances are derived from tryptophan and isoprenic building blocks. The rich 
nucleophilic chemistry of the indole ring has been extensively exploited by Nature to 
create an array of structurally intriguing natural substances such as various ergot 
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alkaloids. A number of structurally interesting natural alkaloids have been isolated from 
various fungi that contain the unique bicyclo [2.2.2] ring system constituted mainly from 
tryptophan, proline or its derivatives, and dimethylallyl pyrophosphate (DMAPP) 
(Figure 3-1) 6. These fungal metabolites include but not limit to brevianamides, 
paraherquamides, asperparalines, notoamides, stephacidins, and malbrancheamides 6-10. 
Interestingly, these alkaloids contain various bioactivities such as allergens, calmodulin 
(CaM) antagonist, antinematodal agents, and anticancer agents, although they possibly 
stem from one common biosynthetic precursor. The brevianamides might be the first 
members of this family of indole alkaloids and are constructed from tryptophan, proline, 
and one isoprene unit (Figure 3-1). Brevianamide A was originally isolated from 
Penicillium brevicompactum 8. The paraherquamides are comprised of two isoprene units, 
tryptophan and variously substituted proline derivatives, making them to be more 
complex in structure. Their potent anthelmintic and antinematodal activities stand them 
out as the next generation of veterinary medicine candidates to treat intestinal parasites 11. 
Although the parent and most potent member, paraherquamide A, was isolated from 
cultures of Penicillium species, other members of paraherquamides have also been 
isolated from various both Penicillium and Aspergillus species. Similar to 
paraherquamides, the asperparalines also have paralytic effects on silkworms 12. 
Structurally, these fungal metabolites contain a spiro-succinimide ring system, which is 
replaced as a spiro-oxindole in the brevianamides and paraherquamides. Asperparaline A 
was isolated from Aspergillus japonicus JV-23. The malbrancheamides have been 
recently isolated from Malbranchea aurantiaca collected from bat guano 9 . 
Malbrancheamide is the first alkaloid in this class of prenylated indole alkaloids to 
contain a halogenated indole ring, and it is further characterized by the lack of a tertiary 
amide in the bicyclo[2.2..2]diazaoctane core. In addition to these notable structural 
features, this fungal alkaloid has been shown to be a CaM antagonist that inhibits the 
activity of CaM-dependent phosphodiesterase (PDE1) in a concentration dependent 
manner. Recently, marine-derived fungi have proven to be rich sources of structurally 
novel and biologically active secondary metabolites, which are emerging as a significant 
resource for new chemicals in drug discovery 13. Several structurally related alkaloids 
have been isolated from marine environments and shown to be anticancer agents.  
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Figure 3-1. Structures of several prenylated fungal alkaloids. These fungal 
metabolites are isolated from various fungal strains but share a common 
bicyclo[2.2.2]diazaoctane core. 
 
Stephacidin A was isolated from afungal strain Aspergillus ochraceus WC76466 and 
exhibited potent in vitro cytotoxicity against various human tumor cell lines through a 
novel mechanism of action different than those of p53, mdr, bcl2, tubulin, or 
topoisomerase II mediating pathways 10. Notoamides were isolated from a culture of 
marine-derived fungus, Aspergillus MF297-2, which was found in the common mussel, 
Mytilus edulis 14. Many of notoamides showed moderate anticancer abilities with a series 
of human tumor cell lines.  
 
The interesting structures and promising bioactivities of these fungal alkaloids 
have attracted considerable efforts to investigate their biosynthetic scheme. In 1974, 
Baldas et al. observed the incorporation of radioactive Trp, Pro, DMAPP, and 
brevianamide F into brevianamide A, making them to propose one brevianamide A 
biosynthetic pathway (Figure 3-2A) 15. Later, the Williams group also conducted a series 
of feeding experiments to explore the biosynthetic origin and pathway of paraherquamide 
16-18. These experiments strongly indicated that this family of prenylated indole alkaloids 
shares a common biosynthetic pathway, and their structural differences come from the 
decoration of pathway-specific tailoring enzymes. However, it is still unknown how 
Nature creates the characteristic bicyclo[2.2.2]diazaoctane core of these natural products, 
although an intramolecular hetero-Diels-Alder reaction of a 5-hydroxypyrazin-2(1H)-one 
has been long proposed (Figure 3-2A). In 2006, one dimodular NRPS gene was mined 
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Figure 3-2. Putative biosynthetic pathways of brevianamide A, paraherquamide A, 
and ergot alkaloids. Feeding experiments and genetic and biochemical characterization 
of FtmA and FtmB (also termed as FtmPT1) led to the understanding of these pathways.  
 
from Aspergillus fumigatus genome and heterologous expression of this gene led to the 
accumulation of brevianamide F, the first genetic evidence about the biosynthesis of 
fumitrmorgins and this family of prenylated indole alkaloids (Figure 3-2B) 19. 
Furthermore, FtmB (previously named as FtmPT1) was derived from the A. fumigatus 
genome, and it catalyzed a regular C-2 prenylation of brevianamide F to produce 
tryprostatin B, providing additional evidence towards the understanding of ergot alkaloid 
biosynthesis 20. However, one reverse prenyltransferse to produce deoxybrevianamide E 
from brevianamide F is desperately required to confirm the biosynthetic scheme of 
prenylated indole alkaloids with bicyclo[2.2.2]diazaoctane core. In this chapter, I will 
describe my studies to isolate key biosynthetic intermediates in paraherquamide, 
asperparaline, and malbrancheamide biosyntheses. Moreover, one regular 
prenyltransferase was isolated from M. aurantica and characterized to be a dimethylallyl 
tryptophan synthase (DMATS). Finally, one putative notoamide gene cluster was 
identified through genome mining of the Aspergillus MF297-2 genome database, and the 
long-sought deoxybrevianamide E synthase was characterized in detail. 
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3.3. Results and Discussion 
 
3.3.1. Isolation of VM55599 and Pre-paraherquamide from A. japonicus and P. 
fellutanum. Biosynthetic Implications 
 
In my studies, P. fellutanum and A. japonicus JV-23 were cultured under the 
conditions described in the experiment section and were first interrogated for viable 
production of paraherquamide A, asperparaline A, and their derivatives, respectively. 
Authentic paraherquamide A was first analyzed by LC-MSn and its MS, MS2, MS3, and 
MS4 spectra were informative to identify this alkaloid, establishing the successful 
application of LC-MSn analysis in this study (Figure S3-1). Next, paraherquamide A in 
the P. fellutanum isolation was eluted at 14.47 min in selective ion monitoring (SIM) 
chromatograph and exhibited an ion at m/z 494.36 (calculated [M+H]+: 494.26) in MS 
analysis (Figure 3-3C and Figure 3-4A). Further MS2, MS3, and MS4 analyses produced 
the identical spectra to those of authentic paraherquamide A (Figure 3-4A and Figure 
S3-1). Along with paraherquamide A, paraherquamides B-G have previously been 
isolated from P. fellutanum (previously named P. charlesii) 6. In this study, one 
compound at m/z 464.29 was detected in the fungal isolation and had the retention time of 
14.95 min (Figure 3-3C and Figure 3-4B). This compound was identified as 
paraherquamide B (calculated [M+H]+: 464.25) by comparing its retention time and MS2 
spectrum to those of an authentic specimen (Figure 3-3 and Figure S3-1).  
 In extracts from A. japonicus JV-23 cultures, asperparaline A had the retention 
time of 7.58 min and exhibited an ion at m/z 360.29 (calculated [M+H]+: 360.22) (Figure 
3-3D and Figure 3-4C). This metabolite was further analyzed with MS2 analysis. In 
previous reports, Aspergillus species IMI 337664 and A. sclerotiorum represented the 
first organisms outside of Penicillium sp. to produce paraherquamide congeners 21, 22. In 
this study, I also investigated paraherquamide production in A. japonicus JV-23. By 
comparing their retention times and MSn spectra to those of authentic compounds, both 
paraherquamide A (14.45 min) and paraherquamide B (14.88 min) were identified in this 
Aspergillus sp. isolation, further indicating that both the Penicillium sp. and the 
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Figure 3-3. Selective ion monitoring (SIM) chromatographs corresponding to the 
authentic paraherquamide A (m/z 494) (A), authentic paraherquamide B (m/z 464) (B), 
isolation from P. fellutanum culture (m/z 464 and 494) (C), and isolation from A. 
japonicus JV-23 (m/z 360, 464, and 494) (D).  
 
Aspergillus sp. are able to produce these anthelmintic alkaloid metabolites (Figure 3-3, 
and Figure S3-2). Moreover, this result strongly suggested one common biosynthetic 
pathway shared by both asperparalines and paraherquamides in this fungus.  
 
 The A. japonicus JV-23 strain produced more paraherquamide B than 
paraherquamide A in PDB medium under the above growth conditions. A. japonicus JV-
23 is the first reported Aspergillus sp. to produce paraherquamide A itself to the best of 
our knowledge, although Everett and co-workers isolated the paraherquamide congeners 
VM54159, SB203105 and SB200437 from Aspergillus strain IMI 337664 21. In extracts 
from P. fellutanum, two metabolites with m/z of 350 were separated and identified by 
LC-MS/MS analysis (Figure 3-5). The first peak had the retention time of 12.15 min 
while the second metabolite was eluted at 12.64 min. These peaks were initially proposed 
to be VM55599 and pre-paraherquamide, considering their theoretical molecular weights 
(C22H27N3O, 349.22) and the previous isolation of VM55599 as the minor metabolite 
from Penicillium sp. IMI337664 23.  
 
To further identify these metabolites, synthetic and authentic (racemic) samples of 
VM55599 and pre-paraherquamide were used to secure standard MS and MS2 




Figure 3-4. MSn spectra of paraherquamide A (1) (A) and paraherquamide B (B) from 
the isolation of P. fellutanum cultures, and asperparaline A (2) (C) from the extracts of A. 
japonicus JV-23. The integral m/z values of ions for each MSn analysis are included in 
corresponding graphs. 
  
diastereomers, exhibited different fragmentation patterns in their MS2 spectra. The ratio 
of the peak at m/z 322.26 to the peak at m/z 305.25 in VM55599 MS2 spectrum was 
larger than 1 while this ratio was significantly smaller than 1 in the pre- paraherquamide 
MS2 spectrum with the fragment at m/z 305.24 as the most intense peak, which likely 
serves as the distinctive feature of these two compounds’ MS2 spectra (Figure S3-3). CO 




Figure 3-5. Selective ion monitoring chromatographs corresponding to the LC-MSn 
analysis of authentic VM55599 (m/z 350) (A), authentic pre-paraherquamide (m/z 350) 
(B), isolation from P. fellutanum cultures (m/z 350) (C), and isolation from A. japonicus 
JV-23 (m/z 350) (D). 
 
322.26, which was further fragmented to give a signal at m/z 305.25 by losing NH3 
(Figure 3-6 and Figure S3-3). The same fragmentation pathway was observed for pre-
paraherquamide. The fragmentation discrepancy observed in VM55599 and pre-
paraherquamide MS2 spectra were apparently affected by the single relative 
stereochemical difference at C14 (paraherquamide numbering) between these two 
compounds. Comparing their MS2 spectra with those of authentic compounds, VM55599 
(12.15 min) and pre-paraherquamide (12.64 min) were identified in the extract from P. 
fellutanum cultures (Figure 3-5A-C and Figure 3-6A-B). Pre-paraherquamide was thus 
observed as one natural metabolite, further strongly validating the putative pathway in 
Figure 3-7. 
 
In extracts from A. japonicus JV-23 cultures, only one metabolite at m/z 350 was 
identified by LC-MS/MS analysis (Figure 3-5D). When compared to the MS and MS2 
spectra of authentic standards, the metabolite with the retention time of 12.62 min was 
validated to be pre-paraherquamide (Figure 3-6C). This represents the first identification 
of this putative precursor in an asperparaline-producing organism. Pre-paraherquamide 
has been proposed as the key, common biosynthetic precursor to both the 
paraherquamides and the asperparalines 6. The identification of this substance in the 




Figure 3-6. MS and MS2 spectra of VM55599 (A) and pre-paraherquamide from the 
isolation from P. fellutanum culture (B), and pre-paraherquamide from the extracts of A. 
japonicus JV-23 cultures (C). The integral m/z values of ions for each analysis are 
included in corresponding graphs.  
 
the unified biogenetic hypothesis detailed in (Figure 3-7). Curiously, VM55599 was not 
detected as a natural metabolite from the A. japonicus JV-23 cultures.  
 
The identification of pre-paraherquamide as a natural trace metabolite suggests 
that structurally related common precursors may be involved in the biosynthesis of the 
family of prenylated indole alkaloids and that the structural diversity of these alkaloids 
are likely introduced by downstream tailoring enzymes following the construction of the 
bicyclo[2.2.2]diazaoctane core. LC-MS/MS analysis has several important advantages 
with respect to sensitivity and selectivity in the detection of trace natural metabolites. In 
natural products identification, NMR techniques are widely used to directly provide 
structural information when sufficient amounts of purified substances are available. 
However, in the case of biosynthetic intermediates, there is often a paucity of material 
that is thus insufficient for NMR structural studies. This is a manifestation of biosynthetic 
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intermediates being largely consumed by downstream tailoring enzymes, and thus these 
substrates do not accumulate. LC-MS/MS is an effective and powerful alternative in 
these cases and has been successfully used to identify many natural products in crude 
extracts by comparison with the respective reference compounds.17 Herein, I was able to 
successfully deploy LC-MS/MS analysis to identify the presence of paraherquamide A, 
paraherquamide B, asperparaline A, VM55599, and pre-paraherquamide in crude fungal 
extracts using this technique.   
 
 
Figure 3-7. Proposed unified biogenesis of paraherquamides and asperparalines. 
 
In conclusion, I have demonstrated for the first time, that pre-paraherquamide is a 
natural, albeit at low levels, secondary metabolite of the paraherquamide-producing 
organism P. fellutanum and the paraherquamide- and asperparaline-producing organism 
A. japonicus JV-23. This report constitutes the first confirmatory evidence for the natural 
existence of pre-paraherquamide and provides additional support for the unified 
biogenesis we have proffered (Figure 3-7). VM55599 is also produced by P. fellutanum 
and is consistent with the initial identification of this substance from the related 
paraherquamide-producing organism Penicillium sp. IMI332995 described by Everett 
and co-workers 23. As the identification of new paraherquamide-producing fungi are 
discovered in various environments around the world, I speculate here, that VM55599 
can be expected to be detected as a co-metabolite. It should be further noted that Miller 
and co-workers recently described the detection of VM55599 as a metabolite in several 
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strains of Penicillium paneum on the basis of mass spectral data 24. It is entirely possible 
that these workers might have instead detected pre-paraherquamide (or both), which has 
the same mass as VM55599. As in the previously established case of P. fellutanum, 
VM55599 is a shunt (dead-end) metabolite as it possesses the incorrect absolute (and 
relative) stereochemistry to be processed further to a paraherquamide-like structure. 
Likewise, in A. japonicus, the major pathway metabolite pre-paraherquamide is largely 
consumed by the down-stream biosynthetic machinery responsible for the substantial 
oxidative elaboration of this biosynthetic intermediate into the asperparalines and 
paraherquamides. 
 
3.3.2. Pre-malbrancheamide: Synthesis, Isotopic Labeling, Biosynthetic 
Incorporation, and Detection in Cultures of Malbranchea aurantiaca 
 
Malbrancheamide and malbrancheamide B have been isolated from M. aurantiaca 
9, 25. In the current study, both natural products were also found in the fungal extract by 
LC-MS analysis (Figure 3-8). The retention times of malbrancheamide and 
malbrancheamide B were 35.3 min and 31.0 min, respectively, in the LC spectrum. Both 
compounds exhibited the expected chlorine isotope patterns and m/z values. In the 
MS/MS analysis, the loss of CO2 (C-14 atom) and then NH3 from the molecular ion of 
malbrancheamide generated fragments at m/z of 376.25 and 359.24, respectively (Figure 
3-9). A similar fragmentation pattern was observed in the malbrancheamide B MS/MS 
spectrum, further confirming the production of this natural product in M. aurantiaca 25. 
Interestingly, one compound in the fungal extract had both the same m/z value (336.31) 
and the retention time (24.6 min) as authentic pre-malbrancheamide (Figure 3-8). 
Moreover, this isolated compound had a similar MS/MS fragmentation pattern compared 
to malbrancheamide and malbrancheamide B, indicative of the structural homology of 
these three compounds (Figure 3-9). Furthermore, the identical MS/MS spectra of this 
compound and synthetic, authentic compound confirmed the presence of pre-
malbrancheamide in the fungal extract (Figure 3-9, Figure S3-4).  
 
In order to investigate the role of pre-malbrancheamide in malbrancheamide 
biosynthesis, doubly 13C-labeled pre-malbrancheamide was synthesized. As shown in 
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Figure 3-8. LC-MS analysis of extracts from M. aurantiaca liquid culture. Lane 1, 
authentic malbrancheamide and malbrancheamide B; lane 2, authentic pre-
malbrancheamide; lane 3, doubly labeled pre-malbrancheamide; lane 4, M. aurantiaca 
fungal extract in feeding experiment with 13C-labeled premalbrancheamide; lane 5, M. 
aurantiaca fungal extract. All natural products exhibited expected m/z values in MS 
analysis. Pre-malbrancheamide was identified in M. aurantiaca fungal extract by 
comparing to authentic compound. In the feeding experiment, both 13C labeled 
malbrancheamide B and native compound were isolated while no 13C labeled 




Figure 3-9. MS/MS spectra of malbrancheamide (A), malbrancheamide B (B), doubly 
13C-labeled malbrancheamide B (C), and pre-malbrancheamide (D) from the fungal 
extract. 
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Figure 3-10, amino acid coupling of the 13C-labeled reverse prenylated tryptophan 
derivative and 13C-labeled cis-3-hydroxyproline ethyl ester (as the TFA salt) in the 
presence of HATU provided a mixture of diastereomers. Treatment of the resulting 
peptide with TFA resulted in deprotection of the carbamate, and subsequent heating of 
the resultant primary amine with 2-hydroxypyridine in toluene gave the dioxopiperazine. 
Dehydration of this intermediate under Mitsunobu conditions led to the enamide, which 
smoothly underwent a hetero-Diels-Alder reaction when treated with aqueous KOH in 
MeOH affording cycloadducts. Treatment of the major cycloadduct with excess DIBAL-
H led to selective reduction of the tertiary amide in the presence of a secondary amide to 
provide double 13C-labeled pre-malbrancheamide in excellent yield.  
 
 Double 13C-labeled pre-malbrancheamide was added to cultures of M. aurantiaca 
in a precursor incorporation experiment. As a putative precursor of pre-malbrancheamide, 
the major cycloadduct was also included in the analysis. Fungal extracts from these 
precursor incorporation studies were analyzed by LC-MS and 13C enrichment was 
revealed by MS/MS analysis. Double 13C-labeled pre-malbrancheamide was clearly 
 
 
Figure 3-10. Doubly 13C-labeled pre-malbrancheamide and product incorporation. 
 
 75
incorporated intact into malbrancheamide B, whose parent ion had an m/z value of 372.29 
(Figure 3-8). Its retention time was the same as that of the native malbrancheamide B. In 
the MS/MS spectrum of doubly 13C-labeled malbrancheamide B, the fragment at m/z of 
343.22 was produced by the loss of 13CO containing a 13C atom at its C-14 position 
(Figure 3-9C). A similar fragmentation pattern was observed in the MS/MS spectrum of 
compound 17 (Figure S3-4). The m/z difference (=1) of many fragments in MS/MS 
spectra of labeled malbrancheamide B and its natural compound is due to 13C atom 
incorporation in the fragments. From analysis of the electrospray mass spectrum, 
incorporation was determined to be 5.5% for the intact doubly labeled material. 
Furthermore, C-5 and C-14 of the isolated malbrancheamide B had significant chemical 
shifts in the 13C NMR spectrum, compared to compound un-labeled malbrancheamide B. 
 
Interestingly, 13C-labeling of malbrancheamide itself was not detected by LC/MS-
MS analysis. Only double 13C-labeled malbrancheamide B was produced in this feeding 
experiment (Figure 3-8). This might be due to the kinetics of the second chlorination 
reaction being considerably slower than the first. Efforts are currently underway to 
prepare doubly 13C-labeled malbrancheamide B in sufficient quantities for analogous 
feeding studies to investigate that malbrancheamide arises from a subsequent C6-
chlorination of malbrancheamide B. Curiously, feeding of doubly 13C-labeled 
dioxopiperazine to M. aurantiaca did not label either malbrancheamide or 
malbrancheamide B, which again raises some important questions regarding timing of 
reduction of the tryptophan carbonyl residue.  
 
3.3.3. Molecular Analysis of a 4-Dimethylallyltryptophan Synthase from 
Malbranchea aurantiaca 
 
Identification and purification of MaPT. Several PT amino acid sequences were 
aligned to identify conserved regions for PT gene degenerate primer design in M. 
aurantiaca RRC1813 (Figure 3-11A). A 750-bp fragment was isolated and predicted to 
be a dimethylallyltryptophan synthase (DMATS) based on sequence comparisons (data 
not shown). TAIL-PCR  was subsequently applied to isolate the 1371-bp full length 
MaPT genomic DNA 26. A 63-bp intron was predicted in the MaPT genomic DNA (BCM  
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Figure 3-11. Preparation of prenyltransferase (MaPT) from M. aurantiaca 
RRC1813 and HPLC analysis of enzyme reactions. A: alignment analysis of several 
members of the new class of PTs. Two motifs were identified for designing degenerate 
primers. Lane 1 to 5 represents DMATS from A. fumigatus, B. obtecta, C. fusiformi, C. 
purpurea, and N. coenophialum, respectively. Lane 6 to 9 are FgaPT1, FgaPT2, FtmPT2, 
and MaPT, respectively. B: 4-12% SDS-PAGE analysis of purified MaPT. Lane 1, 
molecular marker; lane 2, IPTG-uninduced total protein fraction; lane 3, IPTG-induced 
total protein fraction; lane 4, enzyme purified with Ni-NTA agarose; lane 5, enzyme 
purified with gel chromatography. The purified enzyme showed expected molecular 
weight of ~51 kDa. C: HPLC analysis of enzyme reactions. Lane 1, authentic 
dimethylallyltryptophan (DMAT); lane 2, negative control with boiled enzyme used in 
the reaction; lane 3, MaPT enzyme reaction mixture. The product was analyzed by MS 
and showed an expected m/z value of mono-prenylated L-Trp. 
 
Gene Finder) and removed to produce the corresponding MaPT cDNA. The PT encoded 
from this cDNA was aligned with DMATSs from A. fumigatus (EAL94103), Balansia 
obtecta (Q6X1E1), Claviceps fusiformis (Q12594), C. purpurea (Q9C141), and 
Neotyphodium coenophialum (Q6X2E1), FgaPT1 (EAL94098), FgaPT2 (AAX08549), 
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and FtmPT2 (Figure 3-11A) 20. It shares two conserved regions for designing degenerate 
primers with other PTs and has the highest sequence identity with FgaPT2 (64 %). The 
lack of a conserved (N/D)DXXD motif in this PT from M. aurantiaca RRC1813 
indicated that this enzyme is a member of a recently identified new class of PTs. 
 
The MaPT cDNA was cloned into pET28a for protein expression in E. coli 
BL21(DE3). Purified polypeptide was obtained by Ni-NTA agarose and further by gel 
chromatography with a Superdex 200 column to generate a product with apparent 
homogeneity. The observed molecular weight of enzyme in 4-12 % SDS-PAGE analysis 
was about 51 kDa, consistent with a theoretical weight of 52 kDa for His6-MaPT (Figure 
3-11B). Using gel-filtration chromatography, the native molecular weight of the enzyme 
was determined to be 61.6 kDa, suggesting a monomeric species (Figure S3-5). 
 
Enzyme activity and substrate selectivity. L-Trp and a dipeptide, brevianamide F, were 
first tested as enzyme substrates. Brevianamide F was utilized by the enzyme with very 
poor conversion (Table 3-1), whereas L-Trp was converted effectively into product, 
demonstrating it to be a more acceptable enzyme substrate (Table 3-1, Figure 3-11C). 
The m/z of the product corresponds to the theoretical weight of DMAT, suggesting the 
enzyme to be a DMATS. This result further confirms that DMATS is an enzyme 
common in many fungal strains such as Aspergillus sp., Balansia sp., Claviceps sp., 
Neotyphodium sp., and the newly isolated Malbranchea sp. MaPT was specific for 
DMAPP as no product was detected by LC-MS when L-Trp and brevianamide F were 
tested with IPP, GPP, and FPP (data not shown). 
  
Although both L-Trp and brevianamide F were accepted by MaPT, its native 
substrate was not predictable by comparing its sequence to other known enzymes in this 
class. To assess further the substrate flexibility, we interrogated 14 additional compounds 
as substrates with nine converted into products observed by LC-MS analysis (Table 3-1). 
The enzyme activity was less when L-Trp was modified, and this is exemplified by 1-Me-
L-Trp and the dipeptide Ala-Trp with relative activities of 3.2 ± 0.35 % and 0.6 ± 0.06 %, 
respectively. Additionally, amino acid chirality was critical for substrate recognition with 
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Table 3-1. Investigation of MaPT substrate selectivity 
Substrate Relative Activity (%) Mr of Product 
[M+1]+ of 
Product 
L-Trp 100 ± 18.39 272.2 273.1 
D-Trp 0.5 ± 0.04 272.2 273.1 
1-Methyl- L-Trp 3.2 ± 0.35 286.2 287.4 
5-Br-DL-Trp 0.3 ± 0.02 350.1 350.9 
5-F- DL-Trp ND1 ND1 ND1
5-Me- DL-Trp 16.1 ± 0.01 286.2 287.0 
5-MeO- DL-Trp 0.7 ± 0.02 302.2 303.1 
5-OH- L-Trp 17.0 ± 0.37 288.2 289.1 
L-Abrine 24.9 ± 1.45 286.2 287.1 
6-Me- DL-Trp 27.0 ± 2.66 286.2 287.1 
Ala-Trp 0.6 ± 0.06 343.2 344.2 
N-(2,4-Dinitrophenyl)- L-Trp ND1 ND1 ND1
L-Phe ND1 ND1 ND1
L-Tyr ND1 ND1 ND1
L-His ND1 ND1 ND1
Brevianamide F2 0.5 ± 0.03 353.2 354.1 
1: ND represents no product detected; 2: brevianamide F was labeled with two 13C atoms. 
 
0.5 ± 0.04 % relative activity of MaPT toward D-Trp. Finally, the enzyme is strictly 
specific for L-Trp and did not utilize other aromatic amino acid analogues including L-
Phe, L-His, or L-Tyr. 
 
Five substrates used in this study contained side chains with variant 
electronegativity at C-5 of the L-Trp indole ring. 5-OH-L-Trp was the best substrate with 
17.0 ± 0.37 % relative activity, followed by 5-Me-DL-Trp (16.1 ± 0.01 %), 5-MeO-DL-
Trp (0.7 ± 0.02 %), and 5-Br-DL-Trp (0.3 ± 0.02 %), while 5-F-DL-Trp was not utilized 
by the enzyme. Thus, electronegativity of the side chain substituent on the L-Trp indole 
ring was critical for enzyme catalytic efficiency. Interestingly, FgaPT2 exhibits the same 
trend towards these five substrates, suggesting it is common to other DMATSs 27.  
 
Identification of MaPT enzyme reaction products. Products formed by reaction of 
MaPT with L-Trp, L-abrine, 5-OH-L-Trp, and 5-Me-DL-Trp in large-scale reactions were 
purified by semi-preparative HPLC and analyzed by 1H and 13C NMR and HRMS 
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(Figure 3-12). 1H NMR analysis of the MaPT reaction with L-Trp revealed that a 
dimethylallyl group was appended at C-4 of the indole ring (Table S3-1). HRMS analysis 
of this product showed an ion with the m/z of 273.1610, which corresponds to the 
theoretical mass [M+H]+ (273.1603) of prenylated tryptophan. Further analysis of 
products with 5-OH-L-Trp, 5-Me-DL- Trp, and L-abrine as enzyme substrates confirmed 
C-4 of indole as the site for covalent linkage of the dimethylallyl group (Table S3-1). 13C 
NMR analysis provided additional evidence to confirm the structures of 4-prenylated L-
abrine, 5-OH-L-Trp, and 5-Me-DL-Trp. These three products also showed expected m/z 
values in the HRMS analysis.  
 
 
Figure 3-12. Four identified MaPT products. Four different enzyme substrates were 
converted into corresponding products in large scale enzyme reactions. The products 
were isolated by semi-prep HPLC and subjected for 1H and 13C NMR analyses and high 
resolution MS analysis (HRMS). 
 
Metal dependence of MaPT. The optimal temperature and pH value for enzyme 
reactions were 30 °C and 7.4, respectively (Figure S3-6). The product in the reaction 
including L-Trp was produced to be correlated linearly with up to 0.43 µg protein per 100 
µl assay, and up to 12 min under the above optimal conditions. The enzyme activity did 
not require any additive divalent cation while addition of 5 mM of Mg2+ or Ca2+ slightly 
enhanced MaPT activity by about 130% (Figure S3-7).  Five divalent metal ions (Mn2+, 
Fe2+, Co2+, Ni2+, and Zn2+) at 5 mM inhibited the enzyme activity from 50% to 80%, and 
5 mM of Cu2+ or Sn2+ significantly reduced enzyme activity to less than 10%. EDTA was 
found to hinder enzyme activity in a concentration dependent manner (Figure S3-7). 
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More than 4 mM EDTA totally abrogated enzyme activity after incubating it with the 
enzyme at 30 °C for 5 min; this was not restored by addition of 10 mM Mg2+.  
 
Cation dependence in prenyltransferases has been well documented, and 
represents a key feature of the mechanistic biochemistry in these enzymes. Therefore, 
divalent cation content in MaPT was investigated with ICP-MS. Although Ni2+ 
concentration (1.62 µM in 17 µM MaPT solution) was increased about 26 times, all other 
metal ion content values were not changed, and found to be <0.05 mol per mol of MaPT. 
The increased Ni2+ content was presumed to be derived from Ni-NTA agarose used in 
protein purification. Therefore, purified MaPT contained none of the typical metal ion co-
factors, and EDTA presumably exhibited its inhibition through a mechanism that is 
independent of divalent cation sequestration. Enzyme inhibition by metal ion chelating 
agents was further investigated with EGTA, EDDA, DHPTA, and EDTA-Mg2+ complex 
(Figure 3-13A). Dialysis of the enzyme solution containing 5 mM EDTA against 
reaction buffer regenerated active enzyme whose efficiency was similar to the positive 
control (Figure 3-13B), demonstrating EDTA as a reversible inhibitor of MaPT. 
Interestingly, 5 mM EDTA was also reported to reduce CloQ prenyltransferase activity to 
25 % 28, and inhibits horseradish peroxidase, human liver arginase, and lignin peroxidase 
H2 in a metal ion independent manner .  29-31
 
 
Figure 3-13. Reversible inhibition of MaPT activity by EDTA. A: inhibition of MaPT 
by EDTA analogues. Each chemical (5 mM) was incubated with the enzyme at 30 °C for 
5 min before initiating the reaction. B: Regaining enzyme activity by dialysis. EDTA (5 
mM) was incubated with MaPT at 30 °C for 5 min, and then dialyzed against gel 
chromatography running buffer at 4 °C overnight. Line 1 (blue), reaction with 1 mM L-
Trp and dialyzed MaPT treated with EDTA; line 2 (black), reaction with 1 mM L-Trp and 
dialyzed MaPT untreated with EDTA. Mg2+ was not added to either reaction. 
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Kinetic analysis of MaPT. Several DMATS from Claviceps sp. and PTs from A. 
fumigatus have been biochemically characterized with radiolabeled substrates or directly 
by HPLC-UV 20, 32-39 analysis. In this study, HPLC-UV was used to investigate MaPT 
kinetics with L-Trp, 5-OH-L-Trp, and L-abrine coupled with DMAPP as enzyme 
substrates. The enzyme reaction followed Michaelis-Menton kinetics when L-Trp 
concentration was varied and DMAPP concentration held constant at 0.2 mM (Table 3-2). 
The Km and Vmax values for L-Trp were 48.88 ± 1.86 µM and 3.41 ± 0.04 µM/min, 
respectively, giving a turnover value of 80.42 ± 0.94 min-1. Interestingly, DMAPP 
showed self-inhibition when its concentration was varied. The Km and Ks values for 
DMAPP were 13.97 ± 1.86 µM and 126.37 ± 27.30 µM, respectively. Its Vmax value (5.63 
± 0.45 µM/min) was higher than that with L-Trp (measured at 0.2 mM DMAPP in L-Trp 
kinetic analysis). Both 5-OH-L-Trp and L-abrine had higher Km values and lower Vmax 
values than those of L-Trp. 5-OH-L-Trp Km and Vmax values were 303.08 ± 25.73 µM and 
1.43 ± 0.04 µM/min, respectively. No self-inhibition was observed for up to 200 µM 
DMAPP in the presence of 5-OH-L-Trp. L-Abrine was converted into product with lower 
catalytic efficiency and showed self-inhibition in the kinetic assays. Its Km and Ks values 
were 105.99 ± 21.14 µM and 964.15 ± 260.85 µM, respectively. The Vmax value of L-
abrine (2.70 ± 0.30 µM/min) was lower than that of L-Trp. Km and Vmax values of L-Trp 
were comparable to other PTs including FgaPT2 and DMATS from C. purpurea 35. 
MaPT exhibited catalytic efficiencies about 5-fold higher toward both 5-OH-L-Trp and L-
abrine compared to FgaPT2 27. 
 
In the next assay, both L-Phe and D-Trp were included in the enzyme reaction to 
investigate their affect on enzyme kinetics. The kinetic parameters of L-Trp and DMAPP 
were not changed by addition of 100 µM L-Phe.  However, L-Trp kinetic parameters were 
reduced by addition of D-Trp, while DMAPP kinetic data were not changed (Figure 3-
14). For example, Km, obs and Vmax, obs values for L-Trp with 50 µM D-Trp was 107.79 ± 
5.07 µM and 3.56 ± 0.07 µM/min, respectively, while Km, obs and Vmax, obs values for 
DMAPP were 12.14 ± 3.36 µM and 4.87 ± 0.707 µM/min, respectively (Table 3-2). The 
Ki  for D-Trp was determined to be 40.41 µM after plotting Km, obs  values and  
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Substrate Km (µM) 
Vmax 
(µM/min) kcat (min
-1)  kcat/Km     (µM-1 ·min-1) 
L-Trp 48.88±1.86 3.41±0.04 80.42±0.94 1.65±0.04 
5-OH-L-Trp 303.08±25.73 1.43±0.04 33.73±0.94 0.11±0.09 
L-Abrine 105.99±21.14 2.70±0.30 63.68±7.08 0.60±0.23 
L-Trp* 107.79±5.07 3.56±0.07 83.96±1.65 0.78±0.05 
L-Trp† 13.97 ±1.86 5.63 ±0.45 132.78±10.61 9.50±0.16 
5-OH-L-Trp† 41.20 ±3.48 1.40 ±0.04 33.02±0.94 0.80±0.09 
L-Abrine† 19.00 ±3.34 1.19 ±0.06 28.07±1.42 1.48±0.18 
L-Trp*† 12.14 ±3.36 4.87 ±0.70 114.86±16.51 9.46±0.31 




Figure 3-14. MaPT reaction with L-Trp as substrate was inhibited by varying 
concentrations of D-Trp. Line 1, the Michaelis-Menton curve resulting from reactions in 
the presence of 100 µM L-Phe; line 2 to 5, the Michaelis-Menton curve generated by 
reactions in the presence of 0, 10, 50, and 100 µM D-Trp, respectively. The right inset 
graph is the plot of Km, obs vs. [D-Trp] to provide the Ki value. 
 
corresponding D-Trp concentrations by the equation of Km, obs = Km [1 + [D-Trp]/Ki]. The 
data revealed that D-Trp acts as a competitive inhibitor in the MaPT reaction. 
 
Mutagenesis of MaPT. The MaPT amino acid sequence was aligned to Orf2, CloQ, and 
NovQ sequences by ESPript (Figure S3-8). MaPT K261 (corresponding to N173 in Orf2) 
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was identified as a possible key residue involved in DMAPP binding. This residue was 
mutated to Glu and Leu (Figure S3-9). MaPT K261E was highly soluble and readily 
purified, while its K261L form was only partially purified due to significant insolubility. 
No product was generated in either reaction, reflecting the potential key role of K261 in 
enzyme catalysis (Figure 3-15). MaPT K189 (the counterpart of K119 in Orf2) was also 
presumed to be involved in diphosphate binding. Both MaPT K189E and K189L retained 
only 1.1% and 0.9% of wild type enzyme activity, respectively (Figure S3-9, Figure 3-
15). Thus, this residue is also a key candidate for being involved in enzyme catalysis. 
Crystal structure analysis revealed that S51 in Orf2 is involved in substrate binding 
through a hydrogen-bond. A similar residue, T105, is found in MaPT while two basic 
residues are present in CloQ, NovQ, and Fnq26. These positively charged residues have 
been suggested to act as surrogates of Mg2+ for α-phosphate binding. The key residues for 
Mg2+ binding in Orf2 are D62 and D110. Although D62 is not a conserved residue, D110 
is seemingly conserved among these PTs, casting some uncertainty on the role limited to 
metal binding. In this study, MaPT T105 was mutated to Asp and Val while D179 
(corresponding to D110 in Orf2) was mutated to Asn, Glu, and Val (Figure S3-9). MaPT  
 
 
Figure 3-15. HPLC analysis of reaction products using mutant forms of MaPT and 
L-Trp as substrate. All reactions were run with the same reaction components and 
conditions. Addition of 0.86 µg MaPT mutants except K261L initiated the reactions, 
which were incubated at 30 °C for 30 min before termination. Instead, 11.7 µg partially 
purified MaPT K261L was used in the reaction. Peaks with low levels of product were 
labeled with black asterisks. 
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T105V retained about 11% of wild type enzyme activity while the T105D mutant form 
was almost completely inactive (1.4% of wild type MaPT) (Figure 3-15). Considering 
S51 in Orf2 also points toward the GPP binding pocket (5-7 Å distance), this result 
suggests that T105, along with other hydrophobic residues, possibly defines a binding 
pocket for DMAPP. MaPT D179N, D179E, and D179V retained 40%, 25%, and 7% of 
wild type enzyme activity, respectively. 
 
3.3.4. Detailed Characterization of One Deoxybrevianamide E Synthase in 
Stephacidin/Notoamide Biosynthetic Pathway 
 
The biochemical understanding of prenylated indole alkaloids remains limited 
because no biosynthetic gene cluster from any alkaloid producing fungal strain is 
available. My initial efforts to clone out asperparaline and malbrancheamide gene clusters 
relied on pairs of degenerate primers designed from bacterial NRPS A domains, but 
resulted in limited successes possibly because of the inconsistence of A domain specific 
codes between bacterial and fungal NRPS systems.  The advance and low cost of the 
fungal whole genome sequencing represents a new strategy to attack this problem. 
Notoamide- and stephacidin-producing marine Aspergillus sp. was chosen for the whole 
genome sequencing target because of its natural product anticancer activities and 
significantly unique structure features. State-of-the-art 454FLX technology in the 
University of Michigan DNA Sequencing Core facility generated a 480-Mb fungal 
genomic database. With assists from bioinformatics specialists, a partial fungal genome 
has been assembled and the genome size was estimated to be about 36 Mb, similar to all 
published Aspergillus genome sizes 40. This project not only represents the first effort to 
investigate marine Aspergillus sp. to develop an understanding fungal genetic evolution 
and adaptation to different environmental niches, but also provided the possibility to 
study the biosynthesis of prenylated indole alkaloids. 
 
Although there are structural differences among brevianamide A, notoamides, and 
stephacidins, they all may share the same biosynthetic precursor, brevianamide F 15. 
Recently, FtmA in the Aspergillus fumigatus genome was identified and characterized as 
the brevianamide F synthase in ergot alkaloid production 19. In my studies, FtmA was 
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used to screen the Aspergillus MF297-2 preliminary genome, and one putative dimodular 
NRPS gene (NotC) was isolated (Figure 3-16). This 6723-bp intronless gene encodes a 
polypeptide product with 47 % identity to FtmA in A. fumigatus (Table 3-3). Besides this 
gene, 18 other genes were also identified in a 42457-bp chromosomal region. At the left 
side of the gene cluster, the products of Orf1-3 might be involved in a primary metabolic 
pathway. At its right side, the predicted functions of Orf4-9 suggested that they might not 
be directly related to notoamide/stephacidin biosynthesis. Instead, ten genes (NotA-J), 
including NotC, were predicted to be essential. NotA and NotD are two predicted 
DMATSs, which possibly catalyze two required prenylation steps in fungal alkaloid 
biosynthesis. The 1350-bp NotA contained a 69-bp intron and its encoded product 
showed highest identity (50 %) to FtmH (also termed as FtmPT2) in A. fumigatus 41. 
Similarly, NotD whose gene was 1431 bp with a 72-bp intron has the highest identity (40 
%) to one putative DMATS (EER24759) in Coccidioides posadasii. NotB was predicted 
as a flavin-dependent oxidoreductase but its role in notoamide/stephacidin biosynthesis 
remains unknown. NotE and NotF are two P450s, which together might catalyze the 
formation of the terminal 6-membered ring attached to indole ring. The function of NotG 
was predicted as an FAD-dependent oxidoreductase while NotH was a hypothetical 
enzyme whose function remains unknown. The pathway-specific resistant machinery is 
NotI, which was predicted as an efflux pump. NotJ was predicted as a C6 zinc finger 
domain and possibly acts as a pathway-specific transcriptional activator.       
 
 
Figure 3-16. One putative gene cluster for stephacidin/notoamide biosynthesis in 
Aspergillus MF297-2. Besides notoamide A and stephacidin A, one putative biosynthetic 
intermediate, deoxybrevianamide E, was also isolated from marine fungal culture 14.    
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biosynthesis protein from 
Aspergillus fumigatus (43/63) 
XP_748327 
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FAD binding domain protein from 
A. clavatus (44/63) 
XP_001268514 
NotA 1350/427 5819-6996, 7016-7168 prenyl-
transferase 
FtmH from A. fumigatus (50/66) BAH24002 
 
NotB 2025/621 8012-8294, 8389-8927, 
8996-10036 




NotC 6723/2241 10787-17509 NRPS FtmA from A. fumigatus (47/67) XP_747187 



























FAD binding domain protein from 
A. clavatus (44/63) 
XP_001268514 
NotH 1113/371 26391-27503 unknown hypothetical protein from 
Salinispora arenicola (52/65) 
YP_001537335 
NotI 1851/564 28772-29142, 29197-
29570, 29621-30390, 
30446-30622 
efflux pump MFS transporter from Neosartorya 
fischeri (87/93) 
XP_001265322 
NotJ 1455/484 31790-33244 transcriptional 
activator 
C6 zinc finger domain protein from 
N. fischeri (53/62) 
XP_001265321 
Orf4 1266/422 33817-35082 unknown hypothetical protein from 
Talaromyces stipitatus (76/83) 
XP_002482929 
Orf5 1126/340 35194-35246, 35300-
35897, 35950-36319 
dehydrogenase alcohol dehydrogenase from 
Penicillium marneffei (60/76) 
XP_002147947 
Orf6 993/331 36522-37514 short-chain 
dehydrogenases
/reductase 
hypothetical protein from Nectria 
haematococca (66/80) 
EEU36425 
Orf7 1020/322 37772-37932, 37987-
38791 
unknown metallo-β-lactamase domain 
protein from T. 
stipitatus (80/88) 
XP_002482927 
Orf8 569/152 39873-40062, 40122-
40318, 30372-40441 
unknown hypothetical protein from T. 
stipitatus (88/94) 
XP_002482928 








To verify functions of NotA and NotD and their roles in notoamide/stephacidin 
biosynthesis, their cDNAs were prepared by removing introns with overlapping PCR 
(Table S3-2). The predicted cDNAs were sequenced to exclude any error introduced by 
PCR and cloned into the NdeI and NotI sites of pET28a for heterologous overexpression 
in E. coli BL21 CodonPlus-(DE3)-RIPL strain. The N-terminally His-tagged proteins 
were purified with Ni-NTA resin to reach about 90 % purity (Figure S3-10A). The native 
status of NotD (53.6 kD) was determined as the oligomer with observed molecular 
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weight of 292 kD, suggesting the formation of a pentamer or hexamer (Figure S3-10B). 
Protein concentrations were determined with their corresponding extinction coefficients 
at 280 nm (97,950 and 91,853 M-1 cmP-1 for NotA and NotD, respectively). 
 
Next, the functions of NotA and NotD were examined with L-Trp, doubly C-
labeled brevianamide F, deoxybrevianamide E, and doubly C-labelled keto-
premalbrancheamide as substrates (Figure S3-11). No prenylated product was detected 
with LC-MS when L-Trp, doubly C-labeled brevianamide F, and deoxybrevianamide E 
were used in NotA reactions, while one small peak appeared in the LC trace of the 
enzyme reaction with doubly C-labeled keto-premalbrancheamide as its substrate 
(Figure 3-17). The peak content exhibited the m/z value at 420.10. This result indicated 
the single prenylation reaction catalyzed by NotA and its putative position in 
notoamid/stephacidin biosynthetic scheme. The relatively low conversion possibly 
suggested that keto-premalbrancheamide was not the physiological substrate of NotA. 
Subsequently, NotA substrate specificity was preliminarily investigated with several 








Figure 3-17. LC-MS analysis of NotA reactions with several different substrates. 1: 
L-Trp, 2: doubly 13C-labeled brevianamide F, 3: deoxybrevianamide E, 4: doubly 13C-
labelled keto-premalbrancheamide, 5: premalbrancheamide, 6: preparaherquamide, 7: 
VM55599. All peaks labeled with black arrows showed the expected m/z values of singly 
prenylated products. 
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VM55599. Both premalbrancheamide and preparaherquamide were utilized by NotA, 
albeit at the low level, while VM55599 was not an enzyme substrate. The m/z values of 
404.15 and 418.00 indicated the formation of singly prenylated premalbrancheamide and 
preparaherquamide, respectively. Moreover, this study possibly suggested that VM55599 
was the dead end metabolite in paraherquamide/asperparaline biosynthetic pathway.  
 
 NotD showed the relatively high activity toward doubly 13C-labeled brevianamide 
F (Figure 3-18). The product peak retained the same retention time (17.38 min) as 
deoxybrevianamide E and the peak content showed the m/z value at 354.22, 2-Da shift 
from that of authentic deoxybrevianamide E in MS analysis. In MS2 analysis, the NotD 
product showed the same fragmentation pattern as that of deoxybrevianamide E and the 
m/z differences (1 or 2 Da) of some fragments in two MS2 spectra came from the two 
labeled 13C atoms in brevianamide F (Figure S3-12). Subsequently, NotD substrate 
selectivity was investigated with more substrates (Figure S3-11). L-Trp, 
deoxybrevianamide E, and doubly 13C-labelled keto-premalbrancheamide were used to 
probe the timing of NotD reaction in notoamide/stephacidin biosynthesis. None of them 
was utilized by NotD as determined in LC-MS analysis, indicating that NotD is the long-
sought deoxybrevianamide E synthase and catalyzes the committed step to produce the 
key common biosynthetic intermediate shared by the family of unique prenylated indole 
alkaloids. Furthermore, cyclo-(L-Phe-L-Pro), cyclo-(L-Trp-L-Trp), and cyclo-(L-Trp-L-
Tyr) were used as the NotD substrates to determine enzyme substrate selectivity. Singly 
or doubly prenylated chemicals were not detected in enzyme reaction mixtures by LC-
MS. Thus, both amino acid residues in brevianamide F are restrictively critical for 
substrate binding to NotD. However, amino acid residues in NotD contributing to 
substrate recognition remain unknown and X-ray studies of NotD will be necessary to 
provide certain information to understand this process and facilitate future enzyme 
engineering.    
 
Interestingly, NotD exhibited similar catalytic activity toward brevianamide F 
over a broad range of temperature (4 to 42 °C) and in buffers with pH values from 6.0 to 
9.0 (Figure S3-13). The formation of product in the enzyme reaction was linear with up  
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Figure 3-18. LC spectrum of NotD reaction with doubly 13C-labeled brevianamide F 
as substrate. The enzyme product had the same retention time (17.38 min) as authentic 
deoxybrevianamide E.  
 
to 2 µg protein per 100 µl assay for up to 15 min under the above optimal conditions. The 
enzyme activity was not dependent on any additive divalent cation while addition of 5 
mM Mg2+, Ca2+ or Mn2+ slightly enhanced NotD activity by about 106% (Figure 3-19). 
Two divalent metal ions (Co2+ and Ni2+) at 5 mM inhibited the enzyme activity by 5% to 
20% and 5 mM Cu2+, Zn2+, Fe2+, or Sn2+ significantly reduced enzyme activity to 12% to 
35% (Figure 3-19). Unlike to MaPT, 5 mM EDTA caused only minor effect on NotD 




Figure 3-19. Metal dependence of NotD. Addition of 5 mM divalent metal ions or 




In this study, HPLC-UV was used to investigate NotD kinetics with doubly C-
labeled brevianamide F
13
 coupled with DMAPP as enzyme substrates. The enzyme 
reaction followed Michaelis-Menton kinetics when doubly C-labeled brevianamide F 13
concentration was varied (1 - 90 µM) and DMAPP concentration held constant at 0.1 mM 
(Figure S3-14). The Km and Vmax values for doubly C-labeled brevianamide F13  were 
4.33±0.43 µM and 0.89±0.02 µM/min, respectively, giving a maximal turnover value of 
19.1±0.4 min-1. Similarly, the DMAPP concentration was varied (2 - 60 µM) while the 
other substrate concentration was kept as 0.1 mM. Its Km and Vmax values for DMAPP 
were 1.31±0.22 µM and 1.18±0.03 µM/min, respectively. Its maximal turnover value 
(25.3±0.6 min-1) and enzyme catalytic efficiency value (19.31 µM-1• min-1) were slightly 
higher than those of doubly C-labeled brevianamide F (13 19.1±0.4 min-1, 4.41 µM-1• min-
1, respectively). Compared to FtmB (with brevianamide F as its substrate, Km = 55 µM, 
kcat/Km = 6.08 µM-1• min-1), NotD showed more restricted substrate selectivity and greater 
substrate binding affinity but a similar level of enzyme catalytic efficiency 42. 
 
Recently, the FgaPT2 crystal structure was solved to provide sights for 
understanding the reaction mechanism of this group of metal-independent aromatic 
prenyltransferases 43. In my studies, three key amino acid residues located in enzyme 
reaction pocket were mutated to test their importance in this enzyme. The NotD amino 
acid sequence was first aligned to MaPT (ABZ80611), FtmB (AAX56314), FtmH 
(BAH24002), FgaPT1 (EAL94098), FgaPT2 (AAX08549), DMATSs from A. fumigatus 
(EAL94103), Balansia obtecta (Q6X1E1), and Claviceps fusiformis (Q12594) by ESPript 
(Figure S3-15). Both K212 and K282 in NotD (corresponding to K187 and K189 in 
FgaPT2) were identified as two possible key residues involved in DMAPP binding and 
their roles in FgaPT2 reaction have been validated by mutagenesis and structural studies 
43, 44. In FgaPT2 crystal structure, R100 was suggested as the key residue to interact with 
the pyrophosphate group in DMAPP, and subsequent mutagenesis studies confirmed this 
role 43. R108 in NotD is the corresponding residue, and it was mutated into both His and 
Gly to test for its function in reverse prenyltransferase (Figure S3-10). Both NotD lesions 
resulted in less than 2% of wild type catalytic activity (Figure 3-20). Another highly 
conserved residue in NotD suspected to be involved in substrate binding is E108, 
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corresponding to E89 in FgaPT2. This residue in FgaPT2 forms one H-bond with N-H of 
L-Trp indole ring 43. It was expected that E108 will have a similar function in NotD since 
brevianamide F also contain the L-Trp structural moiety. Both NotD E108D and E108G 
mutants had at least 92 % less activity than wild type. The lost function of NotD E108D 
indicated that the proper length of acidic residue side chain is critical for H-bond 
formation in this group of aromatic prenyltransferases and NotD may lack structural 
plasticity to accommodate aromatic substrate analogs. Indeed, two E108 mutants showed 
no activity toward cyclo-(L-Phe-L-Pro) with a phenyl ring instead of indole ring (data not 
shown). The FgaPT2 structure also revealed the presence of one aromatic network 
consisting of five Tyr residues to shield the reactive DMAPP carbocation from solvent 43. 
All of these aromatic residues are conserved in NotD, except that Y413 is replaced with 
W424 in NotD (Figure S3-15). This tryptophan residue was mutated into Tyr and Gly in 
my study. Although the W424G lesion lost at least 98 % of catalytic activity, W424Y 
was capable to produce deoxybrevianamide E with about 25 % efficiency in comparison 
to wild type enzyme. This observation validated the importance of the aromatic network 
in the aromatic prenyltransferase reaction and also suggested that W424 was not the sole 
determining factor for regulating regular or reverse prenylation in NotD.  
 
 
Figure 3-20. Catalytic activities of wild type NotD and its mutants. In enzyme 
reactions, 2 µg of enzyme was used in a 100-µl reaction mixture containing 0.1 mM 
doubly 13C-labeled brevianamide F and 0.1 mM DMAPP. The reactions were conduced 
at room temperature for 1.5 h and performed in duplicate. 
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Overall, my studies in this section isolated and biochemically confirmed one 
putative gene cluster for notoamide/stephacidin biosynthesis. Bioinformatic analysis 
suggested that NotC is a brevianamide F synthase, similar to FtmA in ergot alkaloid 
biosynthesis. Subsequently, the brevianamide F product will be singly prenylated in a 
NotD-catalyzed reaction (Figure 3-21). One oxidoreductase in the gene cluster will then 
oxidize doxybrevianamide E by 2 electrons. Although the subsequent heteroatom Diels-
Alder cyclization in prenylated fungal alkaloid biosynthesis has been proposed for a long 
time, such an enzyme remains unknown here. Since NotA showed limited catalytic 
efficiency toward keto-premalbrancheamide, it is proposed that a P450-catalyzed 
hydroxylation on the indole ring may occur prior to this regular prenylation reaction. The 
subsequent ring closing might be catalyzed by the other P450 to produce stephacidin. 
Recently, a notoamide E feeding experiment indicated that this biosynthetic intermediate 
might not be the direct precursor of notoamide A 45. Thus, stephacidin may be the 
 
 
Figure 3-21. One putative biosynthetic route for stephacidin and notoamide. 
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intermediate in notoamide biosynthetic pathway. I propose that stephacidin will be 
further hydroxylated by one monooxygenase, and it will then undergo a pinacol 
rearrangement. It is unknown whether such a pinacol rearrangement will automatically 
occur under fungal physiological conditions or will be catalyzed by one enzyme. 
Notoamide B will be produced in a pinacol rearrangement reaction and will be subjected 
to an N-hydroxylation reaction to produce the final product notoamide A. It is believed 
that this prototypical biosynthetic pathway will lead to a better understanding of how 
other members in the family of prenylated fungal alkaloids are biosynthesized, and may 
offer opportunities to generate numerous natural product analogs that are beneficial to 
drug discovery and development. 
 
3.4. Materials and Methods 
 
General Chemicals, DNA Sub-cloning, and Bacterial Strains. Chemicals were 
purchased from Sigma-Aldrich, Fisher Scientific and BaChem while acetonitrile used in 
LC-MSn analysis was LC/MS grade. A MilliQ H2O purification system generated water 
for LC-MSn analysis. Trifluoroacetic acid (99%, reagent plus) and formic acid (>98%, 
ACS reagent) were also purchased from Sigma Aldrich. DMAPP was purchased 
Isoprenoids. Authentic paraherquamide A, VM55599, and pre-paraherquamide were 
synthesized following previously published procedures. Paraherquamide B (as the 
unnatural enantiomer) was obtained by total synthesis. Authentic malbrancheamide was 
kindly provided by Professor Rachel Mata of Universidad Nacional Autónoma de 
México while Dr. Anthony E. Glenn of the USDA for provided M. aurantiaca RRC1813 
strain (originally obtained from Dr. María del Carmen González). P. fellutanum 
(ATCC20841) was purchased from American Type Culture Collection (Manassas, VA) 
while A. japonicus JV-23 was provided by Dr. Hideo Hayashi of Osaka Prefecture 
University. Standard methods for DNA isolation and manipulation were performed as 
described by Sambrook et al 46. Genomic DNA from M. aurantiaca RRC1813 was 
isolated with MasterPure Yeast DNA Purification kit (Epicentre Biotechnologies) as 
described in the manual. The MaPT GenBank Accession Numbers are EU420001 for its 
genomic DNA and EU420002 for its putative cDNA. Molecular biology reagents and 
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enzymes were supplied by New England Biolabs with the exception of for Pfu DNA 
polymerase (Stratagene), dNTPs (Takara), T4 DNA Ligase (Invitrogen). Escherichia coli 
XL-1 Blue was used for cloning and plasmid harvesting while E. coli BL21 (DE3) or E. 
coli BL21 CodonPlus-(DE3)-RIPL was used for protein overexpression. All E. coli 
strains were grown in Luria-Bertani broth. DNA sequencing was performed at the 
University of Michigan DNA Sequencing Core. A Beckman Coulter HPLC, fitted with 
an XBridge C18 column (5µm, 4.6 x 250 mm), coupled with a System Gold I68 Detector 
was used for HPLC-UV analysis. A SHIMADZU LCMS-2010EV system was used for 
LC-MS analysis in the studies. 
 
Cultures of Fungal Strains. P. fellutanum and A. japonicus JV-23 were initially grown 
in solid medium (20 g malt extract, 20 g glucose, 1 g peptone, and 20 g agar in 1 L 
deionized water) and solid (20 g potato-dextrose-broth and 20 g agar in 1 L deionized 
water), respectively, at 25 °C in dark for 2 weeks. Fungal mycelium and spores were then 
transferred into 300 ml sterile corn steep liquor medium (22g corn steep liquor and 40 g 
glucose per liter deionized water) for P. fellutanum or 300 ml sterile potato-dextrose-
broth (PDB) (24 g potato-dextrose-broth per liter deionized water) for A. japonicus JV-23, 
in 2 L Erlenmeyer flasks. Both fungal strains were then grown at 25 °C in dark for 4 
weeks. Malbranchea aurantiaca RRC1813 was cultured in potato dextrose broth (PDB) 
at 28 °C, 200 rpm under dark for 14 days.  
 
Sample Extraction. The cultures with P. fellutanum and A. japonicus JV-23 mycelia 
were adjusted to pH 10-12 by 10 M KOH. The cultures were then extracted with the 
equal volume of ethyl acetate twice. The combined organic layer from each culture was 
washed with water, dried over anhydrous magnesium sulfate, and evaporated to dryness. 
The residues were re-dissolved in methanol prior to LC-MSn analysis. Malbrancheamides 
and pre-malbrancheamide were isolated by extracting the fungal culture with equal 
volume of ethyl acetate three times following in vacuo concentration. The dried residue 
was stored at -20 °C until ready to use. 
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Feeding 13C-Labeled Chemicals to M. aurantiaca. The feeding experiment followed a 
modified protocol previously described 18. Briefly, the fungal strain was initially grown in 
PDB for 5 days. Then the mycelium from 500 ml culture was collected and rinsed with 
100 ml of 50 mM Tris-Cl, pH 7.2. Doubly 13C-labeled chemicals were dissolved in 
methanol (1.25 mg/ml) and then 2.5 mg of each compound was added to 50 ml of trace 
element solution (35 mM NaNO3, 5.7 mM K2HPO4, 4.2 mM MgSO4, 1.3 mM KCl, 36 
μM FeSO4•7H2O, 25 μM MnSO4•H2O, 7 μM ZnSO4•7H2O, 1.5 μM CuCl2•2H2O) with 
0.1% Tween-20. The mixture was sonicated for about 15 min to aid in the formation of 
micelle, in which the mycelium from 500 ml culture was resuspended. The fungal strain 
was further grown at 28 °C, 200 rpm under dark for 7 more days. The secondary 
metabolites were extracted with 100 ml of ethyl acetate twice. The aqueous-organic 
mixtures were stirred for about 30 min to facilitate the extraction. Fungal mycelium was 
then removed with Waterman filter paper. The organic layers were treated as above. 13C-
labled malbrancheamide B was purified by semi-preparative HPLC. An Alltech Econosil 
C18 10µ (250 mm x 10 mm) was used with the flow rate of 3 ml/min in an isocratic 50 % 
methanol in 50 % water with 0.1 % TFA over 25 min. The compound was collected with 
detection wavelength 233 nm. The isolated compound was lyophilized and subjected for 
LC-MS analysis.  
 
LC-MSn Analyses. LC-MSn analyses were performed by using a ThermoFinnigan LTQ 
linear ion-trap instrument equipped with electrospray source and Surveyor HPLC system 
at room temperature. Separations were carried out with a Waters XBridgeTM C18 (3.5 μm, 
2.1x150mm) column at a flow rate of 210 μl/min with solvent A (water with 0.1% formic 
acid) and solvent B (acetonitrile with 0.1% formic acid). Solvent B was kept at 15% in 
solvent A for 2.5 min and then was gradually increased to 40% over 12.5 min, 80% over 
2 min, and then was kept at 80% for 6 min to elute fungal metabolites. The column was 
further re-equilibrated with 15% solvent B for 25 min. For mass spectrometry, the 
capillary temperature was set to 275°C with the source voltage at 3.6 kV, the source 
current at 3.5 µA, the capillary voltage at 30 V, and the tube lens at 119 V. Sheath gas 
flow was set to 28 psi and auxiliary gas flow was to be 5 arbitrary units. The normalized 
collision energy for ion fragmentation was 30%. The injection volume was 5-10 µl and 
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spectra were recorded in the positive ion mode. Selective ion monitoring (SIM) 
chromatographs were achieved with the selected m/z values. 
 
Structural Analysis of Naturally Isolated Malbrancheamide B.  1H NMR (400 MHz, 
DMSO-d6) δ 8.41 (s, 1 H), 7.32 (d, J = 8.4 Hz, 1 H), 7.27 (d, J = 1.7 Hz, 1 H), 6.95 (dd, J 
= 8.4, 1.7 Hz, 1 H), 3.36 (s, 1 H), 3.27 (d, J = 10.0 Hz, 1 H), 2.95 (m, 1 H), 2.76 (s, 2 H), 
2.43 (m, 1 H), 2.13 (d, J = 9.9 Hz, 1 H), 2.10-1.70 (comp, 6 H), 1.32 (s, 3 H), 1.26 (s, 3 
H); 13C NMR (100 MHz, DMSO-d6) δ 173.1, 142.6, 136.8, 125.3, 125.2, 118.7, 118.5, 
110.3, 103.7, 64.1, 58.5, 55.3, 53.9, 47.0, 34.0, 31.1, 30.0, 28.7, 26.6, 23.7, 22.5; IR (neat) 
3297, 1652, 1457 cm-1; HRMS (TOF+) calcd for C21H25N3OCl (M+H) 370.1680, found 
370.1670. 
 
MaPT Analytical Methods. A Beckman Coulter HPLC, fitted with an XBridgeTM C18 
column (5µm, 4.6 x 250 mm), coupled with a System Gold I68 Detector was routinely 
used for HPLC-UV analysis. The detection wavelength was set at 269 nm. A linear 
gradient of 20 – 70 % acetonitrile in 0.1 % TFA over 20 min was used for product 
detection. One 10-minute re-equilibration program with 20% acetonitrile in 0.1 % TFA 
followed each run. A SHIMADZU LCMS-2010EV system was used for LC-MS analysis 
with a linear gradient of 20 – 80 % acetonitrile in 0.1 % FA over 15 min. An XBridgeTM 
C18 (3.5 μm, 2.1x150mm) column was used with a flow rate of 208 μl/min. Varian Inova 
500 MHz or Bruker DRX 500 MHz instruments were used to record NMR spectra. VG 
(Micromass) 70-250-S Magnetic Sector Mass Spectrometer in ESI+ mode was used to 
record high resolution mass spectra. 
 
Isolation of MaPT Gene. Degenerate primers were designed from conserved sequences 
of the new class of PTs. The pair of PT-FW and PT-RV primers was used to screen 
putative PTs from isolated M. aurantiaca RRC1813 genomic DNA by PCR (Table S3-3). 
Fragments of about 750 bp were subcloned into pGEM-Teasy vector (Promega) and 
sequenced. BLASTX in NCBI (http://www.ncbi.nlm.nih.gov/BLAST/) was used to 
identify sequenced PT fragments. TAIL-PCR was applied to amplify fragments extended 
from both ends of PT gene to produce full length genomic DNA 26. The long specific 
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primers were designed on the known sequence, while two arbitrary primers were first 
used by Liu and coworkers 26. All primers used in TAIL-PCR are listed in Supplement 
Table S1. BCM Gene Finder (http://www.bioscience.org/urllists/genefind.htm) was used 
to predict putative introns in the full-length PT gene. A 63-bp intron was predicted and 
removed with primers of InterFW and InterRV along with PTFW(NdeI) and 
PTRV(BamHI) to produce the MaPT cDNA. Similarly, Aspergillus MF297-2 genomic 
DNA was isolated and used as the template to generate both NotA and NotD cDNAs with 
the above overlapping PCR technology. 
  
Gene Cloning, Expression and Protein Purification. The purified cDNAs were ligated 
to pET28a for transformation of E. coli DH5α competent cells. The constructs were 
isolated and submitted for sequencing to exclude mutations introduced during PCR 
amplification and gene manipulation. The constructs was transferred into E. coli BL21 
(DE3) competent cells or BL21 CodonPlus-(DE3)-RIPL for protein expression. Cells 
harboring the construct were cultured in LB medium containing 25 µg/ml of kanamycin 
and grown at 37 °C in a shaker at 200 rpm until OD600 reached 0.6. The cultures were 
then induced by IPTG with a final concentration of 0.2 mM. The cultures were further 
grown at 16 °C in a shaker at 180 rpm for 16 hours. The cells were harvested by 
centrifugation (7250 g, 12 min, and 4 °C) and cell pellets were stored in -80 °C or 
directly used for protein purification. For MaPT, cell pellet was resuspended in 50 ml 
lysis buffer [1 X PBS, 3 mM β-mercaptoethanol (BME), 10 % glycerol, 20 mM 
imidazole, pH 7.4], which was sonicated to release soluble proteins. The supernatant after 
centrifugation at 35,000 x g at 4 °C for 36 min was incubated with 5 ml pre-equilibrated 
Ni-NTA agarose resin (Qiagen) at 4 °C for 2 h. The resin was then washed with 150 ml 
lysis buffer and recombinant His6-MaPT was eluted with 10 ml 200 mM imidazole in 1 X 
PBS (pH 7.4), 3 mM BME, and 10 % glycerol. The protein was further purified with 
Superdex 200 column (Amersham Biosciences) with gel chromatography running buffer 
(1 X PBS, 1 mM DTT, 10 % glycerol, pH 7.4). Protein absorbance at 280 nm was 
measured for calculating its concentration with an extinction coefficient of 88490. The 
protein was then aliquoted and stored at -80 °C. The final yield of His6-MaPT was 2.5 
mg/L.  For NotA and NotD purification, the cell pellets were resuspended in 40 ml 
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binding buffer (50 mM Tris-Cl, pH 7.7, 200 mM NaCl, 3 mM β-mercaptoethanol, 10 % 
glycerol) with 20 mM imidazole. The resuspended cell solutions were sonicated to 
release the soluble proteins. The soluble supernatants were collected and incubated with 
2.5 ml pre-equilibrated Ni-NTA agarose resin (Qiagen) after centrifugation at 36 000 g at 
4 °C for 32 min. After 2-hour incubation at 4 °C with gentle shaking, the resin was 
washed with 50 ml binding buffer with 20 mM imidazole, then 50 ml binding buffer with 
30 mM imidazole, and finally 80 ml binding buffer with 40 mM imidazole. The 
recombinant His6-NotA and NotD were gradually eluted with elution buffer (50 mM 
Tris-Cl, pH 7.7, 50 mM NaCl, 3 mM β-mercaptoethanol, 10 % glycerol). Subsequent 
desalting was attained by buffer exchange into elution buffer with a PD-10 column. The 
protein was then aliquoted and stored at -80 °C.  
 
Preparation of Enzyme Mutants. MaPT, NotA, and NotD gene mutants were prepared 
following the protocols from Stratagene QuikChange® II Site-Directed Mutagenesis Kit. 
The mutagenesis primers were shown in Table S3-2 and S3-3. The same procedures for 
preparation of wild type proteins were followed to produce their mutants except that only 
Ni-NTA agarose resin was used for MaPT mutant purification. 
 
Protein Analysis. The subunits of prenyltransferase were analyzed by 4-12 % SDS-
PAGE and protein bands were stained with Commassie brilliant blue R-250. The 
molecular weight of MaPT with His6-tag at its N-terminus was determined by Superdex 
75 column (Amersham Biosciences) with gel chromatography running buffer. The 
column was calibrated with bovine serum albumin (66 kD), chicken egg ovalbumin (43 
kD), bovine trypsinogen (25 kD), and ribonuclease A (13. 7 kD). The molecular weight 
of MaPT was calculated as 61.6 kD. For NotD, Superdex S-200 column (Amersham 
Biosciences) was used with running buffer (50 mM Tris-Cl, pH 7.5, 200 mM NaCl, 10 % 
glycerol, with or without 1 mM DTE). 
 
Enzyme Assays. A). MaPT The 100-µl reaction mixture routinely contained 5 mM 
MgCl2, 0.25 mM L-Trp, 0.2 mM DMAPP, and 1 µl of 0.86 µg/µl MaPT in reaction buffer 
(1 X PBS, pH 7.4, 10 % glycerol, and 3 mM BME). Enzyme reactions were initiated by 
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adding MaPT after pre-warming the other components at 30 °C for 1 min and then kept at 
30 °C for 30 min. Enzyme boiled at 100 °C for 10 min was used as a negative control. In 
the mutagenesis studies, MaPT mutants were used as the enzyme source. The reaction 
was stopped with 10 µl of 1.5 M TCA. The mixture was agitated well and centrifuged at 
13,000 g for 5 min. The enzyme products were detected by HPLC. In order to investigate 
substrate specificity, L-Trp was substituted with a series of derivatives. IPP, GPP, or FPP 
also substituted DMAPP in the reactions. B). NotA and NotD. The 100-µl reaction 
mixture contained 1 µg of NotA or NotD, 5 mM MgCl2, 0.1 mM brevianamide F, 0.1 
mM DMAPP in the reaction buffer (50 mM Tris-Cl, pH 7.5, 10 % glycerol, and 3 mM 
BME). The reaction was initiated by adding enzyme after pre-warming the other 
components at room temperature for 1 min. After mixing well and briefly centrifuging, 
the reactions were further incubated at room temperature for 45 min and stopped with 15 
µl of 1.5 M TCA. The mixtures was mixed well and centrifuged at 13000 g for 5-10 min. 
The mixture was mixed well and centrifuged at 13000 g for 5 min. To detect product, an 
aliquot of 100-µl solution was subjected to HPLC with detection at 222 nm. Solvent B 
(acetonitrile in 0.1 % TFA) was increased from 20 % to 30 % for 5 min and then 
increased to 80 % in next 20 min. One 5-minute re-equilibration program with initial B 
concentration was followed after linear gradient. All experiments were performed in 
duplicate. The area under product peak was measured with Beckman Software and the 
content in the peak was converted into nano-moles with deoxybrevianamide E standard 
curve. 
 
Metal Dependence of Prenyltransferases. 5 mM of divalent metal ions (Mg2+, Ca2+, 
Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Zn2+, and Sn2+) were added to the routine reaction mixture. 
5 mM EDTA, EGTA, ethylenediamine-N,N'-diacetic acid (EDDA), and 1,3-diamino-2-
propanol-N,N,N',N'-tetraacetic acid (DHPTA) were added to reaction buffer containing 
0.86 µg MaPT and the mixture was incubated at 30 °C for 5 min. Then 0.25 mM L-Trp 
and 0.2 mM DMAPP were added to bring the volume to 100 µl and initiate the reaction, 
which was further incubated at 30 °C for 30 min before terminating with 10 µl of 1.5 M 
TCA. The products were detected by HPLC, and experiments were performed in 
duplicate. For NotD, the reaction mixtures were incubated at room temperature. 
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Optimal Conditions for Enzyme Reaction. A). MaPT. For investigation of optimal 
temperature, reactions were conducted under 4 °C, 15 °C, 23 °C, 30 °C, 37 °C, and 42 °C 
in the reaction buffer described above. For investigation of optimal reaction buffer pH 
value, 50 mM Tris-Cl or sodium phosphate with various pH values (5, 6, 7, 7.4, 8, 9, and 
10) were used in the reactions at 30 °C. The same procedure for routine enzyme assay 
was followed in this section. B). NotD. For investigation of optimal temperature, 
reactions were conducted under 4 °C, 20 °C, 26 °C, 30 °C, 37 °C, 42 °C, and 55 °C in the 
reaction buffer described above. For investigation of optimal reaction buffer pH value, 50 
mM Tris-Cl or sodium phosphate with various pH values (4, 5, 6, 7, 7.5, 8, 9, and 10) 
were used in the reactions at room temperature. The same procedure for routine enzyme 
assay was followed in this section. 
 
Kinetics Analysis. A). MaPT. In order to find suitable MaPT concentration linearly 
correlated with product generation, 0.1, 0.25, 0.5, 1, 2, 4, and 8 µl of 0.86 µg/µl enzyme 
was added to reaction mixtures. The reaction was incubated at 30 °C for 6 min before 
terminating with 10 µl of 1.5 M TCA. In order to determine the time course of enzyme 
reactions, 50 µl of reaction mixture was removed and mixed with 5 µl of 1.5 M TCA at 1 
min, 3 min, 5 min, 8 min, 12 min, 16 min, 20 min, 25 min, 30 min, and 35 min. The 
enzyme product was detected with the same method described above.  
 
Reaction mixtures in the enzyme kinetic analysis contained 0.22 µg MaPT, and 5 
mM MgCl2. To determine kinetic parameters of L-Trp, 5-OH-L-Trp, and L-abrine, 0.2 
mM DMAPP was included in the reaction and 2-600 µM L-Trp, 5-1500 µM 5-OH-L-Trp, 
or 5-1000 µM L-abrine was added. To determine kinetic parameters of DMAPP, 0.25 mM 
L-Trp, 2 mM 5-OH-L-Trp, or 1 mM L-abrine was included in the reaction while DMAPP 
final concentration was varied (1-100 µM, 5-200 µM, 5-160 µM, respectively). The 
reaction mixtures without L-Trp, 5-OH-L-Trp, L-abrine, or DMAPP were pre-warmed at 
30 °C for 1 min. The reactions were initiated by mixing them with the single omitted 
component and were further incubated at 30 °C for 5 min and 6 min for L-Trp and 5-OH-
L-Trp or L-abrine, respectively, before terminating with 10 µl of 1.5 M TCA. The 
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mixtures were mixed well and centrifuged at 13,000 x g for 5 min. A 100 µl solution was 
subjected to HPLC for product detection. All experiments were performed in duplicate. 
The area under the product peak was measured and the peak content amount was 
calculated using a dimethylallyltryptophan (DMAT) standard curve. The initial rate was 
calculated with equation of product (nmol)/100 µl x 110 µl/100 µl. The data were fit to 
the Michaelis-Menton equation or the substrate inhibition equation (v = Vmax[S]/(Km + 
[S](1+[S]/Ks)). For the competitive kinetic analysis, 0-100 µM D-Trp was included in the 
reactions containing varied concentration of L-Trp or DMAPP. 100 µM L-Phe was also 
used as the putative inhibitor in the assay.  
 
B). NotD. The NotD concentration and reaction time were investigated to 
examine the linear correlation with product generation. The 100-µl reaction mixture 
contained 0.25 µg of NotD and 5 mM MgCl2 in the reaction buffer (50 mM Tris-Cl, pH 
7.5, 10 % glycerol, and 3 mM BME). For investigation of brevianamide F kinetic 
parameters, 0.1 mM DMAPP was included in the reaction and brevianamide F final 
concentration was varied (1, 2, 3, 5, 70, 10, 30, 60, and 90 µM). For determination of 
DMAPP kinetic parameters, 0.1 mM brevianamide F was included in the reaction while 
DMAPP final concentration was varied (2, 5, 7, 10, 30, and 60 µM). The reactions 
without brevianamide F or DMAPP were pre-warmed at room temperature for 1 min and 
initiated with mixing with the omitted component. After mixing well and briefly 
centrifuging, the reactions were further incubated at room temperature for 5 min and 
stopped with 15 µl of 1.5 M TCA. The mixture was mixed well and centrifuged at 13000 
g for 5 min. To detect product, an aliquot of 100-µl solution was subjected to HPLC with 
detection at 220 nm. All experiments were performed in duplicate. The area under 
product peak was measured with Beckman Software and the content in the peak was 
converted into nano-moles with deoxybrevianamide E standard curve. The initial rate was 
calculated with product (nmol)/100 µl * 115 µl / 100 µl. The data were fit to Micheal-
Menton equation. 
 
Characterization of MaPT Reaction Products. 2 ml reaction mixtures containing 2 mg 
of L-Trp, 5-OH-L-Trp, 5-Me-DL-Trp, or L-abrine and 1.2 mg of DMAPP were incubated 
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at 30 °C overnight and stopped by adding 200 µl of 1.5 M TCA. The mixtures were 
mixed well and centrifuged at 13,000 x g for 5 min. The products were separated by a 
semi-preparative XBridgeTM C18 column with the same program except using a flow rate 
of 3 ml/min. The isolated products were lyophilized and subjected for 1H and 13C NMR 
analyses and high resolution MS analysis (HRMS). DMAT: 1H NMR (D2O, 500 MHz) δ 
7.40 (d, J= 8.0 Hz, 1H), 7.31 (s, 1H), 7.20 (t, J= 8.0, 7.5 Hz, 1H),  6.99 (d, J= 7.0 Hz, 1H), 
5.37 (s, 1H), 4.11 (dd, J= 10.5, 4.5 Hz, 1H); 3.77 (d, J= 6.5 Hz, 1H), 3.74 (dd, J= 15.5, 
4.5 Hz, 1H), 3.27 (dd, J= 15.5, 10.5 Hz, 1H), 1.75 (s, 3H), 1.78 (s, 3H). HRMS (ESI+): 
observed m/z = 273.1610; calculated m/z = 273.1603. Dimethylallyl 5-OH-L-Trp 
(DMA5HT): 1H NMR (CD3OD, 500 MHz) δ 7.09 (d, J=3.0 Hz, 1H), 7.07 (s, 1H), 6.74 (d, 
J=8.5 Hz, 1H), 5.12 (s, 1H), 4.92 (s, 1H), 4.15 (dd, J= 11.5, 3.5 Hz 1H), 3.81-3.84 (m, 
1H), 3.77 (d, J= 15.1, 3.6 Hz, 1H), 3.58 (dd, J= 21.1, 16.3 Hz, 1H), 3.08 (dd, J= 15.4, 
11.4 Hz, 1H), 1.81 (s, 3H), 1.66 (s, 3H). 13C NMR (CD3OD, 500 MHz) δ 171.9, 149.2, 
134.5, 132.9, 126.9, 126.3, 123.1, 119.5, 113.8, 110.9, 108.4, 55.4, 30.2, 26.3, 25.9, 18.6. 
HRMS (ESI+): observed m/z = 289.1552; calculated m/z = 289.1552. Dimethylallyl 5-
Me-DL-Trp (DMA5MT): 1H NMR (CD3OD, 500 MHz) δ 7.14 (d, J=8.5 Hz, 1H), 7.12 (s, 
1H), 6.96 (d, J=8.5 Hz, 1H), 5.10 (s, 1H), 4.16 (dd, J= 11, 4 Hz, 1H); 3.79-3.82 (m, 1H), 
3.77 (d, J= 4 Hz, 1H), 3.67 (d, J= 18 Hz, 1H), 3.12 (dd, J= 15, 11 Hz, 1H), 2.31 (s, 3H), 
1.83 (s, 3H), 1.71 (s, 3H). 13C NMR (CD3OD, 500MHz) δ 171.5, 138.0, 133.5, 132.4, 
126.7, 126.6, 126.5, 125.9, 125.0, 109.8, 108.0, 55.1, 30.6, 29.8, 25.3, 19.1, 18.5. HRMS 
(ESI+): observed m/z = 287.1762; calculated m/z = 287.1760. Dimethylallyl L-abrine 
(DMAA): 1H NMR (CD3OD, 500 MHz) δ 7.23 (d, J=8 Hz, 1H), 7.19 (s, 1H), 7.04 (t, 
J=15.5, 7.4 Hz, 1H), 6.82 (d, J=6.9 Hz, 1H), 5.30 (s, 1H), 4.20 (dd, J= 9.5, 5 Hz, 1H); 
3.40-3.77 (m, 1H), 3.71 (d, J= 4.6 Hz, 1H), 3.34-3.36 (m, 1H), 3.25-3.27 (m, 1H), 2.65 (s, 
3H), 1.78 (s, 3H), 1.75 (s, 3H). 13C NMR (CD3OD, 500 MHz) δ 171.3, 142.3, 139.5, 
135.1, 133.6, 125.8, 125.4, 123.4, 121.2, 111.0, 108.4, 63.8, 33.5, 33.1, 29.6, 26.0, 18.4. 
HRMS (ESI+): observed m/z = 287.1766; calculated m/z = 287.1660. 
 
LC-MS Analysis of NotD Products. LC-MS analysis was performed by using a 
ThermoFinnigan LTQ linear ion-trap instrument equipped with electrospray source and 
Surveyor HPLC system at room temperature. Separations were carried out with a Waters 
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XBridgeTM C18 (3.5 μm, 2.1x150mm) column at a flow rate of 200 μl/min with solvent 
A (water with 0.1% formic acid) and solvent B (acetonitrile with 0.1% formic acid). 
Solvent B was kept at 2% in solvent A for 4 min and then was gradually increased to 
90% over 15 min and then was kept at 90% for 2 min to elute fungal metabolites. The 
column was further re-equilibrated with 2% solvent B for 10 min. For mass spectrometry, 
the capillary temperature was set to 275°C with the source voltage at 3.5 kV, the source 
current at 3.5 µA, the capillary voltage at 30 V, and the tube lens at 119 V. Sheath gas 
flow was set to 28 psi and auxiliary gas flow was to be 5 arbitrary units. The normalized 
collision energy for ion fragmentation was 20 %. The injection volume was 19 µl and 
spectra were recorded in the positive ion mode. Selective ion monitoring (SIM) 
chromatographs were achieved with the selected m/z values. 
 
Analysis of Metal Content of MaPT. Twelve divalent metal ions (Mg2+, Ca2+, V2+, Cr2+, 
Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Zn2+, Cd2+, Pb2+) in MaPT were detected by Inductively 
Coupled Plasma Mass Spectrometry (ICP-MS) (Finnigan) in the Department of 
Geological Science, University of Michigan. The gel chromatography running buffer was 
used as the blank sample.  All detected metal ion content measurements except Ni2+ were 
< 0.05 mol per mol of MaPT. 
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3.5. Supplementary Figures and Tables 
 
 
Figure S3-1. MSn spectra of authentic paraherquamide A (A) and authentic 
paraherquamide B (B). These spectra were used to identify both compounds in extracts 




Figure S3-2. MSn spectra of two metabolites at 14.45 min (A) and at 14.88 min (B) from 
the extract from A. japonicus JV-23. These metabolites were identified as 
paraherquamide A (14.45 min) and paraherquamide B (14.88 min) by comparing their 





Figure S3-3. MS and MS2 spectra of authentic VM55599 (A) and authentic pre-
paraherquamide (B). These spectra were used to identify VM55599 and pre-






Figure S3-4. MS/MS spectrum of authentic pre-malbrancheamide (A) and doubly 13C-
labeled pre-malbrancheamide (B). In the MS/MS spectrum of doubly 13C-labeled pre-
malbrancheamide, fragments at m/z of 177.19 and 178.09 were observed. Similarly, 
fragments at m/z of 160.01 and 161.09 were also identified.  
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Figure S3-5. Determination of molecular weight of native His6-MaPT by gel filtration. 
The Superdex 75 column was calibrated with bovine serum albumin (66 kD), chicken egg 
ovalbumin (43 kD), bovine trypsinogen (25 kD), and ribonuclease A (13. 7 kD). The 
molecular weight of native MaPT was calculated as 61.6 kD. 
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Figure S3-6. Determination of optimal reaction conditions for MaPT. The optimal 





Figure S3-7. Investigation of MaPT metal ion dependence under optimal reaction 
conditions. Addition of 5 mM EDTA caused the total loss of enzyme activity which can 
not be restored by adding 10 mM Mg2+. Experiments were conducted in duplicate. The 





Figure S3-8. Sequence analysis of MaPT with CloQ (AAN65239), NovQ (AF170880), 
Fnq26 (CAL34101) and Orf2 (BAE00106). The alignment was performed with ESPript 
(http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) using the known Orf2 secondary 
structure (1ZCW). The residues labeled with blue asterisks were mutated to investigate 
their potential roles in substrate binding and enzyme catalysis. Residues labeled with 
triangles are additional amino acids corresponding to those involved in binding of 
diphosphate, especially α-phosphate, in Orf2. The sequence labeling corresponds to Orf2.  
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Figure S3-9. 4-12 % SDS-PAGE analysis of MaPT site-directed mutants. All mutants 






Figure S3-10. A. 4-12 % SDS-PAGE analysis of NotA and NotD with its mutants. B. 
Determining molecular weight of native His6-NotD by gel filtration. The molecular 
weight of native NotD was calculated as 292 kD but its monomeric theoretical molecular 




Figure S3-11. Selected substrates to test NotA and NotD activities. Brevianamide F and 
keto-premalbrancheamide were doubly labeled with 13C atoms shown in red.  
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dbe_091016124801 #1786 17.34 1 1.64E5
F:
RT: AV: NL:
ITMS + c ESI d Full ms2 352.00@20.00 [ 85.00-365.00]
 
Figure S3-12. MS2 analysis of NotD enzyme product (top) and authentic 
deoxybrevianamide E (bottom).  
13CBreF #1551 17.33 1 1.52E5
F:
RT: AV: NL:
ITMS + c ESI d Full ms2 354.00@20.00 [ 85.00-365.00]





































145.03 186.05 284.12 354.25129.94 337.01312.18154.08116.06 261.15202.17182.94 238.18






































143.98 186.10 282.20 352.34129.94 335.16310.23268.08153.03115.06 183.15 221.17
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Figure S3-14. Kinetic analysis of NotD. The 100-µl reaction mixture contained 0.25 µg 
of NotD and 5 mM MgCl2 in the buffer (50 mM Tris-Cl, pH 7.5, 10 % glycerol, and 3 




Figure S3-15. Alignment analysis of NotD. NotD shares key amino acid residues with 
other prenyltransferases for DMAPP and indole ring interaction. Two lysine residues 
labeled with stars were responsible for DMAPP interaction. Four tyrosine residues 
labeled with black cycles may shield the reactive carboncation from solvent. Three 
residues mutated in my studies were labeled with red arrows.  
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 Table S3-1 1H NMR analysis of four MaPT products 
 
Proton DMAT DMAT DMA5HT DMA5MT DMAA 
H-2 7.30 s 7.31 s 7.07 s 7.12 s 7.19 s 
H-4 -- -- -- -- -- 
H-5 6.99 d (7.5) 6.99 d (7.0) 4. 92 s (5-
OH) 
2.31 s (5-CH3) 6.82 dd (6.9) 
H-6 7.20 dd (8.1, 
7.5) 
7.20 t (8.0, 
7.5) 
6.74 d (8.5) 6.96 d (8.5) 7.04 dd (15.5, 
7.4) 
H-7 7.41 d (8.1) 7.40 d (8.0) 7.09 d (3.0) 7.14 d (8.5) 7.23 d (8) 
H-α 3.89 dd (10.4, 
4.5) 




4.16 dd (11, 
3.5) 
4.20 dd (9.5, 
5) 
H-β 3.25 dd (15.6, 
10.4) 
3.71 dd (15.6, 
4.5) 
3.27 dd (15.5, 
10.5) 






3.12 dd (15, 
11) 
3.77 d (4) 
3.25-3.27 m 
3.71 d (4.6) 




3.67 d (18) 
3.40-3.77 m 
3.34-3.36 m 
H-2’ 5.37 m 5.37 m 5.12 s 5.10 s 5.30 s 
H3-4’ 1.76 s 1.75 s 1.66 s 1.71 s 1.75 s 
H3-5’ 1.79 s 1.78 s 1.81 s 1.83 s 1.78 s 
NH-CH3 -- -- -- -- 2.65 s 
*: DMAT was dissolved in D2O and other three products were dissolved in CD3OD.  
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Table S3-2 Primers for NotA and NotD intron removal, gene expression, and mutant 
preparation 
 
Name Sequence (5’→3’) Function 
FW1(NdeI) AAGCGCATATGGCCATTGAAGAAAAGTC NotA expression 
RV1(NotI) ATAATGCGGCCGCTCAGAAAGGAGAGTAGTAC NotA expression 
InterF1 GAACGTCCAGTCGTACTATCCCAATCTGGATCTCAA NotA Intron removal 
InterR1 TTGAGATCCAGATTGGGATAGTACGACTGGACGTTC NotA Intron removal 
FW(NdeI) ATCGGCATATGACGGCCCCAGAGCTC NotD expression 
RV(NotI) ATTATGCGGCCGCTCAATCTTCTTCCCACAG NotD expression 
InterF GATACCTTGCAGCAGCTGTACCCCGACCAGGACATTTC NotD Intron removal 
InterR GAAATGTCCTGGTCGGGGTACAGCTGCTGCAAGGTATC NotD Intron removal 
E108GF GTAGCGGACTGCCGATCGGATTCAGTCTCA ACTTCCAG mutagenesis 
E108GR CTGGAAGTTGAGACTGAATCCGATCGGCAGTCCGCTAC mutagenesis 
E108DF GTAGCGGACTGCCGATCGATTTCAGTCTCAACTTCCAG mutagenesis 
E108DR CTGGAAGTTGAGACTGAAATCGATCGGCAGTCCGCTAC mutagenesis 
R122GF GGCTCGCACCGACTGTTGGGCATCGGGTTTGAACCCG mutagenesis 
R122GR CGGGTTCAAACCCGATGCCCAACAGTCGGTGCGAGCC mutagenesis 
R122HF GGCTCGCACCGACTGTTGCACATCGGGTTTGAACCCG mutagenesis 
R122HR CGGGTTCAAACCCGATGTGCAACAGTCGGTGCGAGCC mutagenesis 
F216YF CTCGTCAAGGGCTATGTATACCCGTATCTGAAAGCAAAGGC mutagenesis 
F216YR GCCTTTGCTTTCAGATACGGGTATACATAGCCCTTGACGAG mutagenesis 
F216VF CTCGTCAAGGGCTATGTAGTCCCGTATCTGAAAGCAAAG GC mutagenesis 
F216VR GCCTTTGCTTTCAGATACGGGACTACATAGCCCTTGACGAG mutagenesis 
Y371FF GTTCCCCGTGCCCAAGTTCTTCCTCCCCGTGCATGGC mutagenesis 
Y371FR GCCATGCACGGGGAGGAAGAACTTGGGCACGGGGAAC mutagenesis 
Y371VF GTTCCCCGTGCCCAAGTTCGTCCTCCCCGTGCATGGC mutagenesis 
Y371VR GCCATGCACGGGGAGGACGAACTTGGGCACGGGGAAC mutagenesis 
W424YF GACAACCCGTTTGCAATCTTATATATCGTATTCCTATACTGC mutagenesis 
W424YR GCAGTATAGGAATACGATATATAAGATTGCAAACGGGTTGTC mutagenesis 
W424GF GACAACCCGTTTGCAATCTGGGATATCGTATTCCTATACTGC mutagenesis 




Table S3-3 Primers for MaPT gene identification, intron removal, gene expression, and 
mutant preparation 
 
Name Sequence (5’→3’) Function 
PT-FW GANGAYCASCGNCTNTGGTGG gDNA screening 
PT-RV NCCNCCCAGNGTCCANASRTC gDNA screening 
3SP1 AGGGGCAAGCAAATATATCCTCTTC Specific primer 
3SP2 ATTATCTCGAATGCCGTGGTCCC Specific primer 
3SP3 TGATACGAGACTTATGGGAGGAAATCA Specific primer 
5SP1 AGCCAACGATCTCGATCGTTCGTA Specific primer 
5SP2 CATGTTTCTTGTAGATAGCAAGGTGTCTG Specific primer 
5SP3 GTCATAGTTGGCGGATTGGAGC Specific primer 
AD1 CAWCGICNGAIASGAA Arbitrary primer 
AD2 TCSTICGNACITWGGA Arbitrary primer 
PTFW 
(NdeI) 
CCACATATGTCGACTACAGAATCCTTGACC Gene expression 
PTRV 
(BamHI) 
GCGCGGATCCTTAAAATGATCTAATATATGAC Gene expression 
InterFW GCTTGAAAGCATACTACCCGGATGAAAATTATG Intron removal 
InterRV CATAATTTTCATCCGGGTAGTATGCTTTCAAGC Intron removal 
T105VF CTCAGTAGTCAGATATGTGTTCGAGCCCATAAATGC mutagenesis 







D179EF CAGAACAAGTTAGCTTTGGAATTAAAGGGCGGGGAATTC mutagenesis 
D179ER GAATTCCCCCCCCTTTAATTCCAAAGCTAACTTGTTCTG mutagenesis 
D179NF CAGAACAAGTTAGCTTTGAATTTAAAGGGCGGGGAATTC mutagenesis 
D179NR GAATTCCCCCCCCTTTAAATTCAAAGCTAACTTGTTCTG mutagenesis 
D179VF CAGAACAAGTTAGCTTTGGTTTTAAAGGGCGGGGAATTC mutagenesis 













K261EF CTCCCATAAGTCTCGTATCGAGATCTACATTTCGGAAG mutagenesis 
K261ER CTTCCGAAATGTAGATCTCGATACGAGACTTATGGGAG mutagenesis 
K261LF CTCCCATAAGTCTCGTATCCTGATCTACATTTCGGAAG mutagenesis 
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Substrates in feeding experiments as well as the substrates to test NotA and Not D 




Biochemical Characterization of the Biosynthesis of Anticancer 




This chapter focuses on the first studies of the gene cluster responsible for the 
biosynthesis of trichothecene macrolides in one marine fungal strain, Myrothecium 
verrucaria. Fungal genomic libraries were constructed and screened with specific probes. 
One gene cluster was identified in a 102-kb DNA fragment. In total, 36 genes were 
identified in the gene cluster, and functions of these genes were predicted. VerH 
containing three C2H2 zinc finger domains was predicted as a transcriptional activator. 
Bioinformatic analysis found multiple VerH binding sites in promoter regions of the 
verrucarin biosynthetic genes. VerN was predicted as a sesquiterpene synthase and the 
homolog of Tri5 in acyclic trichothecene biosynthesis. Removal of one intron resulted in 
the generation of its cDNA for heterologous overexpression in E. coli. The purified 
enzyme was shown to convert farnesyl pyrophosphate (FPP) into trichodiene, validating 
its role in natural product biosynthesis. The cDNA of one P450, VerE, was produced after 
removing four introns, and was overexpressed in a yeast strain. The isolated yeast 
microsome fraction was utilized to convert trichodiene into two putative metabolites as 
determined in GC-MS analysis. Finally, a putative biosynthetic pathway to produce 
verrucarin and roridin was proposed, based on predicted functions of genes in the cluster 




Fungi are ubiquitous in Nature and are rich sources of numerous secondary 
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metabolites. Many fungal natural products, such as antibacterial penicillins, 
cephalosporins, immunosuppressive cyclosporine A, and cholesterol-lowering HMG-
CoA reductase inhibitor “statins”, have been clinically used to fight against many 
diseases 1. Conversely, many mycotoxins, which commonly contaminate food supply, 
upon consumption, threaten the lives of animals and human beings and cause enormous 
economical loss. Although mycotoxins are less well known than mushroom poisons, they 
indeed cause a higher incidence of disease, because they contaminate about 25 % of the 
worldwide agricultural crop. As early as 430 B.C., ergot alkaloids commonly produced 
by Claviceps sp., Aspergillus sp., and Penicillium sp., were correlated with a human 
disease called ergotism, or St. Anthony’s Fire (Figure 4-1) 1. The most well-known 
mycotoxins are the aflatoxins named after the producer, Aspergillus flavus. The four 
major aflatoxins — aflatoxin B1, B2, G1 and G2 — were identified on the basis of their 
blue or green fluorescence under ultraviolet light and aflatoxin B1 is one of the most toxic 
and carcinogenic compounds ever discovered (Figure 4-1) 2. A. flavus is widely 
distributed and is highly infective to most major crop plants. These factors make it 
difficult to prevent aflatoxin contamination of foods and feeds. For example, a severe 
outbreak was reported in Kenya and had at least a 39% incidence of death (317 cases 
with 125 deaths) resulting from acute hepatotoxicity in 2004 3. Another group of 
mycotoxins, fumonisins, is mainly produced by the maize pathogens, Fusarium 
verticillioides (formerly F. moniliforme) and F. proliferatum (Figure 4-1). The 
predominant fumonisin, fumonisin B1, is the agent responsible for leukoencephal-
omalacia in horses and pulmonary edema in swine and may be associated with 
esophageal cancer in human 4. Due to the health concerns related to fumonisin 
consumption, the Food and Drug Administration (FDA) has established recommended  
 
 
Figure 4-1. Chemical structures of selected fungal mycotoxins. 
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guidelines for the levels in food and feedstuff. The fumonisin content was recommended 
to be lower than 2 mg / kg in degermed dry milled corn products such as flaking grits, 
corn grits, corn meal, and corn flour, and 5 mg / kg in maize fed to horses 5.  
 
 Trichothecenes are one group of mycotoxins produced by a number of unrelated 
fungal genera including Fusarium, Mycothecium, Trichoderma, Trichothecium, 
Stachybotrys, Verticimonosporium, and Cephalosporium sp. (Figure 4-2) 6. Currently, 
more than 200 trichothecenes have been isolated, and a few cause a range of acute and 
chronic symptoms in animals and human beings after consumption of contaminated crops 
or feeds 7. For example, thousands of people in Russia died after consuming grain 
contaminated with Fusarium species during World War II. One trichothecene, T-2 toxin, 
is believed to correlate with alimentary toxic aleukia outbreaks since the 19th century and 
with outbreaks of hemorrhagic syndrome in farm animals in North America and Europe 8. 
The ease for trichothecene-producing fungal strains growing on crop plants suggests the 
necessity to detect its level in food supplies. Accordingly, about $ 637 million are 
annually lost due to deoxynivalenol (DON) contaminating human crop foods.  
 
Structurally, all trichothecenes are sesquiterpenes with the common features of 
one tricyclic nucleus, one double bond between C-9 and C-10, and one epoxide between 
C-12 and C-13. According to the different side chains attached to the trichothecene 
skeleton, these mycotoxins are divided into four types (A-D) (Figure 4-2) 6. T-2 toxin 
and diacetoxyscirpenol (DAS, also named as anguidine) are two examples in type A, 
while DON belongs to type B because of the presence of keto group at its C-8. Type C 
includes several non-Fusarium trichothecenes that contain an additional epoxide between 
their C-7 and C-8. In contrast to all in the above three types, trichothecenes in type D 
contain a macrocyclic ring between C-4 and C-15. These macrocyclic mycotoxins, such 
as satratoxins, verrucarins, and roridins, are more toxic than their acyclic counterparts 
and have attracted increasing interests to control their production. 
  
The primary mechanism of trichothecene toxicity is to inhibit protein synthesis 9. 
They interact with 60S subunits of the mammalian ribosome in a non-competitive manner,  
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Figure 4-2. Chemical structures of selected trichothecenes. All of trichothecene 
mycotoxins are filled into four types (A-D) based on their side chains. 
 
and the different trichothecenes specifically inhibit initiation, elongation, or termination 
steps in protein synthesis 6, 10.  Moreover, structural differences of their side chains cause 
different degrees of toxicity toward eukaryotic cells 6. The most potent protein synthesis 
inhibitors are T-2 toxin, verrucarin A, and roridin A from a group of nineteen 12,13-
epoxytrichothecene mycotoxins that were tested for their relative capabilities to inhibit 
protein synthesis in Vero cells and rat spleen lymphocytes 11. The other cellular effects of 
trichothecenes on eukaryotic cells include inhibition of DNA and RNA synthesis, 
inhibition of mitosis, and cell membrane effects 12. Recently, some trichothecenes were 
found to induce apoptosis, a programmed cell death response in various cell lines 13. 
Their apoptosis induction ability might require both translational arrest and mitogen-
activated protein kinase activity. However, how trichothecenes activate the eukaryotic 
signal transduction cascades and downstream gene products remains obscure. The overall 
effects of trichothecenes on eukaryotic cells led to develop them as the anticancer agents 
14-16. Anguidine (DAS) showed good potency and excellent selectivity toward leukemia 
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cells 16. However, in the late 1970s, five distinct series of Phase II studies involving 484 
patients produced unfavorable results with serious side effects and a lack of substantive 
anticancer activity 17. 
 
The intriguing structure, potent toxicity, and wide distribution of trichothecences 
has fostered considerable interests in understanding the biosynthetic pathway, genes, 
enzymes, regulation, and evolution, for this group of important mycotoxins. The 
biosynthesis of acyclic trichothecenes (type A and B) produced by Fusarium sp. have 
been extensively studies by one research group of USDA in past 25 years (Figure 4-3) 8. 
Twelve genes were found in the Tri5 gene cluster, and at least three essential genes were 
found to be outside this chromosomal region, but all were required for T-2 toxin 
biosynthesis in F. sporotrichioides 18. Briefly, one sesquiterpene synthase (Tri5) produces 
trichodiene, the key biosynthetic intermediate, from farnesyl pyrophosphate (FPP) 19. 
This intermediate is then converted into isotrichodermol by a single P450, Tri4 20, 21.  
 
 
Figure 4-3. A. One gene cluster for T-2 toxin biosynthesis in F. sporotrichioides. This 
gene cluster contains 12 essential genes. B. One biosynthetic pathway for type A and B 
trichothecenes produced by Fusarium sp. The biosynthetic steps in the box are shared 
by both types of trichothecenes, while T-2 toxin production in F. sporotrichioides 
requires three pathway specific enzymes.  
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This remarkable enzyme is proposed to catalyze at least two hydroxylations and one 
epoxidation on trichodiene. Trichothecene 3-O-acetyltransferase (Tri101) catalyzes the 
next step in trichothecene biosynthesis 22. Its product, isotrichodermin, is then 
hydroxylated by another P450 (Tri11) to generate 15-decalonectrin 23. Calonectrin is 
produced in the next step from acetylation of the OH group at C-15 by the second O-
acetyltransferase (Tri3) 24. All of above enzymes are shared in the biosyntheses of all 
type A and B trichothecenes produced by Fusarium sp. In F. sporotrichioides and F. 
graminearum, DAS is produced after one hydroxylation at C-4 by Tri13, and one 
subsequent C-4-O-acetylation of DAS by Tri7 produces 3,4,15-triacetoxyscirpenol (TAS) 
25. In F. sporotrichioides, three unique enzymes are required to convert TAS into T-2 
toxin, while five pathway-specific enzymes are expected in F. graminearum to produce 
nivalenol, another type B trichothecene 8. The biosynthetic pathway of DON in F. 
graminearum branches from the T-2 toxin pathway after the production of calonectrin.  
The studies of trichothecene serve as the primary model for fungal secondary metabolite. 
The findings not only help to develop practical control strategies but also offer 
opportunities for generating new sesquiterpenes through metabolic engineering.  
 
The biosynthesis of type D trichothecenes has not been studied extensively, in 
contrast to the biosynthesis of the acyclic trichothecenes in Fusarium. Trichothecene 
macrolides are mainly produced by plant fungal pathogens such as Myrothecium and 
Stachybotrys. Stachybotrys species are commonly found in indoor environments, and 
recently, there has been increased public attention to mycotoxins, including the 
satratoxins produced by this fungal species, because of their correlations with many acute 
and chronic diseases (Figure 4-2) 26-28. Moreover, M. verrucaria and M. roridum are 
commonly found on materials such as paper, textiles, and living plants. Fungal infections 
and verrucarins and roridins produced by these fungal strains may cause adverse effects 
on human living environments and crops. An understanding of their biosynthetic systems 
is critical for developing the control of their production. However, only three genes (Tri4, 
Tri5, and Tri6) were previously identified from M. roridum and shown to be involved in 
the biosynthesis of acyclic trichothecene moiety of roridins 29. In 2003, the Crews group 
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at the University of California-Santa Cruz isolated the marine fungus, M. verrucaria, in 
Hawaii. A group of type D trichothecenes, including verrucarins and roridins, were 
purified and characterized from this strain 30. This chapter describes my studies to isolate 
the complete gene cluster for verrucarin and roridin biosynthesis from the marine fungal 
species and the characterization of two enzymes involved in their biosynthetic pathwaies. 
 
4.3. Results and Discussion 
 
4.3.1. Isolation of Trichothecene Macrolide Gene Cluster from the Marine Fungus 
Myrothecium verrucaria 
 
Three genes similar to Tri4, Tri5, and Tri6, and one fungal iterative PKS gene 
were expected to be present in the verrucarin gene cluster. Thus, the Tri4, Tri5, and PKS 
KS domain were used as probes to screen M. verrucaria genome library. The fungal 
genomic DNA was isolated and nebulized into 30-40 kb fragments for the construction of 
the library. The protocols in the Epicentre CopyControlTM Fosmid Library Production Kit 
were followed to guide the processes. Initially, about 10,000 colonies were screened with 
one pair of degenerate primers designed on the basis of PKS KS domain, and two pairs of 
primers on the basis of conserved regions of Tri4 and Tri5 from M. roridium. Initially, 10 
positive hits were found with probes of KS and Tri5 (Table S1). Fosmid N1 was chosen 
for shotgun sequencing. In the 40.5-kb chromosomal fragment, 11 genes were identified. 
Seven exhibited high similarities to the characteristic trichothecene biosynthetic genes, 
Tri5, Tri6, Tri7, Tri9, Tri10, Tri11, and Tri12. Moreover, one fungal iterative PKS gene 
was identified in this region, strongly indicating the isolation of the correct gene cluster 
for verrucarin biosynthesis. Extensive efforts using the probes for the identified CoA 
ligase gene and Tri5 allowed us to identify fosmid C10, adding a new 14.6-kb sequence 
and revealing four more genes. However, the absence of the essential Tri4 caused us to 
prepare and screen the second fungal genomic fosmid library. About 1,500 colonies were 
further screened with the primers from both ends of the above gene cluster, and one 
positive hit covering each end was chosen for the subsequent shotgun sequencing (Figure 
4-4, Table S1). In total, one 101.6-kb chromosomal region was sequenced and its overall 




Figure 4-4 A. One sequenced chromosomal region covered by four fosmids. B. 
Thirty-six open reading frames were predicted in the sequenced region. The 
boundaries of trichothecene macrolide gene cluser were defined by the presence of VerH 
binding motifs in the gene promoter region.  
 
 In total, 36 open reading frames (ORF) were identified in the sequenced region. 
Preliminary functional assignments of individual ORFs were made by comparison of the 
deduced gene products with proteins of known functions in the NCBI database (Table 4- 
1). At the left side of the sequenced fragment, Orf1, Orf2, Orf3 were predicted to be one 
putative fungal phospholipase A2 isoform 1, one putative fungal endoglucanase V, and 
one galactose oxidase precursor, respectively, indicating they may not be involved in 
verrucarin biosynthesis. Orf4 encoded a putative salicylate 1-monooxygenase while Orf5 
may be a C6 transcription factor. Subsequently, Orf6 and Orf8 were predicted as a 
putative short-chain dehydrogenase /reductase and a putative NAD-dependent epimerase 
/dehydratase, respectively, but the function of Orf7 is unknown. The involvement of 
these gene products in verrucarin biosynthesis was predicted by the analysis of their 
promoter regions. VerH shows 66 % identity to Tri6, a C2H2 trichothecene-specific 
transcriptional activator 31. Tri6 binds to the conserved DNA motif of YNAGGCC in the 
promoter regions of all trichothecene biosynthetic genes to directly regulate their 
expression 31. It is expected that all verrucarin biosynthetic genes have at least one copy 
of the YNAGGCC motif in their promoter regions. Bioinformatic analysis indicated that  
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Table 4-1. Features of gene products in the sequenced chromosomal region 
 
Code Position Size Features / putative functions 
Orf1 209-1225 338 
(28/44) 
Partial M. musculus group XII-1 phospholipase A2 isoform 1 
(P_075685.2) 
Orf2 2213-2295        
2347-2595        
2661-3021 
230 N. crassa endoglucanase V (XP_957107.1) 
Orf3 5410-7287 625 (61/72) P. tritici-repentis galactose oxidase precursor (EDU43973.1) 
Orf4 7874-9157 427 (28/46) M. sp. salicylate 1-monooxygenase (ABR69922.1) 
Orf5 9255-10713       
11060-11734      
11799-11872 
735 (33/50) Putative N. fischeri C6 transcription factor (EAW20173.1) 
Orf6 12407-13306 299 (41/59) A. fumigatus short-chain dehydrogenase /reductase (XP_748579.1) 
Orf7 14881-15421      
15570-16138 
369 (36/54) G. zeae hypothetical protein (XP_390502.1); unknown protein 
Orf8 17054-17203      
17275-17823 
232 (46/66) A. fumigatus conserved hypothetical protein (XP_752469.1); putative 
NAD-dependent epimerase /dehydratase 
VerA 18667-19395 242 (66/80) G. zeae hypothetical protein (XP_384723.1); glutathione S-transferase 
VerB 19556-20901      
20966-21116 
498 (66/79) A. fumigatus MFS multidrug transporter (XP_748638.1); self-resistant 
machinery 
VerC 21614-22927 437 (49/69) A. niger   hypothetical protein (XP_001395378.1); C6 finger domain 
protein 
VerD 23814-25196      
25250-25399 
510 (36/53) S. sclerotiorum  hypothetical protein (XP_001589913.1); P450 
VerE 27525-27768      
27825-28684      
28747-28857      
28950-29116      
29187-29391 
528 (81/89) M. roridum cytochrome P450 (AAC49958.1); P450 similar to Tri4 
 
VerF 30693-31490      
31584-32105      
32287-32411      
32469-32601 
525 (44/64) G. zeae trichothecene 15-O-acetyltransferase (BAC22114.1); 
acyltransferase similar to Tri3 
 
VerG 35361-35748      
35881-36749 
418 (52/67) G. zeae  regulatory protein (AAM48887.1); regulatory protein similar 
to Tri10 
VerH 40098-40906 264 (66/73) M. roridum trichothecene biosynthesis transcription factor 
(AAC49959.1); transcription factor similar to Tri6 




A. clavatus polyketide synthase (XP_001273842.1); fungal iterative 
type I polyketide synthase 
VerJ 54048-54998      
55077-55555      
55576-55633      
55721-55842      
55906-56038 
580 (30/50) F. sporotrichioides 15-O-acetyltransferase (AAK33072.1); 
acyltransferase similar to Tri3 
 
VerK 57123-57464      
57525-58670 
495 (52/70) A. clavatus benzoate 4-monooxygenase (XP_001273721.1); putative 
P450 
VerL 59319-59507      
59572-60484 
367 (82/92) S. chartarum TRI14 (AAG47844.1); unknown protein similar to Tri14 
VerM 62090-62702      
62781-63491      
63550-64013 
595 (57/75) F. pseudograminearum trichothecene efflux pump (AAM48858.1); 
self-resistant machinery similar to Tri12 
VerN 65094-65782      
65842-66310 
385 (83/89) M. roridum trichodiene synthase (AAC49957.1); sesquiterpene 
synthase similar to Tri5 
VerO 67949-68077 42 (47/72) F. sporotrichioides TRI9; unknown protien similar to Tri9 
VerP 69419-70888 489 (34/56) N. uncinatum LolU-1 (AAV68707.1); putative DNA binding protein 
VerQ 71352-72723 455 (66/82) G. zeae hypothetical protein  (XP_384510.1); putative acyl transferase 
VerR 73008-74110      
74218-74897 
593 (59/73) A. fumigatus long-chain-fatty-acid-CoA ligase (XP_753087.1); acyl-
CoA ligase 
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VerS 76175-76530      
76581-77391 
388 (33/51) M. grisea hypothetical protein (XP_367888.1); protein similar to AtmA 
VerT 78523-78941      
79016-79610      
79672-79845      
79907-80023      
80076-80306 
511 (39/61) G. fujikuroi  cytochrome P450 monooxygenase (CAA75565.1); P450 
VerU 82487-82725      
82791-83034 
160 (35/59) G. zeae hypothetical protein (XP_387387.1); unknown protein 
VerV 84920-86407 495 (44/62) A. clavatus flavin-binding monooxygenase (XP_001275023); flavin-
binding monooxygenase 
VerW 88228-88780      
88837-88961      
89012-89157      
89213-89308      
89452-89522      
89594-89709 
368 (67/82) N. crassa norsolorinic acid reductase (XP_961973.2); ketone reductase 
VerX 91436-91685 
91747-91836      
91900-92013 
92073-92545      
92603-92769      
92836-92963      
93015-93318 
511 (33/54) P. tritici-repentis ent-kaurene oxidase 
 (XP_001942213.1); putative P450 
 
VerY 93950-94819 289 (38/62) A. fumigatus short-chain dehydrogenase/reductase (XP_747739.2); 
short-chain dehydrogenase/reductase 
VerZ 96428-97270 280 (38/56) S. cellulosum α/β fold hydrolase /acyltransferase (YP_001612520.1); 
hydrolase/acyltransferase 
Orf9 98705-99838 369 (63/75) G. zeae hypothetical protein (XP_390717.1); unknown protein 
Orf10 100491-101638 316 (45/60) Partial A. fumigatus ankyrin repeat protein (EDP48589.1) 
 
such a motif was absent in the promoter regions of Orf1-8, indicating that they might not 
be the verrucarin biosynthetic genes. Similarly, Orf9-10 at the right end of the sequenced 
region lacked this conserved motif in their promoter regions and may define the right 
boundary of verrucarin gene cluster. 
 
 Twenty-six ORFs (VerA-Z) were tentatively identified in the middle of the 
sequenced regions (Figure 4-4). All of these ORFs except VerC contained at least one 
copy of the VerH binding motif in their promoter regions (Table S4-2). Compared to the 
T-2 toxin biosynthetic gene cluster, ten genes in verrucarin gene cluster showed 
homologous (Figure S4-1, Table 4-1). Some of these gene products (VerE, VerF, VerK, 
VerJ, and VerN) were possibly involved in the biosynthesis and diversification of 
verrucarol, while others, including VerG, VerH, VerL, VerM, and VerO, may be 
transcriptional regulators, resistance machinery, or unknown proteins. Based on the 
predicted functions of these enzymes, one putative biosynthetic pathway of verrucarol 
was proposed (Figure 4-5). The pathway was starts with the production of trichodiene 
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Figure 4-5. The putative pathway for verrucarol product. The putative gene product 
catalyzing each step was labeled.  
  
from FPP catalyzed by VerN. Subsequently, VerE homologous to Tri4 transformed 
trichodiene into isotrichodiol after two hydroxylations and one epoxidation. The 
subsequent ring closure might occur spontaneously under physiological conditions or be 
promoted by VerE in fungal cells. Trichodermol is produced in a C-4 hydroxylation 
reaction. This step is catalyzed by another P450, possibly VerT. VerK, another P450 that 
is similar to Tri11, may catalyze the C-15 hydroxylation reaction to generate verrucarol. 
The identification of genes for verrucarol production indicated that the isolated gene 
cluster was responsible for one trichothecene biosynthesis. 
 
 Besides verrucarol, verrucarins and roridins also contain polyketide and 
verrucarinate moieties. VerI was predicted as a fungal iterative PKS and may be involved 
in the biosynthesis of the polyketide moiety (Figure 4-6). Interestingly, this moiety 
contains six carbons in verrucarins but eight carbon atoms in roridins, indicating VerI 
may be capable of producing various lengths of polyketides. The second unique feature 
of this polyketide moiety is the presence of one cis-double bond between C-9’ and C-10’. 
The alkenes in the polyketides are generated by the actions of a ketoreductase-
dehydratase (KR-DH) didomain, and are generally in the trans form 32, 33. The KR 
domain catalyzes a 3-keto reduction while the DH domain facilitates the subsequent Δ2,3 
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elimination reaction. In the formation of a trans double bond, a D-3-hydroxyacyl 
intermediate should be produced while a L-3-hydroxyacyl product indicates the cis 
double bond formation 32, 33. Remarkably, both cis and trans double bond are present in 
the polyketide moiety of verrucarins and roridins, although VerI contains putative KR 
and DH domains. Thus, it is highly possible that the one DH-independent enzymatic 
reaction is involved the formation of cis-double bond between C-9’ and C-10’. Recently, 
one glutathione S-transferase (GST) was proposed to catalyze the cis-trans isomerization 
in the biosynthesis of fungal polyketide hypothemycin 34. VerA was predicted to be a 
GST enzyme and may play the same role in trichothecene macrolide biosynthesis (Figure 
4-6). In verrucarin, one carboxylic group was expected at one end of its polyketide 
moiety. A P450 involved in biotin biosynthesis was shown to produce the carboxylic 
diacid after oxidative cleavage of a fatty acid in Bacillus subtilis 35. The substrate in this 
remarkable P450 reaction was a fatty acid tethered to one fatty acid synthase thiolation (T) 
domain. In the biosynthesis of trichothecene macrolide verrucarin, such a P450, possibly 
VerD, was proposed to introduce a carboxylic acid at C-6’ position. Subsequently, VerR, 
a putative long-chain CoA ligase, will activate this group with CoA. In roridin 
biosynthesis, one epoxide was produced from the double bond between C-6’ and 
 
 
Figure 4-6. One putative pathway for the biosynthesis and modification of the 
polyketide moiety in trichothecene macrolide.  
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C-13’ (Figure 4-6). Possibly, VerV, a putative flavin-binding monooxygenase, will 
catalyze this reaction. The investigation of VerI and VerA activities is in progress to 
probe into fungal iterative PKS biosynthesis and cis-trans isomerization in fungal 
polyketides. 
 
 Unlike the biosyntheses of the verrucarol and the polyketide moieties in 
trichothecene macolides, the production of verrucarinate was only reported in this type of 
trichothecenes and remained obscure. However, the isolation of verrucarin J, verrucarin B, 
and 2’-dehydroverrucarin A suggests one putative pathway from mevalonate into 
verrucarinate (Figure 4-7). It is proposed that Orf8, one presumable dehydratase, may 
catalyze the removal of one molecule of water from mevalonate to produce cis-
anhydromevalonate. The biochemical characterization of this enzyme is in progress to 
test this hypothesis. In the next step, this newly produced cis-double bond was converted 
into an epoxide possibly under the catalysis of the P450, VerX. How this epoxide ring is 
opened to produce a ketone functiona group is unclear, but the ketone was reduced to a 
hydroxyl group by one putative ketoreductase, VerW. It is believed that VerR will 
activate the terminal carboxylic group of verrucarinate with a CoA. 
 
 
Figure 4-7. One putative pathway for the biosynthesis and modification of 
verrucarinate moiety in trichothecene macrolide.  
 
 The last group of enzymes in trichothecene macrolide biosynthesis was 
responsible for the assembly of the three above moieties. Both VerF and VerJ share the 
highly conserved motif (HxxxDG) with Tri3 in F. sporotrichioides and F. graminearum 
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(Figure S4-2A) 36-38. Since Tri3 utilizes one acetyl-CoA to acylate C-15-OH of acyclic 
trichothecenes, acyl-CoA was one of substrates in both VerF and VerJ reactions (Figure 
4-8). However, it is unclear which enzyme acylates the C-15-OH of verrucarol. The third 
acyltransferase in the trichothecene macrolide gene cluster is VerQ. This enzyme showed 
high similarity to Rv1347c in mycobactin biosynthesis (Figure S4-2B). The Rv1347c 
enzyme effectively utilizes both fatty acid bound to the fatty acid synthase T domain and 
acyl-CoA as its substrate. The conserved active residues, H353 and E391, are common 
for both VerQ and Rv1347c, indicating that VerQ may cleave the polyketide intermediate 
from VerI in macrocyclic trichothecene biosynthesis (Figure 4-8). It is proposed that the 
C-4-OH of verrucarol will be positioned in VerQ to attach the polyketide intermediate 
tethered to VerI T domain. Thus, the last step in trichothecene macrolide biosynthesis is 
to attack the terminal CoA of the polyketide intermediate by the terminal OH of 
verrucarinate, which might be catalyzed by either VerF or VerJ. In the roridin 
biosynthesis, this step is to open the terminal epoxide in polyketide intermediate by the 
terminal OH of verrucarinate, and one ether bond instead one ester bond is generated.  
Overall, trichothecene macrolide biosynthesis involves enzymes from sesquiterpene, 
polyketide, and unique verrucarinate biosynthetic pathways. This work offers numerous 
possibilities to control mycotoxin production and generate natural product analogs with 
potential anticancer activities. It also provides basic information to understand natural 
product production with different origins.  
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Figure 4-8. One putative pathway to assemble three moieties of trichothecene 
macrolides. A was proposed for verrucarin A production while B was for roridin A. 
 
4.3.2. Detailed Characterization of One Sesquiterpene Synthase and One 
Multifunctional P450 in the Verrucarol Biosynthetic Pathway 
 
The above proposed biosynthetic pathways for trichothecene macrolides were 
preliminarily validated by the biochemical characterization of VerN and VerE in my 
studies. Bioinformatic analysis indicated that VerN shared three conserved motifs with 
Tri5s from F. sporotrichioides and M. roridum (Figure 4-9). The first aspartate-rich 
motif and two divalent metal ions are responsible for FPP binding in sesquiterpene 
synthase 39. The third divalent metal ion was positioned to enzyme FPP binding pocket 
with the assists from the conserved N, S, and E residues in the second motif. The last 
basic motif was shown to trigger the ionization of the substrate. Thus, VerN was 
predicted to be a sesquiterpene synthase. 
 
 
Figure 4-9. Bioinformatic analysis of VerN. 
 
To validate the role of VerN in verrucarol biosynthesis, a 61-bp intron in this 
1217-bp gene was removed with the use of overlapping PCR technology. The resultant 
cDNA was sequenced and cloned into pET28a for overexpression in E. coli. Single Ni-
NTA resin purification gave VerN in about 80 % purity (Figure S4-3). The activity of 
purified VerN was examined with FPP as the substrate. Two broad peaks were identified 
in GC-MS analysis (Figure 4-10). Each of these products had the molecular ion value at 
204. In fact, from the single substrate FPP, various sesquiterpene synthases produce more 
than 300 known monocyclic, bicyclic, or tricyclic hydrocarbon or alcohol products of 
widely varied structure and stereochemistry 40. Moreover, multiple products were also 
reported in the Tri5 reactions, strongly indicating the feasibility and flexibility of 
sesquiterpene synthase in natural product biosynthesis 41.  Compared to the retention time 
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in the GC trace and MS spectrum of authentic trichodiene, the peak from VerN reaction 
was identified as the trichodiene with retention time of 9.18 min (Figure 4-10, Figure  
 
Figure 4-10. GC-MS analysis of VerN reactions. Lane 1, VerN full reaction; lane 2, 
VerN reaction without Mg2+; lane 3, enzyme reaction with boiled VerN as enzyme source; 
lane 4, authentic trichodiene. 
 
S4-4). The production of one key biosynthetic intermediate by VerN indicated that the 
trichothecene biosynthetic gene cluster was isolated from M. verrucarin.  
 
In the isolated gene cluster, five P450s were predicted and possibly required for 
trichothecene macrolide biosynthesis. All of these remarkable biocatalysts contained 
three conserved motifs (Figure S4-5). The first motif is responsible for protonating the 
reactive iron-oxygen intermediate, while the Cys residue in the third motif serves as the 
fifth ligand of the heme iron. Interestingly, all of these fungal P450s contain a 30-AA 
transmembrane segment at their N-termini. VerE was chosen for further investigation in 
this study. This enzyme may convert trichodiene into isotrichodiol by two hydroxylations 
and one epoxide in an unprecedented manner. Four introns were removed from its gDNA 
to produce its corresponding cDNA by overlapping PCR technology. Initial efforts to 
produce soluble and active full-length and truncated VerE in E. coli failed, possibly 
indicating the codon bias between E. coli and the marine fungal strain. Thus, the VerE 
cDNA was cloned into the pYES2/C NT vector for its overexpression in yeast  
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Figure 4-11. GC-MS analysis of VerE reaction. In the coupled reactions including 
VerN and VerE from the yeast microsomes, FPP was used as the substrate. In SIM mode, 
12,13-epoxy-9,10-trichoene-2α-ol (m/z = 236.2) was identified as the peak with retention 
time of 10.08 min in lane 1 while 2α-hydroxytrichodiene (m/z = 220.2) was found with 
retention time of 9.72 min in lane 2. 
 
Saccharomyces cerevisiae. The resultant yeast microsomes containing VerE were 
isolated and used as the source of enzymes to investigate the P450 reactions (Figure 4-
11). In the preliminary assay, two peaks, one for 2α-hydroxytrichodiene (9.72 min) and 
the other for 12,13-epoxy-9,10-trichoene-2α-ol (10.08 min), were identified in SIM mode. 
These peaks were not observed in the single enzyme (VerN or VerE) reaction, and they 
were characterized by the expected m/z values (Figure S4-6). Further validation of these 
putative products is in progress. Overall, the preliminary analysis of VerE indicated that 
this P450 was able to catalyze one hydroxylation and one epoxidation reaction on 
trichodiene, as would be expected for it to be involved in the early stage of the 
biosynthetic pathway of trichothecene macrolide.   
 
4.4. Materials and Methods 
 
General Chemicals, DNA Sub-cloning, and Bacterial Strains. Chemicals were 
purchased from Sigma-Aldrich and Fisher Scientific. FPP was purchased Isoprenoids. 
Authentic trichodiene, isotrichodiol, and trichothecene were kindly provided by Dr. Susan 
McCormick at the USDA (Peoria, IL). Myrocethium verrucaria was isolated from 
Hawaii Spongia sp. and was provided by Professor Philip Crews in University of 
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California-Santa Cruz. The yeast overexpression system was from Invitrogen. Standard 
methods for DNA isolation and manipulation were performed as described by Sambrook 
et al 42. Genomic DNA from M.verrucaria was isolated with a MasterPure Yeast DNA 
Purification kit (Epicentre Biotechnologies) as described in its manual. Molecular 
biology reagents and enzymes were supplied by New England Biolabs, with the 
exception of for Pfu DNA polymerase (Stratagene), dNTPs (Takara), and T4 DNA 
Ligase (Invitrogen). Escherichia coli XL-1 Blue was used for cloning and plasmid 
harvesting while E. coli BL21 (DE3) or E. coli BL21 CodonPlus-(DE3)-RIPL was used 
for protein overexpression. All E. coli strains were grown in Luria-Bertani broth. DNA 
sequencing was performed at the University of Michigan DNA Sequencing Core.  
 
Construction of Fungal Genomic DNA Library. M. verrucaria was grown in 50 ml of 
1.5 % malt extract broth in artificial sea water at room temperature without shaking. 
Fungal mycelium was collected by filtering through Waterman filter paper #4 and 
washed with 100 ml 50 mM Tris-Cl, pH 7.5. Mycelia were dried with paper and ground 
into powder with mortar and pestle in liquid nitrogen. Mycelia powder was transferred to 
one sterile 1.5-ml Eppendorf tube, and fungal genomic DNA was isolated with an 
Epicentre Masterpure Yeast DNA Purification Kit. The manufacturer protocol was 
followed. The size of the isolated fungal gDNA was checked with pulse field gel 
electrophoresis and was estimated to be about 40 kb. An Epicentre CopyControl™ 
Fosmid Library Production Kit was used to construct the fungal gDNA library. The 
protocols in the kit were used with minor modifications, but the end-repaired DNA was 
not purified from the gel. Instead, DNA was directly precipitated, dried, and re-dissolved 
for library construction. A genomic DNA library was then screened by PCR with one pair 
of degenerate primers designed on the basis of KS domain, one pair of primers on Tri4 
from M. roridium, one pair of primers on Tri5 from M. roridium, one pair on the 
identified CoA ligase region, one pair on the 5’-end of assembled sequence of fosmid N1 
and C10, and one pair on the 3’-end of assembled sequence of fosmid N1 and C10. In 
total, four fosmids were isolated and subjected to shotgun sequencing. The sequencing 
results were analyzed and assembled to reveal a 101638-bp chromosomal region by the 
use of SeqMan in Lasergene 6 package. BLASTX in NCBI 
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(http://www.ncbi.nlm.nih.gov/BLAST/) was used to predict the functions of each open 
reading frame (ORF). Subsequently, BCM Gene Finder 
(http://www.bioscience.org/urllists/genefind.htm) was used to predict putative introns in 
each ORF. 
 
Gene Cloning, Expression and Protein Purification. Primers in Table S4-1 were 
designed to remove intron(s) from the full-length VerN and VerE and to produce te 
corresponding cDNAs by overlapping PCR. The purified VerN cDNA was ligated to 
pET28a for transformation of E. coli DH5α competent cells. The constructs were isolated 
and submitted for sequencing to exclude errors introduced during PCR amplification and 
gene manipulation. The construct was transformed into E. coli BL21 (DE3) competent 
cells for protein expression. Cells harboring the construct were cultured in LB media 
containing 25 µg/ml of kanamycin and grown at 37 °C in a shaker at 200 rpm until OD600 
reached 0.6. The culture was then induced by IPTG with a final concentration of 0.2 mM 
and was further grown at 16 °C in a shaker at 180 rpm for 16 hours. The cells were 
harvested by centrifugation (7250 g, 12 min, and 4 °C) and cell pellets were stored at -80 
°C or used directly for protein purification.  The cell pellet was re-suspended in 40 ml 
binding buffer (50 mM Tris-Cl, pH 7.5, 200 mM NaCl, 3 mM β-mercaptoethanol, 10 % 
glycerol) with 10 mM imidazole. The resuspended cell solutions were sonicated to 
release the soluble proteins. The soluble supernatants were collected and incubated with 
2.5 ml pre-equilibrated Ni-NTA agarose resin (Qiagen) after centrifugation at 36 000 g at 
4 °C for 32 min. After a 2-hour incubation at 4 °C with gentle shaking, the resin was 
washed with 50 ml binding buffer containing 10 mM imidazole, and then with 50 ml 
binding buffer containing 20 mM imidazole. Recombinant His6-VerN gradually eluted 
with the elution buffer (50 mM Tris-Cl, pH 7.5, 50 mM NaCl, 3 mM β-mercaptoethanol, 
10 % glycerol, and 200 mM imidazole). The protein was further purified with FPLC. The 
protein fractions were then combined and the concentration was measured by its specific 
absorbance at 280 nm (ε = 77900 M-1 cm-1). The protein was aliquoted and stored at -80 
°C for use.  
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Yeast Transformation and Protein Overexpression. VerE was obtained as a 
microsomal preparation from yeast that had been transformed with its cDNA 43. Briefly, 
the pYES2/C NT expression vector carrying VerE cDNA was introduced in 
Saccharomyces cerevisiae INVSc1 from Invitrogen. A single transformed yeast colony 
was selected and grown at 30°C for approximately 24 h in 15 ml SC selective medium 
(without uracil) containing 2% glucose as the carbon source. Upon depletion of the 
glucose in the medium, expression of VerE cDNA was initiated by the addition of 
galactose to a final concentration of 2% in 50 ml SC selective medium. The cultures were 
maintained at 30°C for an additional 16 h before collecting the cells by centrifugation at 
7000 g for 10 min. The pelleted cells were then washed with 100 mL of TES buffer 
(50mM Tris–HCl, pH, 7.5, 1mM EDTA, 0.6M sorbitol), centrifuged as above, 
resuspended in 100 mL of TES-M (TES supplemented with 10 mM BME), and allowed 
to incubate at room temperature for 10 min. The cells were collected by centrifugation, 
and the pellet was resuspended in 1 mL of extraction buffer (1% bovine serum albumin 
(fraction V), 2 mM BME, and 1mM PMSF in TES buffer). Glass beads (0.2-0.4 mm in 
diameter) (cleaned by rinsing in ethanol, dilute acid, and copious amounts of water) were 
added until they occupied approximately 90 % of the resuspended cell volume and the 
cells were disrupted by vigorously shaking the mixture in a cold room for 10 min at 30-s 
intervals separated by 30-s intervals on ice. The cell extract was decanted into a 
centrifuge tube and combined with three washes of the glass beads, each with 0.5-1 mL 
of extraction buffer. Microsomes were prepared by differential centrifugation at 10,000 g 
for 10 min at 4°C to remove cellular debris followed by centrifugation at 107,000 g for 
70 min at 4°C. The final microsomal pellets were resuspended in 0.5-1.0 mL of TEG-M 
buffer (50mM Tris–HCl, pH 7.5, 1 mM EDTA, 20% glycerol, and 1.5 mM BME) and 
stored frozen at -80 °C until use. 
 
Enzyme Assays. A). VerN The enzyme reaction mixture contained 10 mM Tris-Cl, pH 
7.5, 5 mM MgCl2, 15 % glycerol, 5 mM BME, 250 µM FPP, and  0.5 µM VerN in one 
200-µl total volume. The reaction mixture was overlaid with HPLC-grade n-pentane 
(10% overall volume) in a glass test tube at 30°C for 30 minutes. The reaction mixture 
was then extracted with HPLC-grade n-pentane (10 %) twice and the extracts were 
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combined and purified on a 3 cm 230-400 mesh silica gel column. The extract was 
further concentrated on an ice-water mixture under reduced pressure. One 10-µl aliquot 
was injected in a splitless mode to GC-MS to analyze the enzyme product. The GC-MS 
analysis was conducted with a Finnigan Trace GC/MS machine. Finnigan Trace GC 2000 
was installed with a DB-1 capillary column (25 meters, 0.2 mm I.D., 0.22 µm film 
thickness) in a split injector. The split ratio is 1:100. The injection temperature was 120 
°C, which was held for 2 min. The initial ramp with a rate of 6 °C/min was utilized to 
increase the temperature to 210 °C, which was held for 1 additional min. The MS used 
the electron impact mode with detection voltage of 300 V.  
B). VerE. Purified microsome was used in VerE reactions with trichodiene as the 
substrate. Otherwise, VerE activity was examined in the coupled reaction containing 
VerN and FPP. The reaction mixture contained 50 mM Tris-Cl, pH 7.5, 10 % glycerol, 3 
mM BME, 5 mM MgCl2, 250 µM FPP, 1 µM VerN, 0.5 mM NADPH, and 30 µl of 
enzyme microsome in a 200-µl total volume. The reaction mixture was overlaid with 
HPLC-grade n-pentane (10% overall volume) in a glass test tube at 30°C for 2 hours, and 
reaction mixture was then extracted with HPLC-grade n-pentane (10 %) twice. The 
combined extracts were concentrated on an ice-water mixture under reduced pressure. 
One 10-µl aliquot was injected to GC-MS to analyze the enzyme product. The injection 
temperature was 120 °C, which was held for 2 min. The initial ramp with a rate of 15 
°C/min was utilized to increase the temperature to 210 °C, which was held for 1 
additional min. Subsequently, the final temperature of 260 °C was reached with the 
second ramp of 10 °C/min and was held for 3 min. The MS used the electron impact 




4.5. Supplementary Figures and Tables 















Figure S4-1. Several genes shared in the T-2 toxin gene cluster and the trichothecene 
macrolide gene cluster. 
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Figure S4-2. A. One conserved motif shared by Tri3 and VerF and VerJ. B. One 








Figure S4-4. MS spectra of VerN product (top) at 9.18 min and authentic trichodiene 
(bottom). 
trichodiene#1148 RT: 6.59 AV: 1 NL: 2.76E6
T: {0,0} + c EI det=300.00 Full ms [ 61.00-351.00]
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Figure S4-5. Three conserved motifs are shared by five P450s involved in trichothecene 
macrolide biosynthesis. Moreover, all of these enzymes contained a transmembrane 




Figure S4-6. SIM spectra of 2α-hydroxytrichodiene (top) and 12,13-epoxy-9,10-
trichoene-2α-ol (bottom) 
ss with tri4#1859-1866 RT: 10.06-10.09 AV: 8 SB: 418 9.63-10.02, 10.25-11.89 NL: 7.98E4
T: {0,0} + c EI det=300.00 Full ms [ 61.00-351.00]
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Table S4-1 Primers for gene cluster isolation, intron removal, and gene expression 
 
Name Sequence (5’→3’) Function 
KS3 TTYGAYGCIGCITTYTTYAA KS domain 
KS4C RTGRTTIGGCATIGTIATICC KS domain 
Mrtri4F TTCTACCATGAAGTCATCCG Mrtri4 primer 
Mrtri4R ATCCATCGCTCAGGCTTGAA Mrtri4 primer 
Mrtri5F CTTGTCAACGAGCACTTCCCCAACG Mrtri5 primer 
Mrtri5R GCCAGGTGATGTAGCCGTGCATAAA Mrtri5 primer 
N1CLF TGGCAGGTTACCAACTACAG CoA ligase primer  
N1CLR CAAGGGAGCGATTCTTTC CoA ligase primer 
DY5F CATAGCAGATCACACCGGTTATTC Mv-92-1-9F isolation 
DY5R CGTTGGTTATCGTGCTGTGAATC Mv-92-1-9F isolation 
DY3F CGTTTGGAGAGTGTGTGCAGT Mv-94-1-9B isolation 
DY3R GACACCTACTGACCTTCCCAGT Mv-94-1-9B isolation 
VerNF(NdeI) AACCCATATGGATACCTTCCCCACC VerN expression 
VerNR(HindIII) CCGAAAGCTTTTACACCAGAACCTCATG VerN expression 
VerNIF ACGCTTGACTTCGAGGGCTGCTGGATT VerN intron removal 
VerNIR GCCCTCGAAGTCAAGCGTGCTGCGAAT VerN intron removal 
VerEF(EcoRI) GCGGAATTCATGCCCTCCTTCTCTGAT VerE yeast expression 
VerER(XhoI) GCGCTCGAGTTAAATCAACTGCTTGGC VerE yeast expression 
VerEI1F AGATGCACGAGAAATATGCACAAGGCCCCATTGTCC VerE intron1 removal
VerEI1R GGACAATGGGGCCTTGTGCATATTTCTCGTGCATCT VerE intron1 removal
VerEI2F GAAAGTCTTCCTTACTTGAGCGGTGTCGTCCATGAG VerE intron2 removal
VerEI2R CTCATGGACGACACCGCTCAAGTAAGGAAGACTTTC VerE intron2 removal
VerEI3F TACACTATTCCCGCTGGAACCCCATTGAGCATGTCC VerE intron3 removal
VerEI3R GGACATGCTCAATGGGGTTCCAGCGGGAATAGTGTA VerE intron3 removal
VerEI4F ACAGTGCATTGGTATCAACATGTCTTTTGCCGAAATT VerE intron4 removal
VerEI4R ATTTCGGCAAAAGACATGTTGATACCAATGCACTGT VerE intron4 removal
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Table S4-2 Putative VerH binding sites in the promoter region of each trichothecene 









(5’ → 3’) 
Position 
VerA CCAGGCC 18537-18543 VerM TCAGGCCT 61450-61457
VerB GGGCTCG 21468-21474 VerN AGGCCTAG 66812-66819
VerC - -  GGCCTTA 67700-67706
VerD GGCCTCA 26485-26491 VerO AGGCCTGA 68557-68564
 AGGCCTGA 26634-26641 VerP GGCCTTA 71148-71154
 AGGCCTGA 26681-26688 VerQ TAAGGCC 71066-71072
 GGCCTGA 27234-27240 VerR AGGCCTTG 75686-75693
VerE TAAGGCCT 25583-25590 VerS TTAGGCC 75149-75155
 TAAGGCC 26338-26344  TTAGGCC 75171-75177
 CGAGGCC 26995-27001  TAAGGCCT 75359-75366
VerF CTAGGCC 29394-29400  TCAGGCCT 75684-75691
 TCAGGCCT 30410-30419  TTAGGCC 76005-76011
VerG CTAGGCC 33626-33632 VerT GGCCTTA 80560-80566
 TTAGGCC 33658-33664 VerU AGGCCTTA 83768-83775
 TCAGGCC 33954-33960 VerV GGCCTGA 86841-86847
 TAAGGCC 34304-34310 VerW GGCCTTA 89983-89989
 TCAGGCC 34950-34956  GGCCTGA 90484-90490
 CTAGGCC 35011-35017  GGCCTAA 91145-91151
VerH GGCCTTA 43956-43962  AGGCCTAA 91195-91202
 AGGCCTCA 43968-43975 VerX TCAGGCC 90886-90892
VerI+J TAAGGCCTGA 53524-53533 VerY AGGCCTAG 96007-96014
 TACGGCCTCA 53760-53769 VerZ TAAGGCC 95091-95097
VerK GGCCTGA 58983-58989  TAAGGCCT 96005-96012
 GGCCTGA 59157-59163    
VerL TGAGGCCT 58836-58843    
 CTAGGCC 58898-58904    
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Natural products contribute to the majority of currently used drugs in the market. 
However, new and drug-resistant diseases have been reported more frequently in recent 
decades. Along with the advances in identification and characterization of novel targets, 
numerous secondary metabolites have been isolated, purified, and characterized from 
different environmental niches. For example, 961 new natural products were isolated 
from marine organisms in 2007, an increase of 24% from 2006 1. These new natural 
products not only attracted more efforts to understand their production in Nature, but also 
provided a tremendous source of novel chemical architectures for the development of 
new analogs with the hope to identify useful drugs.  
 
Undoubtedly, chemical synthesis is the primary method for generating the most 
drugs used to treat various diseases. However, the required asymmetric synthesis steps 
remain challenging for many complex natural product drug candidates or analogs. 
Moreover, chiral centers in drugs critically contribute to their bioactivities and 
specificities. For example, over 54% of current drugs contain at least one stereogenic 
centre, and most must be developed as single stereoisomers 2. As a result, the chemical 
route leads to high cost and lengthy separation process, and also produces undesired side 
products. On the other hand, the unbeatable selectivity of biocatalysts makes 
chemoenzymatic approaches to be energy efficient and environment friendly. The 
development of biocatalysts has been further boosted by the exponential growth in 
publicly available genome sequences and the recent advances in metagenomics, high 
throughput screening technology, and directed enzyme evolution 3-5. As one important 
and integral part of new drug development, studies of natural product biosynthesis 
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have characterized a considerable number of excellent biocatalysts. 
 
In my studies, several enzymes from natural product biosynthetic pathways have 
been identified and characterized. These studies not only deeply probed into the natural 
product assembly, but also provided a basis for generating both natural and unnatural 
analogs. For example, the regio- and stereo-selective cryptophycin P450 epoxidase 
catalyzes a β-epoxidation reaction in the maturation of bioactive cryptophycins in 
cyanobacterium Nostoc sp. More importantly, this enzyme was utilized in a 
chemoenzymatic approach to overcome the most challenging step in the natural product 
chemical synthetic route. Similar to the chemical syntheses of many other macrolactones 
and macrolactams, inefficient and unspecific macrocyclization challenged organic 
chemists to properly produce cryptophycins with traditional methods.  The cryptophycin 
TE domain exhibited excellent catalytic ability to overcome this issue in cryptophycin 
production. Moreover, the substrate tolerance of this enzyme offers more opportunities to 
generate novel analogs for clinical evaluation. Besides these biocatalysts from bacterial 
strains, fungi also are rich sources for pharmaceutically valuable natural products and 
practical biocatalysts. In numerous fungal alkaloid biosyntheses and chemical syntheses, 
deoxybrevianamide E and its analogs serve as the key precursors. NotD identified in my 
studies is a putative biocatalyst to specifically and efficiently produce this compound for 
pharmaceutical production 6.  
 
To be considered as practical industrial biocatalysts, enzymes need to contain a 
number of features such as high catalytic turnover (>500 min−1), strict selectivity for the 
particular transformation, and good process stability under the non-native conditions 7. In 
most cases, the enzymes must be optimized through direct evolution to improve their 
thermostability, pH tolerance, and catalytic capability 5. For many enzymes that I studied, 
further optimization may be necessary before their practical application in large scale. 
For example, the inconsistent performance of CrpE may be derived from its instability. 
Thus, one important future direction in cryptophycin studies will be to improve CrpE 
stability and catalytic efficiency. Based on my studies, the MBP tag seemed to be 
required to maintain the solubility of enzyme in the reaction. Although the tag itself 
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causes no harm to enzyme activity, the codon optimized CrpE gene may increase enzyme 
overexpression level in E. coli strain, which may be inversely correlated to proper folding 
of the nascent polypeptide in heterologous host. For cryptophycin TE, avoiding of 
hydrolytic activity may be critical for its application in generating the large quantities of 
anticancer agent analogs. NotD showed very strict substrate selectivity to brevianamide F. 
To make it to be more applicable, its crystal structure will be important for understanding 
the structural determinants contributing to enzyme specificity. These determinants will be 
manipulated in the next step to expand the NotD substrate library to generate more 
reversibly prenylated cyclo-dipeptide analogs for drug development. 
 
Besides identification of biocatalysts from natural product biosynthetic pathways, 
another valuable contribution is to produce natural products and their analogs in 
heterologous hosts. Complex secondary metabolites are produced by their producers 
mainly to compete with other habitants and/or to sense surroundings in natural 
environments. This can be a potential limitation in obtaining large quantity of natural 
products as leads in drug discovery and development. Moreover, more than 99 % of 
microorganisms in the environment fail to grow in the laboratory while the potential to 
find pharmaceutically important natural products from this unexplored source seems 
limitless. Thus, it is critical in natural product drug development to introduce natural 
product gene clusters into more technically- and industrially-amenable microorganisms 
such as Escherichia coli, Bacillus subtilis, Pseudomonas putida, Saccharomyces 
cerevisiae, or Streptomyces coelicolor 8. Furthermore, heterologous product of secondary 
metabolites offers possibility to manipulate their gene clusters to produce novel analogs 
or fine tune their production yields. The cryptophycin gene cluster represents an idea 
model for future hetereologous production. The codon bias between the cyanobacterium 
Nostoc sp. and a foreign strain such as E. coli will be considered. Moreover, optimizing 
the promoter for use in the E. coli system will also be important to improve product yield. 
Other strategies to facilitate cryptophycin production in E. coli may be to amplify rate-
controlling reactions and to remove unnecessary genes and/or regulators. Heterologous 
production of fungal secondary metabolites may be more challenging, but yeast strains 
have been industrially applied to produce many pharmaceuticals and their precursors 
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such as taxol precursor and nicotianamine 9. The identification of the notoamide gene 
cluster sheds lights on how unique prenylated indole alkaloids with diversified 
bioactivities are produced. Moreover, it will be one of the future directions to continue 
this study by heterologous production of these fungal alkaloids in yeast strain. 
 
Recent advances in system biology and synthetic biology make it possible to 
perform metabolic engineering at the whole cell level, thus enabling more optimal design 
of a microorganism for the efficient production of drugs and drug precursors. Along with 
the developments in other fields, natural product studies will play increasingly important 
roles in new drug discovery and will be an integrated component in the battle against old 
and new human diseases.  
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